UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: September 30, 2013

¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2021

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT

For the transition period from ______ to _______

Commission File Number:000-53223

000-53223MARIZYME, INC.

GBS ENTERPRISES INCORPORATED

(Exact name of registrant as specified in its charter)

Nevada27-375505582-5464863
(State or other jurisdictionOther Jurisdiction of incorporation or(I.R.S. Employer
Incorporation or Organization)Identification No.)
organization)

585 Molly Lane

Woodstock, GA

30189
(Address of principal executive offices)(Zip Code)

(404) 891-1711555 Heritage Drive, Suite 205, Jupiter, Florida33458

(Address of principal executive offices) (Zip Code)

(925)400-3123

(Registrant’s telephone number, including area code)number)

With a copy to:

Philip Magri, Esq.

The Magri Law Firm, PLLC

11 Broadway, Suite 615

New York, NY 10004

T: (646) 502-5900

F: (646) 826-9200

pmagri@magrilaw.com

www.MagriLaw.com

N/A

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrantregistrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.Yes ☒ No ☐

Yes   x No   ¨

Indicate by check mark whether the registrantRegistrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 229.405232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrantRegistrant was required to submit and post such files).Yes ☒ No ☐

Yes   ¨ No   x

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large“large accelerated filer," "accelerated filer"” “accelerated filer,” and "smaller“smaller reporting company"company” in Rule 12b-2 of the Exchange ct.Act. (Check one):

Large accelerated filer¨Accelerated filer¨
Non-accelerated filer¨ (Do not check if a smaller reporting company)Smaller reporting companyx
Emerging growth company

Indicate by checkmarkcheck mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No

Yes   ¨ No   x

APPLICABLE ONLY TO CORPORATE REGISTRANTS

IndicateIf an emerging growth company, indicate by check mark if the number of shares outstanding of eachregistrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the registrant’s classes of common stock, asExchange Act.

Securities registered pursuant to Section 12(b) of the latest practicable date. Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Not applicable.

As of November 14, 2013, there were 30,837,62422, 2021, the registrant had 35,928,188 shares of common stock ($0.001 par value $0.001 per share, of the Registrant issued andvalue) outstanding.

 
 

MARIZYME, INC.

FORM 10-Q

TABLE OF CONTENTS

Page No:
PART I - FINANCIAL INFORMATION
Item 1.Financial Statements3
ItemITEM 1.Consolidated Financial Statements (unaudited)3
Condensed Consolidated Balance Sheets3
Condensed Consolidated Statements of Operations4
Condensed Consolidated Statements of Stockholders’ Equity5
Condensed Consolidated Statements of Cash Flows7
Notes to Unaudited Condensed Consolidated Financial Statements8
ITEM 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations4519
ItemITEM 3.Quantitative and Qualitative Disclosures About Market Risk5926
ItemITEM 4.Controls and Procedures5926
PART II - OTHER INFORMATION
Item 1.Legal Proceedings60
Item 1A.ITEM 1.Risk FactorsLegal Proceedings6028
ItemITEM 1A.Risk Factors28
ITEM 2.Unregistered Sales of Equity Securities and Use of Proceeds6028
ItemITEM 3.Defaults Upon Senior Securities6028
Item 5.ITEM 4.Other InformationMine Safety Disclosures6028
Item 6.ITEM 5.ExhibitsOther Information6128
SignaturesITEM 6.Exhibits29
62Signatures31

PART I - FINANCIAL INFORMATION

Item 1.          Financial Statements

GBS Enterprises Incorporated

Interim Consolidated Balance Sheets

September 30, 2013 (Unaudited) and December 31, 2012 (Audited and Restated)

     Restated 
  September 30,  December 31, 
  2013  2012 
  $  $ 
Assets        
Current Assets        
Cash and cash equivalents - Note 6  259,614   1,154,602 
Accounts Receivable - Note 7  3,528,260   4,143,448 
Inventory - Note 3  21,684   - 
Prepaid expenses - Note 8  207,811   84,304 
Other current receivables - Note 9  276,856   676,976 
Assets held for sale  -   384,862 
Total current assets  4,294,224   6,444,192 
         
Non-Current Assets        
Assets held for sale  -   1,846,645 
Property, plant and equipment - Note  11  282,601   332,839 
Other non-current receivables - Note 12  1,217   428,422 
Deferred tax assets non-current - Note 10  1,076,010   1,132,103 
Goodwill - Note 13  31,260,500   34,254,881 
Software - Note 14  10,232,633   12,207,031 
Other assets - Note 15  132,489   156,379 
Total non-current assets  42,985,450   50,358,300 
         
Total assets  47,279,675   56,802,492 
         
Liabilities and stockholders' equity        
Current liabilities        
Notes payable  1,775,010   2,313,572 
Liabilities to banks - Note 16  3,887,764   6,774 
Accounts payables and accrued liabilities - Note 17  3,946,070   6,241,733 
Deferred income - Note 18  6,846,920   6,099,570 
Other short term liabilities - Note 19  242,252   860,032 
Due to related parties  -   2,115,869 
Liabilities held for sale  -   589,634 
Total current liabilities  16,698,017   18,227,184 
         
Non-Current liabilities        
Liabilities to banks  -   3,716,102 
Retirement benefit obligation  172,414   165,876 
Liabilities held for sale  -   159,898 
Total non-current liabilities  172,414   4,041,876 
         
Total liabilities  16,870,431   22,269,060 
         
Stockholders' equity        
Capital stock - Note 20        
Authorized:        
75,000,000 common shares of $.001 par value each        
25,000,000 preferred shares of $.001 par value each        
Issued and outstanding:        
30,837,624   shares of common stock        
(29,461,664  shares of common stock at December 31, 2012)  30,838   29,462 
Additional paid in capital  50,009,107   49,691,195 
Subscription Receivable  50,000   - 
Accumulated deficit  (21,646,422)  (18,974,582)
Other comprehensive income  (299,034)  442,841 
         
   28,144,489   31,188,916 
Noncontrolling interest in subsidiaries  2,264,754   3,344,516 
         
Total stockholders' equity  30,409,243   34,533,432 
         
Total stockholders' equity and liabilities  47,279,675   56,802,492 

Subsequent events - Note 25

GBS Enterprises Incorporated

Interim Consolidated Statements of Operations and Comprehensive Income/(Loss)

For the three and nine month periods ended September 30, 2013 and September 30, 2012 (Restated)

(Unaudited)

  For the three months ended  For the nine months ended 
     Restated     Restated 
  September 30,  September 30,  September 30,  September 30, 
  2013  2012  2013  2012 
  $  $  $  $ 
             
Revenues - Note 21                
Products  4,133,565   4,719,446   13,170,113   15,247,883 
Services  932,091   990,333   2,442,935   3,516,745 
   5,065,656   5,709,778   15,613,048   18,764,628 
Cost of goods sold                
Products  563,950   922,839   2,738,549   3,833,550 
Services  1,709,105   2,289,927   4,951,817   6,616,975 
   2,273,055   3,212,767   7,690,366   10,450,525 
Gross profit  2,792,601   2,497,011   7,922,682   8,314,103 
                 
Operating expenses                
Selling expenses  2,033,242   2,625,773   6,627,311   9,990,170 
Administrative expenses  1,145,304   1,229,281   3,922,440   3,940,092 
General expenses  120,364   318,350   392,329   711,227 
   3,298,910   4,173,403   10,942,080   14,641,489 
                 
Operating income (loss)  (506,309)  (1,676,392)  (3,019,398)  (6,327,386)
                 
Other Income (expense) - Note 22                
Other Income (expense)  44,726   892,702   566,430   52,543 
Interest income  -   209   420   2,866 
Interest expense  (140,213)  (133,741)  (546,333)  (241,405)
   (95,487)  759,169   20,517   (185,996)
                 
Income (loss) before income taxes  (601,796)  (917,223)  (2,998,882)  (6,513,382)
                 
Income tax (income) expense  487   (287,718)  13,807   (1,409,759)
                 
Income (loss) before discontinued operations  (602,283)  (629,504)  (3,012,689)  (5,103,623)
                 
Discontinued operations - Note 4  -   (33,125)  -   63,246 
                 
Net income (loss)  (602,283)  (662,629)  (3,012,689)  (5,040,377)
                 
Net Loss Attributable to noncontrolling Interest  535,588   (271,574)  (340,849)  (1,699,550)
Net income (loss) attributable to stockholders  (1,137,871)  (391,055)  (2,671,840)  (3,340,827)
                 
Net earnings (loss) per share, basic and diluted $(0.0373) $(0.0137) $(0.0879) $(0.1168)
                 
Weighted average number of common stock outstanding, basic and diluted  30,492,650   28,611,701   30,379,612   28,611,701 
                 
Statement of Comprehensive Income (Loss):                
                 
Net Income (Loss)  (602,283)  (662,629)  (3,012,689)  (5,040,377)
Foreign currency Translation Adjustment  (365,488)  (2,503,497)  (1,480,788)  (116,135)
                 
Comprehensive income (loss)  (967,771)  (3,166,126)  (4,493,477)  (5,156,512)
                 
Less: Net Income (Loss) attributable to noncontrolling interest  535,588   (271,574)  (340,849)  (1,699,550)
Less: Other Comprehensive Income (Loss) attributable to noncontrolling interest  (182,378)  (1,223,936)  (738,913)  (32,642)
                 
Total Comprehensive income (loss) attributed to stockholders  (1,320,981)  (1,670,617)  (3,413,715)  (3,424,320)

GBS Enterprises Incorporated

Interim Consolidated Statements of Cash Flows

For the nine months ended September 30, 2013 and September 30, 2012 (Restated)

(Unaudited)

     Restated 
  September 30, 2013  September 30, 2012 
  $  $ 
       
Cash flow from operating activities        
Net loss / net income  (3,012,689)  (5,103,623)
Adjustments        
Deferred income taxes  56,093   (1,421,720)
Depreciation and amortization  3,399,200   3,289,383 
Write-down of Goodwill and Intangibles  -   3,079,168 
Consulting expense  74,000   - 
Interest Expense  195,288   - 
Gains (Losses)  on Sale of Assets  -   (1,566,119)
Gains (Losses) from equity investment  -   (26,751)
Changes in operating assets and liabilities:        
Accounts receivable, prepaid assets, other current receivables  3,574,403   1,471,490 
Other Assets  -   (37,398)
Retirement benefit obligation  6,538   - 
Inventories  (21,684)  119,245 
Accounts payable and other liabilities  (2,915,625)  (2,438,073)
         
Net cash provided (used) by operating activities  1,355,523   (2,634,397)
Net cash provided (used) by discontinued  -   63,246 
         
Cash flow from investing activities        
Sale (Purchase) of intangible assets  

487,309

   (2,527,077)
Sale (Purchase) of property, plant and equipment  -   (579,206)
Increase (Decrease) in Financial assets  -   614,480 
         
Net cash provided (used) in investing activities  

487,309

   (2,491,803)
         
Cash flow from financing activities        
Net borrowings - banks  164,889   1,067,397 
Other borrowings  (538,562)  (2,074,044)
Capital paid-in  100,000   3,583,176 
Loans from related party  (2,115,869)  (28,432)
         
Net cash provided (used) in financing activities�� (2,389,541)  2,548,096 
         
Effect of exchange rate changes on cash  (348,280)  6,991 
         
Net increase (decrease) in cash  (894,988)  (2,507,867)
Cash and cash equivalents - Beginning of the year  1,154,602   3,250,821 
         
Cash and cash equivalents - End of Quarter  259,614   742,954 

Notes to the Interim Financial Statements

September 30, 2013

GBS Enterprises Incorporated

Unaudited

Note 1          COMPANY AND BACKGROUND

GBS Enterprises Incorporated, a Nevada corporation, through its subsidiaries, is a global provider of technology solutions for businesses and government agencies. We focus on developing and delivering solutions that help our customers to gain value and reduce cost in the development, deployment and management of the applications used in the course of conducting their business (“business applications”). We do this by building software and providing services that aid in:

¨Information Technology (“IT”) systems analysis, planning and management;
¨Automating business processes;
¨Optimizing system and application performance;
¨Ensuring the security and compliance of systems, applications and processes; and
¨Migrating and integrating systems, applications and processes.

Our customers include corporate and government IT departments, solutions integrators (“SIs”) and independent software vendors (“ISVs”). Our corporate customers are from a variety of industries, including insurance, financial services, pharmaceuticals, healthcare, manufacturing, logistics, and education. The install-base of our software products spans more than 5,000,000 users in 38 countries on four continents. We principally market and sell our products and services directly in the United States, Canada, United Kingdom, Germany, Austria, Switzerland, the Nordics and India; and indirectly through local distributors and resellers representing Australia, South America and regionally in Europe.

Our software and services are designed to mainly serve organizations that have investments in IBM’s Lotus® Notes and Domino platform. The IBM Lotus® Notes and Domino platform is both a system for enterprise email as well as an application platform, meaning that it can be used as both an email system and an environment in which business applications can be deployed and used. This platform was originally brought to market by Lotus Development Corp. in 1989, and was subsequently acquired by IBM in 1995. According to Radiate, in 2011, IBM Lotus Domino will have a worldwide installed base of 189 million mailboxes. Currently, the installed base for On-Premises IBM Lotus Domino mailboxes represents the majority of worldwide IBM Lotus Domino mailboxes, accounting for 87% of worldwide IBM Lotus Domino mailboxes. By 2015, this percentage is expected to decrease to 80%, as hosted email grows in popularity. (The Radiate Group Inc., April 2011, “IBM Lotus Notes/Domino Market Analysis, 2011-2015“)

Notes to the Interim Financial Statements

September 30, 2013

GBS Enterprises Incorporated

Unaudited

We, through our subsidiaries, have executed our strategy to acquire companies, which have developed software and specialized services for the Lotus Notes and Domino market. This growth by acquisition strategy has resulted in less competition for our software products; a large concentration of highly skilled employees with unique expertise in the area of Lotus Notes and Domino; staff and physical offices on three continents providing greater access to a global market; significant market awareness and greater market share amongst organizations that use Lotus Notes and Domino; and a comprehensive portfolio of solutions specific to the needs and requirements of organizations which use Lotus Notes and Domino.

While our products and services remain in use and demand, over the last several years, the market itself has been undergoing a paradigm shift. New technologies, especially in the areas of Cloud Computing and Mobile applications, have grown in popularity due to the potential cost savings and operational efficiencies they can offer. As organizations make investments in these new technologies, they are faced with highly complex and costly projects to migrate (“migration”) or replace their existing systems that don’t operate in the cloud or on mobile devices (“modernization”) – this includes their existing email and business applications that run on Lotus Notes and Domino.

To that end, we have acquired and developed technologies that help organizations reduce the time, cost, resources and risks associated with these highly complex migration and modernization projects.

General Corporate History

We were incorporated in Nevada on March 20, 2007 as SWAV Enterprises Ltd. (“SWAV”). SWAV was an importer and wholesaler of Chinese manufactured goods.

On April 26, 2010, SWAV purchased certain technology assets of Lotus Holdings Ltd. (“Lotus”) in exchange for 2,265,240 shares of SWAV common stock. Also on April 26, 2010, Lotus (on behalf of the SPPEF Members as discussed below) purchased an aggregate of 11,984,770 of the outstanding shares of common stock from the selling shareholders of SWAV for an aggregate of $370,000. As a result of the two sets of transactions, Lotus owned an aggregate of 14,250,010 shares of common stock of SWAV, representing approximately 95.0% of the 15,000,000 shares of SWAV common stock outstanding on April 26, 2010.

Notes to the Interim Financial Statements

September 30, 2013

GBS Enterprises Incorporated

Unaudited

On September 6, 2010, SWAV’s name was changed to GBS Enterprises Incorporated. On October 14, 2010, the Company’s trading symbol on the OTC Bulletin Board was changed from SWAV to GBSX.

About Lotus Holdings, Ltd.

Lotus is a holding company which was formed under the laws of Gibraltar for the purpose of financing merger and acquisition projects, specifically in the niche market of small or microcap companies listed on the Frankfurt Stock Exchange with complex shareholder structures and whose stock is trading below one Euro (€1.00) per share.

SPPEFs

Lotus typically finances its merger and acquisition projects through the use of Special Purpose Private Equity Funds (“SPPEFs”). Typically, SPPEFs are funded by a company’s major shareholders (the “Major Shareholders”) seeking to raise capital for projects and who fund at least 50% of the SPPEF, with the remaining portion being provided through the investment community and network of investors in Lotus. Each SPPEF is co-managed by a representative of the company’s Major Shareholders (the “Representative Secretary”) and an attorney appointed by Lotus (the “Lotus Representative”).

On February 25, 2010, a group of shareholders (the “GROUP Major Shareholders”) of GROUP Business Software AG, a German public company trading on the Frankfurt Stock Exchange under the symbol “INW” (“GROUP”), engaged Lotus to provide financial consulting and advisory services, on a non-exclusive basis, for the primary task of establishing a SPPEF. On March 12, 2010, the GROUP Major Shareholders and Lotus established and funded a SPPEF with $1,400,000, consisting of $1,000,000 from the GROUP Major Shareholders and $400,000 from a Lotus investor (collectively, the “SPPEF Members”).

In early April 2010, the SPPEF Members decided to acquire SWAV. As disclosed above, on April 26, 2010, Lotus, on behalf of the SPPEF Members, acquired an aggregate of 11,984,770 shares of SWAV common stock from the selling shareholders of SWAV for an aggregate purchase price of $370,000. The 11,984,770 shares of SWAV common stock represented approximately 79.9% of the 15,000,000 outstanding shares of SWAV common stock on April 26, 2010. Upon the consummation of the acquisition, the then executive officers and directors of SWAV resigned and Mr. Joerg Ott, the Chief Executive Officer of GROUP and a GROUP Major Shareholder, was appointed the Chief Executive Officer of SWAV and sole member of SWAV’s Board of Directors.

Notes to the Interim Financial Statements

September 30, 2013

GBS Enterprises Incorporated

Unaudited

Transactions following the acquisition

On November 1, 2010, the Company repurchased an aggregate of 3,043,985 of the 11,984,770 shares of the Company’s common stock originally purchased by Lotus on April 26, 2010. In consideration for the 3,043,985 shares of the Company’s common stock, the Company issued to Lotus a Secured Demand Note, dated November 1, 2010 (the “First Demand Note”), for the principal amount of $300,000 bearing interest at the rate of 5% per annum. The First Demand Note was repaid in September 2011.

Effective December 30, 2010, pursuant to securities purchase agreements between the Company and six GROUP Major Shareholders, the Company purchased an aggregate of 7,115,500 shares of GROUP common stock from the six GROUP Major Shareholders in consideration for an aggregate for 3,043,985 shares of the Company’s common stock (the “December Transaction”). As a result the Company owned approximately 28.2% of the outstanding common stock of GROUP.

Reverse Merger

After the December Transaction was completed, the additional GROUP Major Shareholders accepted the share swap offer from the Company and effectuated a reverse merger of GROUP and the Company. To effectuate the reverse merger, on January 5, 2011, the Company repurchased from Lotus an aggregate of 2,361,426 of the 11,984,770 shares of the Company’s common stock originally purchased by Lotus on April 26, 2010. In consideration for these 2,361,426 shares, the Company issued to Lotus a Secured Demand Note, dated January 5, 2011 (the “Second Demand Note”), for the principal amount of $200,000 bearing interest at the rate of 5% per annum. The Second Demand Note was repaid in November 2011.

Effective January 6, 2011, pursuant to securities purchase agreements between the Company and the remaining GROUP Major Shareholders, the Company purchased an aggregate of 5,525,735 shares of GROUP common stock from the remaining GROUP Major Shareholders in consideration for an aggregate of 2,361,426 shares of the Company’s common stock (the “January Transaction”). The 5,525,735 GROUP shares represented approximately 21.9% of the outstanding shares of common stock of GROUP. As a result of the December Transaction and January Transaction, the Company purchased an aggregate of 12,641,235 shares of GROUP from the GROUP Major Shareholders in consideration for an aggregate of 5,405,411 shares of the Company’s common stock, resulting in the Company owning approximately 50.1% of the outstanding common stock of GROUP and effectuating a reverse merger of the Company and GROUP whereby GROUP became the accounting acquirer.

Notes to the Interim Financial Statements

September 30, 2013

GBS Enterprises Incorporated

Unaudited

Additional Acquisition

On February 27, 2012, the Company acquired an additional 883,765 shares of common stock of GROUP from GAVF LLC for an average purchase price of $.070 per share, or approximately $619,000, after an outstanding loan of GROUP was converted into an aggregate of 1,750,000 shares of GROUP common stock, thereby increasing GROUP’s outstanding common stock to 26,982,000 shares. By acquiring the new shares, the Company increased its ownership of GROUP common stock to an aggregate of 13,525,000 shares, representing approximately 50.1% of the outstanding common stock of GROUP.

Acquisition/Dissolution of Subsidiary Companies

Pavone AG

Effective April 1, 2011, the Company acquired 100% of the outstanding common shares of Pavone AG, a German corporation, for $350,000 in cash and 1,000,000 shares of its common stock. The fair value of the common stock was determined to be $4.90 per share, representing the market value at the end of trading on the date of the acquisition. The total value of the investment, including the assumption of $ 583,991 in debt was $5,843,991. Pavone’s extensive workflow software for Lotus Notes and Domino along with their large customer base is well suited to GBS Enterprises portfolio strategy. The acquisition of Pavone complements GBS's majority ownership in GROUP and the Company believes that it further strengthens their leading industry position on the IBM Lotus Platforms and expands their cloud computing technology offerings beyond the IBM Lotus market. Pavone currently has offices in Germany and the UK. They have over 2,500 customers and over 150,000 users worldwide.

GroupWare, Inc.

Effective June 1, 2011, the Company acquired 100% of the outstanding common shares of GroupWare, Inc., a Florida corporation (“GroupWare”). As consideration the Company paid $250,000 and issued 250,000 shares of its common stock. The fair value of the common stock was determined to be $4.34 per share, representing the market value at the end of trading on the date of the acquisition. The total value of the investment, including the assumption of $ 694,617 in debt was $ 2,029,617. Upon the consummation of the acquisition, the management and board of GroupWare resigned and Joerg Ott, the Company’s Chief Executive Officer and sole director, was appointed as the Chief Executive Officer and sole director of GroupWare. GroupWare is based in Lubeck, Germany with offices in St. Petersburg, Florida. GroupWare's ePDF server delivers centralized, network-wide PDF solutions for messaging, workflow, document, content and data management. The Company believes that the acquisition strengthens the GBS Modernizing/Migrating offering, which helps bring IBM Lotus Notes client applications to the web, by substituting traditional printing methods provided by the Notes client with simple-to-use print-to-PDF capabilities in the browser.

Notes to the Interim Financial Statements

September 30, 2013

GBS Enterprises Incorporated

Unaudited

IDC Global, Inc.

On July 25, 2011, the Company acquired 100% of the issued and outstanding shares of common stock of IDC Global, Inc., a Delaware corporation (“IDC”). Pursuant to the acquisition agreement, dated July 15, 2011, the Company agreed to issue the shareholders an aggregate of 800,000 shares of common stock and made a cash payment of $750,000. The agreement required an additional payment to the management shareholders of 80,000 shares of common stock and signing bonuses to personnel of $35,000. The Company also agreed to reimburse IDC up to $25,000 for incurred accounting and legal fees related to the transaction. The fair value of the common stock was determined to be $3.70 per share, representing the market value at the end of trading on the date of the agreement. The total value of the investment, including $883,005 of debt assumption, was $4,066,000. IDC was a privately held company that provides nationwide network and data center services. IDC delivers customized, high availability technology solutions for WAN, Wireless Services, Co-location & Hosting, Managed Services, and Network Security. IDC includes two Data Center facilities located in the downtown Chicago area and Colocation facilities in three other Data Centers in New York, London, England and Frankfurt, Germany. IDC provides internet infrastructure Services (IaaS) to the business community helping customers make the transition from large, static and expensive on-premise computing to dynamic, flexible and cost-effective off-premise computing. IDC is helping customers make the transition from large, static and expensive on-premise computing to dynamic, flexible and cost-effective off-premise computing.

Due to the Company’s perceived increase in the demand for Modernization, Mobility and Optimization offerings, the Company made a strategic decision in 2012 to focus on its core offerings in the IBM Notes and Domino market and to divest its non-core businesses, including IDC.

Notes to the Interim Financial Statements

September 30, 2013

GBS Enterprises Incorporated

Unaudited

On February 1, 2013, GBS entered into a Stock Purchase Agreement, dated February 1, 2013 (the “Agreement”), with IDC and Global Telecom & Technology Americas, Inc., a Virginia corporation (“GTT). Pursuant to the Stock Purchase Agreement, we sold 100% of the issued and outstanding capital stock of IDC to GTT for an aggregate purchase price of $4,600,000 (the “Purchase Price”), subject to certain holdback provisions amounting to $1.093 million as described more fully in the Stock Purchase Agreement. The Purchase Price is also subject to adjustment on a dollar-for-dollar basis for adjustments the Net Working Capital (defined as Current Assets minus Current Liabilities) of IDC by GTT within 90 days of closing.

SD Holdings, Ltd.

On September 27, 2011, the Company entered into an acquisition agreement with SD Holdings, Ltd. (“SYN”), a Mauritius corporation, and the shareholders of SYN owning 100% of issued and outstanding shares of SYN. SYN owns 100% of all issued and outstanding shares of Synaptris, Inc., a California corporation (“Synaptris”), and 100% of all issued and outstanding shares of Synaptris Decisions Private Limited, a company formed in India (“Synaptris India”). Pursuant to the acquisition agreement, the Company purchased one hundred percent (100%) of the issued and outstanding shares of SYN (“SYN Shares”) effective November 1, 2011 in consideration for $525,529 and agreed to issue 700,000 shares of common stock, subject to adjustment. Actual shares issued were 612,874. The fair value of the common stock was determined to be $2.05 per share, representing the market value at the end of trading on the date of the agreement.

On April 1, 2012, the Company sold SYN, Synaptris and Synaptris India for $1,877,232 to Lotus Holding, Ltd. in an effort to restructure the Company’s multilevel subsidiary - structure derived from the historical mergers and acquisitions, and to reduce overhead and administrative costs.

GBS India Private Limited

Pursuant to an existing transfer agreement, effective July 1, 2012, the Company entered into a purchase agreement with SYN for $1,877,232, which transferred all assets, including intellectual property rights, and liabilities of the IntelliPRINT and FewClix product lines, customer contracts and certain employees for operations in a new subsidiary, GBS India Private Limited, an incorporated entity formed under the Indian Companies Act 1956 (“GBS India”). A royalty fee in the amount of approximately $350,000 has been agreed upon for the benefit the Company. Additionally a profit based fee of up to $700,000 may be earned based on license and revenue recognized from the sold IntelliVIEW and IntelliVIEW NXT products.

Notes to the Interim Financial Statements

September 30, 2013

GBS Enterprises Incorporated

Unaudited

On August 1, 2012, the Company acquired 100% of the outstanding shares of capital stock of GBS India. We anticipate GBS India’s presence in India to accelerate our plan to expand our product development team particularly for our strategic offerings in India.

Pavone AG/Groupware AG

On July 6, 2012 and August 9, 2012, wholly-owned subsidiaries Pavone AG and Groupware AG, respectively, were merged into Pavone GmbH. The mergers were consummated solely for administrative purposes. Pavone GmbH is a wholly-owned subsidiary of the Company.

Pavone, Ltd.

The Company serves the UK market with GROUP’s subsidiary GBS, Ltd. Therefore, subsidiary Pavone, Ltd, as being a shell company, was dissolved on July 8, 2012.

EbVokus, GmbH.

On October 1, 2012, GROUP Business Software AG sold all of the software and operational assets (constituting substantially all of the assets) of its wholly-owned subsidiary, ebVokus GmbH, along with the associated maintenance and project agreements to a non-affiliated third party for a purchase price of approximately $459,000, approximately $258,000 (200,000 Euros: 1 EUR = $1.29 USD on October 1, 2012) was paid at closing and the remaining $201,000 was paid on February 15, 2013 (150,000 Euro: 1EUR = $1.35 USD on February 15, 2013).

B.E.R.S. AD

On November 23, 2012, GROUP Business Software AG sold its entire participation (50%) in B.E.R.S AD for a total of 25,000 BGN.

Group Live, N.V.

Group Live N.V. operating under the laws of the Netherlands and a 100% subsidiary of GROUP declared its end of business May 31, 2012, registered in the commercial register June 22, 2012. Following the local procedures the company has been dissolved from the register as per April 5, 2013, registered April 16, 2013.

132
 

NotesPART I – FINANCIAL INFORMATION

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

MARIZYME, INC.

Condensed Consolidated Balance Sheets

  September 30, 2021  December 31, 2020 
  

(Unaudited)

    
ASSETS:        
Current        
Cash $16,673  $2,902,762 
Accounts receivable  96,291   40,585 
Prepaid expense  35,000   106,390 
Inventory  15,390   56,340 
Total current assets  163,354   3,106,077 
Non-current        
Property, plant and equipment, net  1,273   7,122 
Operating lease right-of-use assets, net  1,163,159   1,317,830 
Intangible assets, net  46,385,121   42,278,211 
Prepaid royalties, non-current  340,969   344,321 
Deposits  30,000   30,000 
Goodwill  5,416,000   - 
Total non-current assets  53,336,522   43,977,484 
Total assets $53,499,876  $47,083,561 
         
LIABILITIES AND STOCKHOLDERS’ EQUITY:        
Current        
Accounts payable and accrued expenses $1,396,945  $478,103 
Due to related parties  638,530   - 
Operating lease obligations  260,106   243,292 
Total current liabilities  2,295,581   721,395 
Non-current        
Operating lease obligations, net of current potion  941,732   1,074,538 
Convertible notes, net of debt discount  179,457   - 
Derivative liabilities  391,648   - 
Contingent liabilities  9,454,000   - 
Total non-current liabilities  10,966,837   1,074,538 
Total liabilities 13,262,418  1,795,933 
         
Commitments and contingencies (Note 12)  -   - 
         
Stockholders’ equity:        
Preferred stock, $0.001 par value, 25,000,000 shares authorized, 0 shares issued and outstanding as of September 30, 2021 and December 31, 2020  -   - 
Common stock, par value $0.001, 75,000,000 shares authorized, 35,928,188 shares issued and outstanding as of September 30, 2021 and December 31, 2020  35,928   35,928 
Additional paid-in capital  82,509,957   82,077,334 
Accumulated deficit  (42,308,427)  (36,825,634)
Total stockholders’ equity  40,237,458   45,287,628 
Total liabilities and stockholders’ equity $53,499,876  $47,083,561 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

3

MARIZYME, INC.

Condensed Consolidated Statements of Operations

(Unaudited)

             
  Three Months Ended  Nine Months Ended 
  September 30,  September 30, 
  2021  2020  2021  2020 
Revenue $37,215  $124,985  $271,952  $124,985 
                 
Operating expenses:                
Direct costs of revenue  18,356   25,714   168,419   25,714 
Professional fees (includes related party amounts of $90,000, $90,000, $270,000, and $90,000, respectively)  556,254   170,753   1,808,093   494,295 
Salary expenses  617,826   433,318   2,478,357   433,318 
Stock-based compensation  64,074   1,107,085   626,449   1,674,200 
Other general and administrative expenses  536,483   453,158   1,071,017   468,782 
Total operating expenses  1,792,993   2,190,028   6,152,335   3,096,309 
Total operating loss  (1,755,778)  (2,065,043)  (5,880,383)  (2,971,324)
                 
Other income (expense):                
Interest and accretion expenses  (70,221)  -   (74,410)  - 
Change in fair value of contingent liabilities  194,000   -   472,000   - 
Total other income  123,779   -   397,590   - 
                 
Net loss $(1,631,999) $(2,065,043) $(5,482,793) $(2,971,324)
                 
Net loss per share – basic and diluted $(0.05) $(0.07) $(0.15) $(0.13)
                 
Weighted average number of shares of common stock outstanding – basic and diluted  35,928,188   29,288,226   35,928,188   23,161,329 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

4

MARIZYME, INC.

Condensed Consolidated Statements of Stockholders’ Equity

(Unaudited)

                
  Common Stock  Additional Paid-in  Accumulated    
  Shares  Amount  Capital  Deficit  Total 
Balance, December 31, 2020  35,928,188  $35,928  $82,077,334 -$(36,825,634) $45,287,628 
Sale of common stock                    
Sale of common stock, shares                    
 Issuance of common stock for acquisition                    
 Issuance of common stock for acquisition, shares                    
Issuance of warrants for acquisition                    
Issuance of warrants for services                    
 Common shares issued in lieu of AP                    
 Common shares issued in lieu of AP , shares                    
Exercise of options                    
Exercise of options, shares                    
Common stock issued for services                    
Common stock issued for services, shares                    
Stock-based compensation  -   -   334,385   -   334,385 
Issuance of common stock for services                    
Issuance of common stock for services, shares                    
Warrants issued                    
Net loss  -   -   - - (2,211,866)  (2,211,866)
Balance, March 31, 2021  35,928,188  35,928  82,411,719 -(39,037,500) 43,410,147 
Stock-based compensation  -   -   194,657   -   194,657 
Adjustment of warrants value in connection with finalizing the business combination  -   -   (732,300)  -   (732,300)
Net loss  -   -   - - (1,638,928)  (1,638,928)
Balance, June 30, 2021  35,928,188  35,928  81,874,076 -(40,676,428) 41,233,576 
Stock-based compensation  -   -   64,074   -   64,074 
Warrants issued in connection with convertible notes  -   -   571,807   -   571,807 
Net loss  -   -   - - (1,631,999)  (1,631,999)
Balance, September 30, 2021  35,928,188  $35,928  $82,509,957 -$(42,308,427) $40,237,458 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

5

MARIZYME, INC.

Condensed Consolidated Statements of Stockholders’ Equity

(Unaudited)

                   
     Additional
Paid-in
  Treasury  Accumulated    
  Shares  Amount  Capital  Stock  Deficit  Total 
Balance, December 31, 2019  19,858,939  $19,859  $59,319,594  $(16,000) $(30,980,581) $28,342,872 
Common stock issued for services  125,000   125   124,875   -   -   125,000 
Stock-based compensation  -   -   221,058   -   -   221,058 
Net loss  -   -   -   -   (471,370)  (471,370)
Balance, March 31, 2020  19,983,939  19,984  59,665,527  (16,000) (31,451,951) 28,217,560 
Common shares issued in lieu of AP  195,000   195   184,665   -   -   184,860 
Exercise of options  5,000   5   5,045       -   5,050 
Stock-based compensation  -   -   221,057   -   -   221,057 
Net loss  -   -   -   -   (434,911)  (434,911)
Balance, June 30, 2020  20,183,939  20,184  60,076,294  (16,000) (31,886,862) 28,193,616 
Sale of common stock  5,600,192   5,600   6,269,464   -   -   6,275,064 
Issuance of common stock for acquisition  10,000,000   10,000   12,490,000   -   -   12,500,000 
Issuance of warrants for acquisition  -   -   1,932,300   -   -   1,932,300 
Issuance of warrants for services  -   -   253,749   -   -   253,749 
Stock-based compensation  -   -   802,926   -   -   802,926 
Issuance of common stock for services  50,000   50   62,450   -   -   62,500 
Exercise of options for common stock  54,057   54   59,399   -   -   59,453 
Net loss  -   -   -   -   (2,065,043)  (2,065,043)
Balance, September 30, 2020  35,888,188  $35,888  $81,946,582  $(16,000) $(33,951,905) $48,014,565 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

6

MARIZYME, INC.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

       
  Nine Months Ended September 30, 
  2021  2020 
       
Cash flows from operating activities:        
Net loss $(5,482,793) $(2,971,324)
Adjustments to reconcile net loss to net cash used in operations:        
Depreciation and amortization  (76,013)  342,583 
Stock-based compensation  593,116   1,420,451 
Stock-based compensation - restricted common stock  33,333   - 
Interest and accretion  74,410   - 
Issuance of warrants for services  -   253,749 
Change in fair value of contingent liabilities  (472,000)  - 
Change in operating assets and liabilities:        
Accounts receivable  (55,706)  (93,010)
Prepaid expense  38,057   (62,487)
Inventory  40,950   21,500 
Accounts payable and accrued expenses  721,078   140,233 
Due to related parties  272,530   - 
Net cash used in operating activities  (4,313,038)  (948,305)
         
Cash flows used in investing activities:        
Purchase of intangible assets  -   (130,333)
Net cash used in investing activities  -   (130,333)
         
Cash flows from financing activities:        
Proceeds from promissory notes due to related parties  366,000   - 
Proceeds from convertible notes, net of issuance cost  1,060,949   - 
Shares issued for cash, net of offering costs  -   6,275,064 
Net cash provided by financing activities  1,426,949   6,275,064 
         
Net (decrease)/ increase in cash  (2,886,089)  5,196,426 
         
Cash at beginning of period  2,902,762   90 
         
Cash at end of period $16,673  $5,196,516 
         
Non-cash investing and financing activities:        
Derivative liabilities $391,648  $- 
Contingent liabilities $9,926,000  $- 
Warrants issued in connection with convertible notes $571,807   - 
Issuance of common stock in lieu of payables $-  $261,453 
Issuance of common stock in connection with business combination $-  $12,500,000 
Issuance of warrants in connection with business combination $-  $1,932,300 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

7

MARIZYME, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 – DESCRIPTION OF BUSINESS

Maryzime, Inc. (the “Company” or “Marizyme”) is a Nevada corporation originally incorporated on March 20, 2007, under the name SWAV Enterprises, Ltd. On September 6, 2010, the Company name was changed to the Interim Financial Statements

September 30, 2013

GBS Enterprises IncorporatedInc. and from 2010 to September 2018 the Company was in the software products and advisory services business for email and instant messaging applications. The Company divested that business between December 2016 and September 2018 and focused on the acquisition of life science technologies.

Unaudited

On March 21, 2018, the Company’s name was changed to Marizyme, Inc., to reflect the new life sciences focus. Marizyme’s common stock is currently quoted on the OTC Markets’ QB tier under the symbol “MRZM”.

Note

NOTE 2 INTERIM REPORTINGGOING CONCERN

The accompanyingCompany’s unaudited interimcondensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial statements prepared under the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America. They do not include all information and footnotes required by generally accepted accounting principles for complete financial statements. However, except as disclosed herein, they include all adjustments, which are, in the opinion of management, necessary to present fairly the financial position, results of operations and cash flows for the interim periods presented in accordance with accounting principles generally accepted in the United States of America. These interim financial statements follow the same accounting policies and methods of their application as the Company’s audited financial statements. All adjustments are of a normal recurring nature.

Operating results for the nine months ended September 30, 2013 are not necessarily indicative of the results that can be expected for the year ending December 31, 2013.

Note 3         ACCOUNTING POLICIES

The financial statements and accompanying notes are prepared in accordance with accounting principlesusing principals generally accepted in the United States of America applicable to a going concern, which contemplates the morerealization of assets and liquidation of liabilities in the normal course of business. However, the Company does not have an established source of revenues sufficient to cover its operating costs and to allow it to continue as a going concern. The Company, since its inception, has incurred recurring operating losses and negative cash flows from operations and has an accumulated deficit of $42,308,427 at September 30, 2021. Additionally, the Company has negative working capital of $2,132,227 and $16,673 of cash on hand. These factors raise substantial doubt about the Company’s ability to continue as a going concern.

Under the going concern assumption, an entity is ordinarily viewed as continuing its business for the foreseeable future with neither the intention or necessity of liquidation, ceasing trading, or seeking protection from creditors pursuant to the laws and regulations. Accordingly, assets and liabilities are recorded on the basis that the entity will be able to realize its assets and discharge its liabilities in the normal course of business.

The ability of the Company to continue as a going concern is dependent upon its ability to continue to successfully develop its intangible assets, receive an approval from the U.S. Federal and Drug Administration (the “FDA”) to extend the selling of the products into the U.S. market which will allow the Company to attain profitable operations.

During the next twelve months, the Company’s foreseeable cash requirements will relate to continuous operations of its business, maintaining its good standing and making the required filing with the Securities and Exchange Commission (the “SEC”), and the payment of expenses associated with its product development. The Company may experience a cash shortfall and be required to raise additional capital. Management intends to raise additional funds by way of a private or public offering. While the Company believes in the viability of its strategy to continue to develop and expand its products and generate sufficient revenue and in its ability to raise additional funds, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and generate sufficient revenue and its ability to raise additional funds by way of a public or private offering.

The unaudited condensed consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation and Principles of Consolidation

The accompanying unaudited condensed consolidated financial statements include the consolidated accounts of the Company and its wholly owned subsidiaries, Somahlution, Inc. (“Somahlution”), Somaceutica, Inc. (“Somaceutica”) and Marizyme Sciences, Inc. (“Marizyme Sciences”). All intercompany transactions have been eliminated on consolidation.

The accompanying unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q have been prepared in conformity with generally accepted accounting principles in the U.S. (“U.S. GAAP”). The unaudited condensed consolidated financial statements presented in this Quarterly Report should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form 10-K filed with the SEC on April 15, 2021 (the “2020 Form 10-K”). The balance sheet as of December 31, 2020 was derived from audited consolidated financial statements included in the 2020 Form 10-K but does not include all disclosures required by U.S. GAAP for complete financial statements. The Company’s significant accounting policies are described in Note 3 to those consolidated financial statements.

Interim results may not be indicative of the results that may be expected for the full year. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these interim financial statements. The unaudited condensed consolidated financial statements reflect all adjustments which in the opinion of management are necessary for a fair statement of results of operations, financial condition, cash flows and stockholders’ equity for the periods presented. Except as follows:otherwise disclosed, all such adjustments are of a normal recurring nature.

8

Critical Accounting Policies andUse of Estimates

The preparation of the unaudited condensed consolidated financial statements in conformityaccordance with accounting principles generally accepted in the United States of AmericaU.S. GAAP requires management to make use of certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosuresdisclosure of contingent assets and liabilities atas of the date of the consolidated financial statements and the reported amounts of revenuesrevenue and expenses during the reporting period.reported periods. The Company bases its estimates on historical experience and on various other assumptions that management believes are reasonable under the circumstances, the results of which form the basis for making judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. Significant estimates are related to the allocation of the purchase price in a business combination to the underlying assets and liabilities, recoverability of long-term assets including intangible assets and goodwill, amortization expense, valuation of warrants, stock-based compensation, derivative liabilities, contingent liabilities and deferred tax valuations.

Fair Value Measurements

The Company uses the fair value hierarchy to measure the value of its financial instruments. The fair value hierarchy is based on inputs to valuation techniques that are used to measure fair value that are either observable or unobservable. Observable inputs reflect assumptions market participants would use in pricing an asset or liability based on market data obtained from independent sources, while unobservable inputs reflect a reporting entity’s pricing based upon its own market assumptions. The basis for fair value measurements for each level within the hierarchy is described below:

Level 1 – Quoted prices for identical assets or liabilities in active markets.
Level 2 – Quoted prices for identical or similar assets and liabilities in markets that are not active; or other model-derived valuations whose inputs are directly or indirectly observable or whose significant value drivers are observable.
Level 3 – Valuations derived from valuation techniques in which one or more significant inputs to the valuation model are unobservable and for which assumptions are used based on management estimates.

The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value.

 

Segment Reporting

The Financial Accounting Standards Board (“FASB”) authoritative guidance regarding segment reporting establishes standards for the way that public business enterprises report information about operating segments in annual financial statements and requires that those enterprises report selected information about operating segments in interim financial reports. It also establishes standards for related disclosures about products and services, geographic areas and major customers. The Company has determined that it operates in only one segment – the development and maintenancecarrying amounts of computer software programs and support products.

Notes to the Interim Financial Statements

September 30, 2013

GBS Enterprises Incorporated

Unaudited

Comprehensive Income (Loss)

The Company adopted the FASB Codification topic (“ASC”) 220, “Reporting Comprehensive Income”, which establishes standards for the reporting and display of comprehensive income and its components in the financial statements. Comprehensive income consists of net income and other gains and losses affecting stockholder's equity that are excluded from net income, such as unrealized gains and losses on investments available for sale, foreign currency translation gains and losses and minimum pension liability. Since inception, the Company’s other comprehensive income represents foreign currency translation adjustments and small net actuarial losses on pension plans.

Net Income per Common Share

ASC 260, “Earnings per share,” requires dual presentation of basic and diluted earnings per share (EPS) with a reconciliation of the numerator and denominator of the EPS computations. Basic earnings per share amounts are based on the weighted average shares of common stock outstanding. If applicable, diluted earnings per share would assume the conversion, exercise or issuance of all potential common stock instruments such as options, warrants and convertible securities, unless the effect is to reduce a loss or increase earnings per share. Diluted net income (loss) per share on the potential exercise of the equity-based financial instruments is not presented where anti-dilutive. Accordingly, although the diluted weighted average number of common stock outstanding is disclosed on the statements of operation, the calculated net loss per share is the same for both the basic and diluted as both are based on the basic weighted average of common stock outstanding. There were no adjustments required to net income for the period presented in the computation of diluted earnings per share.

Financial Instruments

Financial instruments consist ofcertain cash and cash equivalents, accounts and other receivable, financial assets, notes payable, liabilities to banks, accounts payable and accrued liabilitiesexpenses, and other liabilities,amounts due to related parties and retirement benefit obligations. Financial assets and liabilities are measured upon first recognition and reviewed at the financial statement date. Changes inapproximate fair value are recognized through profit and loss. Unless otherwise noted, it is management’s opinion that the Company is not exposed to significant interest or credit risks arising from these financial instruments.

Notesdue to the Interim Financial Statementsshort-term nature of these instruments.

September 30, 2013

GBS Enterprises IncorporatedThe fair value of lease obligations is determined using discounted cash flows based on the expected amounts and timing of the cash flows discounted using a market rate of interest adjusted for appropriate credit risk.

Unaudited

The contingent liabilities assumed on the acquisition of Somah (Note 4) consist of present values of royalty payments, performance warrants and pediatric voucher warrants, future rare pediatric voucher sales, and liquidation preference. Management measured these contingencies in accordance with Level 3 of the fair value hierarchy.

Currency Risk

i.The performance warrants and pediatric vouchers warrants liabilities were valued using a Monte Carlo simulation model utilizing the following weighted average assumptions: risk free rate of 1.19%, expected volatility of 69.62%, expected dividend of $0, and expected life of 6.21 years. For the three and nine months ended September 30, 2021, changes in these assumptions resulted in $574,000 and $1,870,000 decrease in fair value of these liabilities, respectively. At September 30, 2021 the fair market value of performance warrants and pediatric vouchers warrants liabilities was $2,899,000.
ii.The present value of royalty payments was measured using the scenario-based methodology. In assessing the value attributed to the royalty payments, the estimated future cash flows were discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the revenue from net sales of the product. The cash flows derived from the Company’s fifteen-year strategic plan are based on managements’ expectations of market growth, industry reports and trends, and past performances. These projections are inherently uncertain due to the evolving impact of the COVID-19 pandemic. The discounted cash flow model included projections surrounding revenue, discount rates, and growth rates. The discount rates used to calculate the present value of royalty payments reflect specific risks of the Company and market conditions and the mid-range was estimated at 20.6%. For the three and nine months ended September 30, 2021, changes in these assumptions resulted in $380,000 and $1,396,000 increase in fair value of these liabilities, respectively. At September 30, 2021 the fair market value of royalty payments was $3,582,000.
iii.Rare pediatric voucher sales liability was valued based on the scenario-based methodology where the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset – 20.6%. For the three and nine months ended September 30, 2021, changes in these assumptions resulted in $Nil and $2,000 increase in fair value of this liability, respectively. At September 30, 2021 the fair market value of rare pediatric vouchers was $1,150,000.
iv.The present value of liquidation preference liability, included in the contingent consideration, was determined using the Black-Scholes option pricing method and represents the fair value of the maximum payment amount according to the Agreement. The following assumptions were used in the Black-Scholes option pricing model: risk free rate of 0.21%, expected volatility of 78.93%, expected dividend of $0, and expected life of 5 years. No changes to the fair value of liquidation preference liability were recorded in the three and nine months ended September 30, 2021. At September 30, 2021 the fair market value of liquidation preference was $1,823,000.

We use the US dollar as our reporting currency. The functional currenciesderivative liabilities consisted of our significant foreign subsidiaries are the local currency, which includes the Euro, the British Pound, the Indian Rupee,optional and automatic conversion features and the Bulgarian Lev. Accordingly, some assets and liabilities are incurred in those currencies and we are subjectshare redemption feature attached to foreign currency risks.the convertible notes, issued pursuant to the Unit Purchase Agreement (Note 9).

Fair Value Measurements

9

The Company follows ASC 820, “Fair Value Measurements and Disclosures”, for allhas no financial instruments and non-financial instruments accounted forassets measured at fair value on a recurring basis. This new accounting standard establishes a single definitionNone of fair value and a framework for measuring fair value, sets out a fair value hierarchy to be used to classify the source of information used in fair value measurement and expands disclosures about fair value measurements required under other accounting pronouncements. It does not change existing guidance as to whetherCompany’s non-financial assets or not an instrument is carried at fair value. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities which are required to be recorded at fair value on a non-recurring basis. No transfers between levels have occurred during the Company considersperiods presented.

Marizyme measures the principal or most advantageous market in which the Company would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as inherent risk, transfer restrictions and credit risk.

The Company has adopted ASC 825, Financial Instruments, which allows companies to choose to measure eligiblefollowing financial instruments and certain other items at fair value that are not required to beon a recurring basis. As at September 30, 2021, the fair values of these financial instruments were as follows:

SCHEDULE OF FAIR VALUES OF FINANCIAL INSTRUMENTS

  Fair Value Hierarchy    
September 30, 2021 Level 1  Level 2  Level 3  December 31, 2020 
Liabilities                
Derivative liabilities $-  $-  $391,648  $- 
Contingent liabilities  -   -   9,454,000   - 
Total $-  $-  $9,845,648  $- 

The following table provides a rollforward of all liabilities measured at fair value. The Company has not elected the fair value option for any eligible financial instruments.using Level 3 significant unobservable inputs:

RECONCILIATION OF LIABILITIES AT FAIR VALUE

September 30, 2021 Contingent Liabilities 
Balance at December 31, 2020  - 
Derivative liabilities $391,648 
Initial valuation of contingent liabilities in connection with the Somah acquisition1 9,926,000 
Change in fair value of contingent liabilities  (472,000)
Balance at September 30, 2021 $9,845,648 

 

Cash

1Measured as at Somah acquisition date of July 31, 2020, see Note 4.

Intangible Assets and cash equivalentsGoodwill

The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents.

Inventories

Pursuant to ASC 330 (Inventories), inventories held for sale are recognized under inventories. Inventories were measured at the lower of cost or market. Cost is determined on a first-in-first out basis, without any overhead component.

Notes to the Interim Financial Statements

September 30, 2013

GBS Enterprises Incorporated

Unaudited

Goodwill and other Intangible Assets

Intangible assets predominately comprise goodwill, acquired softwareare recorded at cost less accumulated amortization and capitalized software development services.accumulated impairment losses. Intangible assets acquired in exchange for payment are reflected at acquisition costs. If the development costs can be capitalized per ASC 985-20-25, these are reflected as ascribable personnel and overhead costs.

Company created software can be intended for sale to third parties or used by the Company itself. If the conditions for capitalization are not met, the expenses are recorded with their effect on profit in the year in which they were incurred.

The Company amortizes intangible assets with a limited useful life to the estimated residual book value in accordance with ASC regulations. In addition, in special circumstances according to ASC 350-30, a recoverability test is performed and, if applicable, unscheduled amortization is considered.

The useful life of acquired software is between three and five years and three years for Company created software.

Intangible assets obtained as partresult of an acquisition which do not meetor in a business combination are measured at fair value at the criteriaacquisition date.

The useful lives of intangible assets are assessed as either finite or indefinite. Intangible assets with finite lives are amortized over the estimated useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The estimated useful life and amortization method are reviewed at the end of each reporting period, with the effect of any changes in estimates being accounted for on a separate entry are identified as goodwill. prospective basis.

Goodwill is reviewed once a year during an impairment test, wherebyrepresents the appraisedexcess of the purchase price paid for the acquisition of subsidiaries over the fair value of the invested capitalnet assets acquired. Following the initial recognition, goodwill is measured at cost less any accumulated impairment losses.

In-Process Research and Development

The Company evaluates whether acquired intangible assets are a business under applicable accounting standards. Additionally, the Company evaluates whether the acquired assets have a future alternative use. Intangible assets that do not have future alternative use are considered acquired in-process research and development. When the acquired in-process research and development assets are not part of a business combination, the value of the reporting unit,consideration paid is compared with the carrying (book) value of its invested capital amount (including goodwill.) Use value is generally applied in order to determine the recoverability of goodwill and intangible assets with an indefinite useful life. The projected financial plan prepared by the management serves as the basis for this determination of use value and the planning assumptions are each adjusted for the current state of knowledge. Reasonable assumptions regarding macroeconomic trends and historical developments are taken into account in making these adjustments. Future estimated cash flows are determined basedexpensed on the expected growth ratesacquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred.

Impairment of the markets in question.Long-Lived Assets

 

IfThe Company reviews long-lived assets, including property, plant and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the reporting unit exceedsassets may not be fully recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the appraised fair value,use of the impairment based on use value measuresasset and its eventual disposition are less than the amount ofcarrying amount. The impairment loss, if any, and an unscheduled amortization expense is recorded. If the appraised value of the reporting unit exceeds its carrying amount, goodwill of the reporting unit is not considered torecognized, would be impaired.

Property, Plant and Equipment

Property, plant and equipment are valued at acquisition or manufacturing costs reduced by scheduled and, if necessary, unscheduled depreciation. Fixed assets are depreciated on a straight-line basis, prorated over their expected useful life. Scheduled depreciation for property, plant and equipment is based on useful lives of 3 to 10 years. Leasehold Improvements are depreciated up to 40 years.

Notes to the Interim Financial Statements

September 30, 2013

GBS Enterprises Incorporated

Unaudited

If fixed assets are sold, retired or scrapped, the profit or loss arising from the difference between the net sales proceeds and the residual book value are included under other operating earnings and expenses.

Impairment or Disposal of Long-Lived Assets

The Company evaluates the recoverability of its fixed assets and other assets in accordance with ASC topic, 360.10. This guidance requires recognition of impairment of long-lived assets in the event the net book value of such assets exceeds its’ expected cash flows or appraised value In this instance, the asset is considered to be impaired and is written down to fair value.

Revenue Recognition

Sources of Revenues:

License revenues

Our license revenues consist of revenues earned from the licensing of our software products. These products are generally licensed on a perpetual basis. Pricing models have generally been based either upon the physical infrastructure, such as the number of physical desktop computers or servers, on which our software runs or on a per user basis. License revenues are recognized when the elements of revenue recognition for the licensed software are complete, generally upon electronic shipment of the software and the software key to provide full access to all functionalities for our customers. In general, our invoices reflect license, service and maintenance components. In the case of multi element contracts, the revenues allocated to the software license in most cases represent the residual amount of the contract after the fair value of the other elements has been determined. Certain products of our software offering are licensed on a subscription basis.

Software maintenance revenues

Software maintenance revenues are recognized ratably on a pro-rata basis over the range of the contract period. Our contract periods typically range from one to five years. Vendor-specific objective evidence (“VSOE”) of fair value for software maintenance services is established by the rates charged in stand-alone sales of software maintenance contracts or the stated renewal rate for software maintenance. Customers who are party to software maintenance agreements with us are entitled to receive support, product updates and upgrades on a when-and-if-available basis.

Notes to the Interim Financial Statements

September 30, 2013

GBS Enterprises Incorporated

Unaudited

Professional services revenues

Professional services include pre-project consulting, software design, customization, project management, implementation and training. Professional services are not considered essential to the functionality of our products, as these services do not alter the product capabilities and may be performed by our customers or by other vendors. Professional services engagements performed for a fixed fee, for which we are able to make reasonably dependable estimates of progress toward completion, are recognized on a proportional performance basis based on hours incurred and estimated hours of completion. Professional services engagements that are on a time and materials basis are recognized based on hours incurred. Revenues on all other professional services engagements are recognized upon completion. Our professional services may be sold with software products or on a stand-alone basis. Vendor Specific Objective Evidence (VSOE) of fair value for professional services is based upon the standard rates we charge for such services when sold separately.

Foreign Currency Translation

The functional currency of the Company is US dollars. For financial reporting purposes, the financial statements of the subsidiary companies whose functional currency is other than US dollars were translated into US dollars using the current rate method. Assets and liabilities were translated at the exchange rates at the balance sheet dates, revenue and expenses were translated at the average exchange rates and stockholders’ equity was translated at historical exchange rates. Any translation adjustments resulting are not included in determining net income but are included in foreign exchange adjustment to other comprehensive income, a component of stockholders’ equity.

Other Provisions

According to FASB ASC 450 “Contingencies”, provisions are made whenever there is a current obligation to third parties resulting from a past event which is likely in the future to lead to an outflow of resources and of which the amount can be reliably estimated. Provisions not already resulting in an outflow of resources in the following year are recognized at their discounted settlement amount on the financial statement date. The discount taken is based on market interest rates. The settlement amount also includes the expected cost increases. Provisions are not set off against contribution claims. If the amended estimate leads to a reduction of the obligatory amount, the provision is proportionally reversed and the earnings are recognized in other operating earnings.

Notes to the Interim Financial Statements

September 30, 2013

GBS Enterprises Incorporated

Unaudited

Deferred Taxes

Income taxes are provided in accordance with FASB Codification topic 740, “Accounting for Income Taxes”. A deferred tax asset or liability is recorded for all temporary differences between financial and tax reporting and net operating loss-carry forwards.

Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that, that some portion or all of the deferred tax asset will not be realized. Deferred tax assets and liabilities are adjusted for the effect of changes in tax laws and rates on the date of enactment.

Recent Accounting Pronouncements

In July 2012, the FASB issued ASU 2011-08, Intangibles – Goodwill and Other (Topic 350): Testing Goodwill for Impairment. With the objective of reducing the cost and complexity of performing an impairment test for indefinite-lived intangible assets by simplifying how an entity tests those assets for impairment and to improve consistency in impairment testing guidance among long-loved asset categories. The amendments permit an entity first to assess qualitative factors to determine whether it is more likely than not that an indefinite-lived intangible asset is impaired as a basis for determining whether it is necessary to perform the quantitative impairment test in accordance with Subtopic 350-30, Intangibles – Goodwill and Other – General Intangibles Other than Goodwill. The more-likely-than-not threshold is defined as having the likelihood of more than 50 percent. The amendments are effective for annual and interim impairment tests performed beginning April 1, 2013. Adoption of this new standard is not expected to have significant impact to the Company’s financial statement.

Off - Balance Sheet Arrangements

We have not entered into any other financial guarantees or other commitments to guarantee the payment obligations of any third parties. We have not entered into any derivative contracts that are indexed to our shares and classified as shareholder’s equity or that are not reflected in our consolidated financial statements. Furthermore, we do not have any retained or contingent interest in assets transferred to an unconsolidated entity that serves as credit, liquidity or market risk support to such entity. We do not have any variable interest in any unconsolidated entity that provides financing, liquidity, market risk or credit support to us or engages in leasing, hedging or research and development services with us.

Notes to the Interim Financial Statements

September 30, 2013

GBS Enterprises Incorporated

Unaudited

Principles of Consolidation and Reverse Acquisition

As previously disclosed, the Company has exchanged a total of 5,405,411 shares of common stock in exchange for 50.1% of the outstanding common shares of GROUP. Although the Company was the legal acquirer, the transaction was accounted for as a recapitalization of GROUP in the form of a reverse merger, whereby GROUP becomes the accounting acquirer and is deemed to have retroactively adopted the capital structure of the Corporation. Accordingly, the accompanying consolidated financial statements reflect the historical consolidated financial statements of GROUP for periods presented prior to January 6, 2011. All costs associated with the reverse merger transaction were expensed as incurred. Those expenses totaled approximately $300,000 and were included in professional fees in administrative expenses.

The Company has based its financial reporting for the consolidation with GROUP in accordance with the FASB ASC 805-40 as it relates to reverse acquisitions. Goodwill has been measured as the excess of the faircarrying value of the consideration effectively transferredimpaired asset over its respective fair value. NaN impairment losses have been recorded through September 30, 2021.

Segment Reporting

Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assess performance. The Company the acquiree, for financial reporting purposes, overviews its operations and manages its business as 1 operating segment.

Net Loss Per Share

Basic net loss per share is computed by dividing the net amountloss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. Dilutive common stock equivalents are comprised of unvested common stock, options and warrants. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the Company’s recognized identifiable assetspotentially dilutive securities (warrants, stock options, and liabilities.common shares subject to repurchase) would be antidilutive.

 

WeRecently Adopted Accounting Standards

There are no recently adopted accounting standards and recent accounting standards not yet adopted that the Company believes will have recorded the acquired assets and liabilities of Group Business Software Enterprises, Inc.a material impact on the acquisition date of January 6, 2011, at their fair value and the operations of Group Business Software Enterprises, Inc. have been included in theCompany’s unaudited condensed consolidated financial statements since the acquisition date.statements.

The assets and liabilities of GROUP, the acquirer for financial reporting purposes, are measured and recognized in the consolidated financial statements at their precombination carrying amounts in accordance with ASC 805-40-45-2(a). Therefore, the non-controlling interest reflects the non-controlling shareholders’ proportionate interest in the pre-combination carrying amounts of GROUP’s net assets even though the non-controlling interests in other acquisitions are measured at their fair values at the acquisition date.

NOTE 4         DISCONTINUED OPERATIONS

Due to the Company’s perceived increase in the demand for Modernization, Mobility and Optimization offerings, the Company made a strategic decision in 2012 to focus on its core offerings in the IBM Notes and Domino market and to divest its non-core businesses. As a result, on February 1, 2013, GBS entered into a Stock Purchase Agreement, dated February 1, 2013 (the “Agreement”), with IDC Global, Inc., a Delaware corporation and a wholly-owned subsidiary of GBS (“IDC”), and Global Telecom & Technology Americas, Inc., a Virginia corporation (“GTT). Pursuant to the Stock Purchase Agreement, we sold 100% of the issued and outstanding capital stock of IDC to GTT for an aggregate purchase price of $4,600,000 (the “Purchase Price”),

Notes to the Interim Financial Statements

September 30, 2013

GBS Enterprises Incorporated

Unaudited

Discontinued Operations and their results of operations, financial positions and cash flows are shown separately for the nine months ended on September 30, 2012 for comparative purposes. Summarized financial information for discontinued operations is set forth as follows:

Revenues
Services(2,648,976)
Cost of goods sold
Products(1,278,740)
Services(589,808)
Operating expenses
Selling expenses(554,448)
Administrative expenses(109,845)
General expenses(33,250)
Operating income(82,885)
Other Income (expense)
Other Income (expense)(13,486)
Income (loss) before income taxes(96,371)

Note 5          SUBSIDIARY COMPANIES

The subsidiaries listed below were included in the basis of consolidation (KUSD = 1,000’s of US Dollars):

    Stockholders' Equity as of 9/30/2013  Percentage of Subscribed Capital    Profit of the consolidated quarter  Date of the First
  Headquarters KUSD  KUSD  in %  Ownership KUSD   Consolidation
                   
                   
GROUP Business Software (UK) Ltd. Manchester  -1,236   23   50,1% I  93  12/31/2005
GROUP Business Software Corp. Woodstock  -15,601   1   50,1% I  225  12/31/2005
GROUP LIVE N.V. Den Haag  1,274   134   50,1% I  -3  12/31/2005
Permessa Corporation Waltham  10   0   50,1% I  0  9/22/2010
Relavis Corporation Woodstock  -842   2   50,1% I  -23  1/8/2007
GROUP Business Software AG Eisenach  9,973   36,107   50,1% I  291  6/1/2011
Pavone GmbH Boeblingen  -863   47   100.0% D  334  1/4/2011
Groupware Inc. Woodstock  -482   1   100.0% D  0  1/6/2011
GBS India Chennai  191   12   100.0% D  46  9/30/2012

D - Direct Subsidiary

I -   Indirect Subsidiary

Indirect Subsidiaries are owned 50.1% through GROUP Business Software AG

Notes to the Interim Financial Statements

September 30, 2013

GBS Enterprises Incorporated

Unaudited

Note 6          CASH AND CASH EQUIVALENTS

As of the financial statement date, the Company’s cash and cash equivalents totaled 259 KUSD (December 31, 2012 restated year end: 1,155 KUSD). Included in that amount are cash equivalents of 3 KUSD (December 31, 2012 restated year end: 3 KUSD).

Note 7          ACCOUNTS RECEIVABLE

As of the financial statement date, Accounts Receivable was 3,528 KUSD (December 31, 2012 restated year end: 4,143 KUSD). Receivables are generally measured at their nominal value and taking into account all foreseeable risks. Probable default risks are handled with specific allowances for bad debts. With regard to the trade receivables which are neither impaired nor delinquent, there are no indications as of the financial statement date that the debtors will not meet their payment obligations.

Note 8          PREPAID EXPENSES

Prepaid expenses in the amount of 208 KUSD were primarily recorded for prepaid rent, insurance and advance on technological collaboration events (December 31, 2012 restated year end: 84 KUSD).

Note 9          OTHER RECEIVABLES - CURRENT

Other Receivables as of the financial statement date were 277 KUSD (December 31, 2012 restated year end: 677 KUSD) which includes tax deposits (248 KUSD), benefit credits (14 KUSD), other deposits (4K USD) and other miscellaneous receivables (11 KUSD).

2310
 

Notes toRecently Issued Accounting Pronouncements

The Company assesses the Interim Financial Statements

September 30, 2013

GBS Enterprises Incorporated

Unaudited

Note 10          DEFERRED TAX ASSETS

Deferred tax assets asadoption impacts of the financial statement date were 1,076 KUSD (December 31, 2012 restated year end: 1,132 KUSD). All deferred tax assets are long term.

Deferred Tax Assets KUSD  KUSD 
  9/30/2013  12/31/2012 
       
Deferred Tax Assets – Current  0   0 
         
Deferred Tax Assets – Non-current  1,076   1,132 
         
Balance  1,076   1,132 

Note 11          PROPERTY, PLANT AND EQUIPMENT

Property, plant and equipment are measured at cost less scheduled straight-line depreciation. Depreciation of the computer hardware listed as office equipment is distributed over a period of three to five years. The depreciation period for other office equipment is three to ten years. Office furnishings are depreciated over a period of eight to ten years. Leasehold Improvements are depreciated up to 40 years.

Property, Plant and Equipment 
kUSD
 Development
of the cost
  Development
of
accumulated
depreciation
  Balance 
          

12/31/2012

  7,219.4   6,893.7   325.7 
Additions  42   12     
Disposals  33   6     
Currency differences  8   3     
Reclassifications  0   0     
9/30/2013  7,219.4   6,893.7   325.7 

Notes to the Interim Financial Statements

September 30, 2013

GBS Enterprises Incorporated

Unaudited

Note 12         OTHER RECEIVABLES NON-CURRENT

The major components of the Non-current Receivables include the following:

  KUSD
Restated
  KUSD
Restated
 
  9/30/2013  12/31/2012 
       
Cooperative shares  1   0 
Intercompany Loan Values during the quarter  0   0 
Other long term receivables  0   428 
Balance  1   428 

Note 13         GOODWILL

Goodwill derives from the following business acquisitions:

 30-Sep-13 Date of
first
Consolidation
  12/31/2012    Additions   Adjustments     Written off    9/30/2013  
GROUP Business Software AG 1/6/2011  18,425.6   -   -   -   18,425.60 
GROUP Business Software (UK) Ltd. 12/31/2005  2,765.1   -   -   -   2,765.10 
IDC Global, Inc. 7/25/2011  2,994.4           (2,994.4)  0.00 
Permessa Corporation 9/22/2011  2,387.4   -   -   -   2,387.40 
Pavone GmbH 1/4/2011  5,950.5   -   -   -   5,950.50 
GBS India 8/1/2012  1,731.9   -   -   -   1,731.90 
     34,254.9   -   -   -   31,260.50 

Note 14          SOFTWARE

Development costs

The costs of developing new software products and updating products already marketedrecently issued accounting standards by the Company are generally recognized as expenses inFinancial Accounting Standards Board or other standard setting bodies on the period in which they arise. Provided they meet the conditions for capitalization as per FASB ASC 985-20-25, they are capitalized. Capitalized development costs can be attributed to the defined products. These products are technically realizable and there is a target market for them.

The development costs arising in the reporting period result from the personnel costs attributed to the development workCompany’s financial statements as well as overhead costs, providedmaterial updates to previous assessments, if any, from the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. There were no new material accounting standards issued in the nine months ended September 30, 2021, that these are related toimpacted the development work and do not represent general administrative costs. The ascribable overhead costs are directly recognized.Company.

Capitalized development costs are generally amortized over a period of three years starting withCOVID-19

Since December 31, 2019, the date of marketabilityoutbreak of the new products or major releases.

Notesnovel strain of coronavirus, specifically identified as “COVID-19”, has resulted in governments worldwide enacting emergency measures to combat the Interim Financial Statements

September 30, 2013

GBS Enterprises Incorporated

Unaudited

Concessions, Industrial Property Rights, Licenses

The intangible financial assets carried in this item are licenses acquired in exchange for payment.

These financial assets are measured at acquisition cost less scheduled straight-line amortization. The assets added in the scopespread of the cost price allocationvirus. These measures, which include the implementation of travel bans, self-imposed quarantine periods and physical distancing, have caused material disruptions to businesses globally resulting in an economic slowdown. Global equity markets have experienced significant volatility and weakness. The duration and impact of the business divisions acquiredCOVID-19 outbreak is unknown at this year.

The useful life spans were based uniformly throughouttime, as is the Company according to those used by the parent company. Scheduled amortization is performed over a period from three to ten years.

The useful lifeefficacy of the domain “gbs.com”, was estimated as unlimited. This is because no other legal, contractual or other factors exist which would limit its useful life.government and central bank interventions. It is not systematically amortized, but rather annually. Should there exist signs indicating towards impairment it is tested for recoverabilitypossible to reliably estimate the length and if necessary, written down toseverity of these developments and the amount which could be obtained for it if sold.

Amortization of concessions, industrial property and similar rights and assets, as well as licenses to such rights and assets are presented in the Statement of Operations and Comprehensive Income/Loss within Cost of Goods Sold.

Concessions and licenses
kUSD
 Development
of the cost
  Development
of
accumulated
depreciation
  Balance 
          

12/31/2012

  31,913.9   21,341   10572.9 
Additions  907   159     
Disposals  1,018   122     
Currency differences  143   126     
Reclassifications  0   0     
9/30/2013  31,913.9   21,341.0   10,572.9 

Note 15        OTHER ASSETS

The balance of this account of 132 KUSD primarily includes rent and other security deposits (December 31, 2012 restated year end: 156 KUSD).

Notes to the Interim Financial Statements

September 30, 2013

GBS Enterprises Incorporated

Unaudited

Note 16        LIABILITIES TO BANKS – CURRENT

Included in this account of 3,888 KUSD (December 31, 2012 restated year end: 7 KUSD) is primarily an operating line of creditof GROUP AG.

Note 17       ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

Trade payables

As ofimpact on the financial statement date, trade accounts payable amounted to 2,061 KUSD (December 31, 2012 restated year end: 3,095 KUSD). Trade payables are carried at their repayment amountresults and all have a residual term of up to one year.

Other Accrual

Other provisions are created as of the financial statement date in an amount necessary according to a reasonable commercial appraisal, to cover future payment obligations, perceivable risks and uncertain liabilities of the Company. Amounts deemed to be most likely to occur, in careful assessment, are accrued.

  12/31/2012  9/30/2013 
  KUSD  KUSD 
Tax provision  53   21 
Salary  861   599 
Vacation  315   247 
Workers Compensation Insurance Association  25   20 
Compensation Levy for Non-Employment of Severely Handicapped Persons  19   13 
Outstanding Invoices  1,059   196 
Annual accounting and consulting  128   109 
Other Provisions  446   465 
Warranties  96   82 
Provision for Legal Costs  73   68 
Severance  70   64 
Total  3,147   1,885 

Notes to the Interim Financial Statements

September 30, 2013

GBS Enterprises Incorporated

Unaudited

Provisions for salaries of 599 KUSD (December 31, 2012 restated year end: 861 KUSD) include the provisions created for the variable salaries of the sales staff for the sales objectives reached in this business period.

Vacation provisions of 247 KUSD (December 31, 2012 restated year end: 315 KUSD) include the obligations of GROUP’s companies to their employees for remaining vacation claims from the reporting period. The amount of the provision is calculated on the gross salary of the individual employee plus the employer contribution to social security/Medicare and based on the unused vacation days as of the financial statement date.

Other employment of 97 KUSD (December 31, 2012 restated year end: 114 KUSD) were accrued for severance and compensation insurance and compensation levy.

For liabilities not yet settled, a provision totaling 196 KUSD (December 31, 2012 restated year end: 1059 KUSD) was created.

Other Provisions of 465 KUSD (December 31, 2012 restated year end: 446 KUSD) include miscellaneous provisions.

Expenses of accounting and other external consultingcondition of the Company were recognized at 109 KUSD (December 31, 2012 restated year end: 128 KUSD).in future periods.

A provision for anticipated legal consulting of 68 KUSD was recorded (December 31, 2012 restated year end: 73 KUSD).

For warranty claims, a provision of 82 KUSD (December 31, 2012 restated year end: 96 KUSD) was created determined by service income.

Note 18       DEFERRED INCOME

Accruals for future periods leadingMarizyme continues to realization of sales aftermaintain business continuity during the COVID-19 pandemic and takes its cues from the U.S. government and public health officials to keep employees and business partners safe and healthy. Although the financial statement date are reported under deferred income. The deferred income items listed asresults for three and nine months ended September 30, 2021 were not significantly impacted by COVID-19, Marizyme experienced decrease in sales due to a slow-down in the product manufacturing. During 2021, Marizyme’s business partners were focused on addressing specific manufacturing needs of the financial statement dateU.S. government in battling COVID-19 pandemic. Additionally, during 2021, demand for elective surgeries have decreased due to overloaded medical systems and potential risks related to patients’ recovery during the pandemic.

The Company cannot predict the impact of the progression of COVID-19 on future results or the Company’s ability to raise capital due to a variety of factors, including but not limited to the continued good health of Company employees, the ability of suppliers to continue to operate and deliver, the ability of the Company to maintain operations, any further government and/or public actions taken in response to the pandemic and ultimately the length of the pandemic.

NOTE 4 – ACQUISITIONS

DuraGraft®

On December 15, 2019, the Company entered into a contingent asset purchase agreement (the “Agreement”), as amended on March 31, 2020 and May 29, 2020, with Somahlution, LLC, Somahlution, Inc., and Somaceutica, LLC, companies duly organized under the laws of Delaware (collectively, “Somah” or “Seller”) to acquire all of the assets and none of the liabilities of Somah (the “Acquisition”), including DuraGraft®, a one-time intraoperative vascular graft treatment for use in vascular and bypass surgeries that maintains endothelial function and structure, and other related properties.

On July 31, 2020, the Company and Somah entered into Amendment No. 3 to the Agreement and the Agreement was finalized. Pursuant to the terms of this amendment, it was agreed that, as part of the Acquisition, the Company would acquire the outstanding capital stock of Somahlution, Inc., held by Somahlution, LLC, rather than the assets of Somahlution, Inc. This change to the Agreement was made to accommodate the European Union (“EU”) requirements with respect to the future manufacturing under Somahlution, Inc. of CE marked products for sale in the amountEU. In Amendment No. 3, the Company agreed to assume certain payables of 6,847 KUSD (December 31, 2012 restated year end: 6,100 KUSD) primarily include maintenance income collected in advance forSomah related to clinical and medical expenses. It was agreed that the period afterpayments on the end of the financial statement date. They are amortized onassumed debts would be recorded as a straight-line basis over their respective contract terms.

Notes to the Interim Financial Statements

September 30, 2013

GBS Enterprises Incorporated

Unaudited

Note 19        OTHER SHORT TERM LIABILITIES

Other short-term liabilities of 242 KUSD (December 31, 2012 restated year end: 860 KUSD) and includes miscellaneous short term obligations including amounts due on business assets

Note 20         COMMON STOCK

The Company has authorized capital of 75,000,000 shares of common stock and 25,000,000 shares of “blank check” preferred stock, each with a par value of $0.001. No class of preferred stock has been designated or issued.prepaid royalty against future royalties. As of September 30, 2013, there2021 and December 31, 2020, prepaid royalties were shares 30,837,624 of common stock outstanding. At$340,969 and $344,321, respectively, and were recorded as a non-current asset.

Pursuant to the timeAgreement and in consideration of the Reverse Mergeroutstanding capital stock of Somahlution, Inc., the Company by GROUP on January 6, 2011, there were 16,500,000 shares of common stock of the Company outstanding and, as the Reverse Merger was accounted for as a recapitalization and applied retroactively, this balance is recorded as the balance outstanding since inception.agreed to issue to Somah:

Transactions occurring in 2012

·In March, 2012 another investor exercised their private purchase warrant and bought 5,00010 ,000,000 restricted shares of common stock for net proceeds of $7,500.

·Also in March, 2012, as a result of purchasing warrants at nominal value, wherein each warrant allowed the holder to purchase one common share at $0.50 for a period of three years, certain investors exercised those warrants and bought 900,000 shares of common stock for net proceeds of $450,000.

·On April 16, 2012, the Company sold 120,000 Units to Joerg Ott, the then Chief Executive Officer and Chairman of the Board of Directors of the Company, for a price of $1.50 per Unit, for a total purchase price of $180,000. Each Unit consisted of one share of Common Stock of the Company and one warrant to purchase one share of Common Stock of the Company from the date of issuance until the third anniversary date of the date of issuance for $1.50 per share. The Company sold the Units and underlying securities to Mr. Ott in reliance on Section 4(a)(2) (formerly Section 4(2)) of the Securities Act due to the fact that the issuance was isolated and did not involve a public offering of securities.

Notes to the Interim Financial Statements

September 30, 2013

GBS Enterprises Incorporated

Unaudited

·On April 28, 2012, $632,500 in notes payable were converted at $1.15 per unit into 550,000 units with each unit consisting of one common share of common stock and one warrant. Each warrant allows the holder to purchase one common share at $1.75 for a period of three years. The Company issued the Note pursuant to Section 4(a)(2) (formerly Section 4(2)) under the Securities Act due to the fact that the issuance was isolated and did not involve a public offering of securities.

·On April 30, 2012, $460,000 in notes payable to Lotus Holdings Ltd. (“Lotus Holdings”) were converted at $1.15 per unit into 400,000 units, with each unit consisting of one share of common stock and one warrant. Each warrant allows the holder to purchase one common share at $1.75 for a period of three years. The Company issued the Lotus Note pursuant to Section 4(a)(2) (formerly Section 4(2)) under the Securities Act due to the fact that the issuance was isolated and did not involve a public offering of securities.

·Also on April 30, 2012, $172,500 in debt to a company owned by Joerg Ott, the then Chief Executive Officer and Chairman of the Board of Directors of the Company, were converted at $1.15 per unit into 150,000 units, with each unit consisting of one share of common stock and one warrant. Each warrant allows the holder to purchase one common share at $1.75 for a period of three years. The Company issued the debt pursuant to Section 4(a)(2) (formerly Section 4(2)) under the Securities Act due to the fact that the issuance was isolated and did not involve a public offering of securities.

·On May 10, 2012, the Company sold 30,000 Units to Markus R. Ernst, the Chief Financial Officer of the Company, for a purchase price of $1.50 per unit, for a total purchase price of $45,000. Each unit consists of one share of common stock of the Company and one warrant, allowing the holderCompany;
Warrants to purchase one share of3,000,000 restricted common stockshares of the Company from the datewith a strike price of issuance until the third anniversary date$5.00 per common share and a term of the date of issuance for $1.50 per share. five years;
The Company, soldon a pro rata basis, shall grant the unitsSeller the following contingent consideration upon receiving the FDA final approval and underlying securities to Mr. Ernst in relianceinsurance reimbursement approval on Section 4(a)(2) (formerly Section 4(2)) of the Securities Act due to the fact that the issuance was isolated and did not involve a public offering of securities.

Notes to the Interim Financial Statements

September 30, 2013

GBS Enterprises Incorporated

Unaudited

·On May 15, 2012, the Company issued 150,000 unregistered shares of common stock to Kjell Jahn, the former selling stockholder of GroupWare, AG, a Florida corporation purchased by the Company in June 2011. The Company issued the shares in reliance on Section 4(a)(2) (formerly Section 4(2)) of the Securities Act due to the fact that the issuance was isolated and did not involve a public offering of securities.product:

 

·On July 5, 2012,Grant of performance warrants for 4,000,000 restricted common shares of the Company, entered intowith a convertible promissory note agreement (the “Loan Agreement”) with Mohammad A. Shihadah, a memberstrike price determined based on the average of the Board. Pursuant toclosing prices of the Loan Agreement, the Company issued a convertible promissory note, dated July 5, 2012 (the “Note”), to Mr. Shihadahcommon shares for the principal amount of $50,000, bearing interest at a rate of 8% per year and maturing on30 calendar days following the earlier of the first anniversary date of the datepublic announcement of issuance or such other time as described in more detail inFDA approval;
Royalties to be paid on all net sales of the Note.product acquired from Somah of 6% on the first $50 million of international net sales (and 5% on the first $50 million of U.S. net sales), 4% for greater than $50 million up to $200 million, and 2% for greater than $200 million;

The Note was convertible in full at $0.50 per share into common stock of the Company if this conversion was exercised on or before September 30, 2012. If not exercised, Mr. Shihadah would receive a 3-year warrantPayment of 10% of cash value of the rare pediatric voucher sales following the FDA approval and subsequent sale to an unaffiliated third party of a rare pediatric voucher based on Somah’s DuraGraft product;Grant of rare pediatric voucher warrants to purchase an aggregate of 250,000 commons shares with a term of five years and a strike price determined based on the average of the closing prices of the common shares at 50,000 shares of common stock at $1.00 per share.

The conversion was not exercised by September 30, 2012, therefore, as per the termsof the Loan Agreement Mr. Shihadah was issued a 3-year warrant to purchase shares at 50,000 shares of common stock at $1.00 per share.

·On July 5, 2012, the Company entered into a convertible promissory note agreement (the “Loan Agreement”) with K Group Ltd. Pursuant to the Loan Agreement, the Company issued a convertible promissory note, dated July 5, 2012 (the “Note”), to K Group Ltd. for the principal amount of $250,000, bearing interest at a rate of 8.5% per year and maturing on30 calendar days following the earlier of the first anniversary date of the datepublic announcement of issuance or such other time as described in more detail inFDA approval, and
Liquidation preference, up to a maximum of $20 million upon the Note.

Notes to the Interim Financial Statements

September 30, 2013

GBS Enterprises Incorporated

Unaudited

The Note was convertible in full at $0.50 per share into common stock of the Company if this conversion was exercised on or before September 30, 2012. If not exercised, K Group Ltd. would receive a 3-year warrant to purchase shares at 250,000 shares of common stock at $1.00 per share.

The conversion was not exercisedsale by September 30, 2012, therefore, as per the terms of the Loan Agreement K Group was issued a 3-year warrant to purchase shares at 250,000 shares of common stock at $1.00 per share.

·On July 5, 2012, the Company entered into a convertible promissory note agreement (the “Loan Agreement”) with Vitamin B Venture GmbH. Pursuant to the Loan Agreement, the Company issued a convertible promissory note, dated July 5, 2012 (the “Note”), to Vitamin B Venture GmbH for the principal amount of $252,500, bearing interest at a rate of 8.5% per year and maturing on the earlier of the first anniversary date of the date of issuanceall or such other time as described in more detail in the Note.

The Note was convertible in full at $0.50 per share into common stock of the Company if this conversion was exercised on or before September 30, 2012. If not exercised Vitamin B Venture GmbH would receive a 3-year warrant to purchase shares at 250,000 shares of common stock at $1.00 per share.

The conversion was not exercised by September 30, 2012, therefore, as per the terms of the Loan Agreement Vitamin B Venture GmbH was issued a 3-year warrant to purchase shares at 250,000 shares of common stock at $1.00 per share.

·On August 13, 2012, the Company entered into a note purchase and security agreement (the “Loan Agreement”) with John A. Moore, a member of the Board. Pursuant to the Loan Agreement, the Company issued a secured promissory note, dated October 26, 2012 (the “Note”), to Mr. Moore for the principal amount of $1,000,000, bearing interest at a rate of 20% per year and maturing on the earlier of the first anniversary date of the date of issuance or such other time as described in more detail in the Note, without any penalty for prepayment. To secure the obligations of the Company under the Note, the Company granted Mr. Moore a secured priority security interest in the Company’s Accounts Receivable and its subsidiaries located in the United States of America, as more fully described in the full text of the document.

Notes to the Interim Financial Statements

September 30, 2013

GBS Enterprises Incorporated

Unaudited

In connection with the execution of the Loan Agreement, on October 26, 2012, the Company issued the Lender a common stock purchase warrant (the “Warrant”), pursuant to which the Lender is entitled to purchase 100,000 shares of common stock at an exercise price of $0.35 until the third anniversary date of the date of issuance. The Warrant was issued in a private transaction between the Company and the Lender and was exempt from registration under the Securities and Exchange Act of 1933, as amended, pursuant to Section 4(a)(2) (formerly Section 4(2)) thereof.

In connection with the Loan Agreement, on February 22, 2013, the Company and Mr. Moore amended the Note pursuant to which Mr. Moore agreed to convert the interest due under the Note into shares of GBSX common stock at a rate of $0.30 per share. Pursuant to the amendment, the Company issued 450,960 shares of Common Stock to Mr. Moore. The Company issued the shares in reliance on Section 4(a)(2) (formerly Section 4(2)) of the Securities Act due to the fact that the issuance was isolated and did not involve a public offering of securities.

·On October 26, 2012, the Company entered into a note purchase and security agreement (the “Loan Agreement”) with Stephen D. Baksa, a member of the Board. Pursuant to the Loan Agreement, the Company issued a secured promissory note, dated October 26, 2012 (the “Note”), to Mr. Baksa for the principal amount of $1,000,000, bearing interest at a rate of 20% per year and maturing on the earlier of the first anniversary date of the date of issuance or such other time as described in more detail in the Note, without any penalty for prepayment. To secure the obligations of the Company under the Note, the Company granted the Baksa a first priority security interest insubstantially all of the Company’s right, title and interest in andassets relating to the sharesSomah products. Upon the sale of IDC Global, Inc. then owned by the Company. The Note contains customary provisions upon an Event of Default, as more fully described in the full texteither or both of the document.DuraGraft or Somah derived solid organ transplant products, the Company will pay 15% of the net sale proceeds towards the liquidation preference maximum amount.

Notes

11

On July 30, 2020, the Company completed the acquisition of Somah (the “Somah Transaction”). The acquisition of Somah provides the Company with access to DuraGraft and other related intangible assets, which upon approval by FDA, will further the Interim Financial StatementsCompany’s continued growth and international-wide product rollout.

September 30, 2013

GBS Enterprises Incorporated

Unaudited

In connectionaccordance with ASC 805-10 the substance of a transaction constitutes a business combination as the business of Somah meets the definition of a business under the standard. Accordingly, the transaction was accounted for in accordance with the executionacquisition method of accounting, and the assets acquired, and the liabilities assumed have been recorded at their respective estimated fair values as of the Loan Agreement,acquisition date. The purchase price is based on October 26, 2012, the Company issued the Lender a common stock purchase warrant (the “Warrant”), pursuant to which the Lender is entitled to purchase 500,000 sharesmanagement’s estimate of common stock at an exercise price of $0.20 until the third anniversary date of the date of issuance. The Warrant was issued in a private transaction between the Company and the Lender and was exempt from registration under the Securities and Exchange Act of 1933, as amended, pursuant to Section 4(a)(2) (formerly Section 4(2)) thereof. On February 12, 2013, Mr. Baksa exercised the right to purchase 500,000 shares of common stock at the exercise price of $0.20.

In connection with the Loan Agreement, on February 22, 2013, the Company and Mr. Baksa amended the Note pursuant to which Mr. Baksa agreed to convert the interest due under the Note into shares of GBSX common stock at a rate of $0.30 per share. Pursuant to the amendment, the Company issued 200,000 shares of Common Stock to Mr. Baksa. The Company issued the shares in reliance on Section 4(a)(2) (formerly Section 4(2)) of the Securities Act due to the fact that the issuance was isolated and did not involve a public offering of securities

Transactions occurring in 2013

·As stated above, on February 12, 2013, and in connection with the above October 26, 2012 Loan Agreement the Company issued an aggregate of 500,000 restricted shares of Common Stock to Board Member, Stephen Baksa pursuant to exercise of a common stock purchase warrant issued on October 26, 2012 and exercisable for $0.20 per share. The Company issued the securities in reliance on Section 4(a)(2) (formerly Section 4(2)) of the Securities Act due to the fact that the issuance was isolated and did not involve a public offering of securities.

·On February 12, 2013, the Company sold an aggregate of 250,000 restricted shares of Common Stock to an Accredited Investor (as that term is defined the Securities Act) pursuant to exercise of a common stock purchase warrant issued on November 30, 2012 and exercisable for $0.20 per share. The Company issues the securities in reliance on Section 4(a)(2) (formerly Section 4(2)) of the Securities Act due to the fact that the issuance was isolated and did not involve a public offering of securities.

Notes to the Interim Financial Statements

September 30, 2013

GBS Enterprises Incorporated

Unaudited

As of March 31, 2013, these shares had not yet been issued and remain as Subscriptions Receivable.

·As stated above, on February 22, 2013 and in connection with the above August 13, 2012 Loan Agreement, the Company and Board Member, John Moore amended the Note pursuant to which Mr. Moore agreed to convert the interest due under the Note into shares of GBSX common stock at a rate of $0.30 per share. Pursuant to the amendment, the Company issued 450,960 shares of Common Stock to Mr. Moore. The Company issued the shares in reliance on Section 4(a)(2) (formerly Section 4(2)) of the Securities Act due to the fact that the issuance was isolated and did not involve a public offering of securities.

·As stated above, on February 22, 2013, and in connection with the above October 26, 2012 Loan Agreement, the Company and Board Member Stephen Baksa amended the Note pursuant to which Mr. Baksa agreed to convert the interest due under the Note into shares of GBSX common stock at a rate of $0.30 per share. Pursuant to the amendment, the Company issued 200,000 shares of Common Stock to Mr. Baksa. The Company issued the shares in reliance on Section 4(a)(2) (formerly Section 4(2)) of the Securities Act due to the fact that the issuance was isolated and did not involve a public offering of securities.

·On March 20, 2013, the Company issued an aggregate of 450,950 restricted shares of Common Stock to Board Member, John Moore pursuant to a February 22, 2013 amendment to a Secured Promissory Note Agreement entered into on August 13, 2012 between the Company and the Board Member. The Company issued the securities in reliance on Section 4(a)(2) (formerly Section 4(2)) of the Securities Act due to the fact that the issuance was isolated and did not involve a public offering of securities.

·On March 27, 2013, the Company issued an aggregate of 200,000 restricted shares of Common Stock to Board Member, Stephen Baksa pursuant to a February 22, 2013 amendment to a Secured Promissory Note Agreement entered into on October 26, 2012 between the Company and the Board Member. The Company issued the securities in reliance on Section 4(a)(2) (formerly Section 4(2)) of the Securities Act due to the fact that the issuance was isolated and did not involve a public offering of securities.

Notes to the Interim Financial Statements

September 30, 2013

GBS Enterprises Incorporated

Unaudited

·On March 27, 2013, the Company issued 200,000 restricted shares of Common Stock to a third party non-affiliated consultant in consideration for consulting services rendered by the consultant to the Company. The Company issued the securities in reliance on Section 4(a)(2) (formerly Section 4(2)) of the Securities Act due to the fact that the issuance was isolated and did not involve a public offering of securities.

·On April 26, 2013, the Company entered into a note purchase and security agreement (the “Loan Agreement”) with Stephen D. Baksa (the “Lender’), a member of the Board. Pursuant to the Loan Agreement, the Company issued a secured promissory note, dated April 26, 2013 (the “Note”), to Mr. Baksa for the principal amount of $200,000, bearing interest at a rate of 2% per month and maturing on June 30, 2013 or such other time as described in more detail in the Note, without any penalty for prepayment. This Note is secured by fifty percent (50%) of certain financial holdbacks to the Company pursuant to the Stock Purchase Agreement, dated February 1, 2013, by and among the Company, IDC Global, Inc. and Global Telecom & Technology Americas, Inc. The Company issued the Note upon reliance on Section 4(a)(2) (formerly 4(2)) of the Securities Act in light of the fact it was a private transaction and did not involve a public offering of securities.

§In connection with the execution of the Loan Agreement, on April 29, 2013, the Company issued the Lender a common stock purchase warrant (the “Warrant”), pursuant to which the Lender is entitled to purchase 100,000 shares of common stock at an exercise price of $0.25 from May 1, 2013 until April 30, 2016. The Warrant was issued in a private transaction between the Company and the Lender and was exempt from registration under the Securities pursuant to Section 4(a)(2) (formerly Section 4(2)) thereof.

§In connection with the execution of the Loan Agreement, on April 29, 2013, the Company issued the Lender a conditional common stock purchase warrant (the “Conditional Warrant”) which is exercisable in the event that Note is not paid in full by June 30, 2013, pursuant to which the Lender is entitled to purchase 100,000 shares of common stock at an exercise price of $0.25 from July 1, 2013 until June 30, 2016 as described more fully in the Note. The Conditional Warrant was issued in a private transaction between the Company and the Lender and was exempt from registration under the Securities Act, pursuant to Section 4(a)(2) (formerly Section 4(2)) thereof.

Notes to the Interim Financial Statements

September 30, 2013

GBS Enterprises Incorporated

Unaudited

·On April 26, 2013, the Company entered into a note purchase and security agreement (the “Loan Agreement”) with Vitamin B Venture GmbH (the “Lender”), an entity of which Joerg Ott, the Company’s Chairman and Chief Executive Officer, has voting and dispositive control. Pursuant to the Loan Agreement, the Company issued to the Lender a secured promissory note, dated October 26, 2012 (the “Note”), for the principal amount of $200,000, bearing interest at a rate of 2% per month and maturing on June 30, 2013 or such other time as described in more detail in the Note, without any penalty for prepayment. This Note is secured by fifty percent (50%) of certain financial holdbacks to be paid to the Company pursuant to the Stock Purchase Agreement, dated February 1, 2013, by and among the Company, IDC Global, Inc. and Global Telecom & Technology Americas, Inc. The Company issued the Note upon reliance on Section 4(a)(2) (formerly 4(2)) of the Securities Act in light of the fact it was a private transaction and did not involve a public offering of securities.

§In connection with the execution of the Loan Agreement, on April 29, 2013, the Company issued the Lender a common stock purchase warrant (the “Warrant”), pursuant to which the Lender is entitled to purchase 100,000 shares of common stock at an exercise price of $0.25 from May 1, 2013 until April 30, 2016. The Warrant was issued in a private transaction between the Company and the Lender and was exempt from registration under the Securities Act pursuant to Section 4(a)(2) (formerly Section 4(2)) thereof.

§In connection with the execution of the Loan Agreement, on April 29, 2013, the Company issued the Lender a conditional common stock purchase warrant (the “Conditional Warrant”) which is exercisable in the event that Note is not paid in full by June 30, 2013, pursuant to which the Lender is entitled to purchase 100,000 shares of common stock at an exercise price of $0.25 from July 1, 2013 until June 30, 2016 as described more fully in the Note. The Conditional Warrant was issued in a private transaction between the Company and the Lender and was exempt from registration under the Securities Act, pursuant to Section 4(a)(2) (formerly Section 4(2)) thereof.

Notes to the Interim Financial Statements

September 30, 2013

GBS Enterprises Incorporated

Unaudited

·On August 6, 2013, the Company issued 25,000 restricted shares of Common Stock to a third party non-affiliated consultant in consideration for consulting services rendered by the consultant to the Company. The Company issued the securities in reliance on Section 4(a)(2) (formerly Section 4(2)) of the Securities Act due to the fact that the issuance was isolated and did not involve a public offering of securities.

Other changes in common stock are disclosed in Note 23, Supplementary Cash Flow Disclosures.

Options

The Company has not issued any options, so that none are outstanding as of September 30, 2013.

Warrants

The Company has issued warrants in four different manners. In each instance, the warrant allows the holder to purchase a common share within a three year period from issuance at a specific price per share. In the first instance, warrants have been issued as part of a private placement offering wherein the investor purchases a common share, and a warrant. The fair value of thosethe common shares and warrants issued as well as contingent consideration and liquidation preference given up. The final allocation of the purchase price consideration to the assets acquired and liabilities assumed has been determined (and is shown below) by utilizing the residual method, whereby the current market valuecompleted and finalized.

Details of the stock is deducted from the unit pricecarrying amount and the remainder is allocated to the warrant. The valuation of the warrants issued is for disclosure purposes only and has no impact to the financial statements. A description of those warrants has been described above under common shares.

The second manner in which warrants are issues is in respect to financing by way of the issuance of notes payable or the conversion of debt into shares. In these instances, the fair value of the warrant has been determined using the effective interest rate method whereby the noteidentifiable assets and liabilities acquired and purchase consideration paid are as follows:

SCHEDULE OF PRELIMINARY ALLOCATION OF CONSIDERATION

Consideration    
Common shares $12,500,000 
Warrants  1,200,000 
Contingent consideration1  9,926,000 
Total consideration $23,626,000 
     
Fair value of identifiable assets acquired, and liabilities assumed    
Net working capital $30,908 
Property, plant, and equipment  9,092 
Intangible assets  18,170,000 
Goodwill  5,416,000 
Total identifiable assets $23,626,000 

1 Contingent consideration, for the purposes of the final allocation of the purchase price consideration, was measured as at the date of Somah acquisition – July 31, 2020. During the nine months ended September 30, 2021, the fair market value of the contingent liabilities, measured in accordance with Level 3 of the fair value hierarchy, has decreased by $472,000 (Note 3).

The intangible assets acquired include:

DuraGraft patent, with estimated remaining economic life of 13 years,
“Distribution relationships” intangible asset related to DuraGraft products, with estimated remaining economic life of 10 years, and
In-process research and development intangible asset – “Cyto Protectant Life Sciences” with indefinite economic life.

Goodwill is discounted when the interest rate is less than other similar notes and discount is allocatedattributed to the warrantworkforce and credited to additional paid in capital. The corresponding charge to discount is then amortized over the lifeprofitability of the note. Where thereacquired business and is no differencenot deductible for tax purposes. A residual method methodology was used to estimate the fair market value goodwill. A pre-tax discount rate based on weighted average cost of capital of 33.8% was used in interest terms, no value is attributable to the warrant.

Notes to the Interim Financial Statements

September 30, 2013

GBS Enterprises Incorporated

Unaudited

The Company has also sold warrants at nominal value to certain investors. In this instance the fair value assumptions for the assembled workforce acquired.

Pro-forma revenue, net income, and earnings per share are not presented for this acquisition as they are not material.

12

NOTE 5 – LEASES

On December 11, 2020, the Company entered into a 5.5 - year lease agreement for administrative office and laboratories, which commenced in December 2020 at a monthly rent of approximately $10,817, increasing by 2.5% annually beginning in the second year of the warrants has been determined using a Black-Scholes option pricing model with volatility, equity value and interest rate inputs noted below. The valuationlease until the end of the warrants issued is for disclosure purposes only and has no impactterm. Additionally, pursuant to the financial statements.

Lastly,agreement, the Company has issued warrants to outside consultantswill pay approximately $12,000 per month in payments for services.operating expenses. As at September 30, 2021, the remaining lease term was 4.67 years. The warrants are issuedlease had been classified as “cashless” warrantsan operating lease.

The assets and have been valued using a Black-Scholes option pricing model with volatility, equity value and interest rate inputs noted below.. The fairliabilities from the lease were recognized at the lease commencement date based on the present value of warrants issued for financing are determined for disclosure purposes as there is no impact toremaining lease payments over the financial statements. The fair value for other services, namely legal, and consulting have been recorded in the financial statements with a charge to the corresponding expense account and a credit to additional paid in capital.

Black Scholes assumptions for warrants issued were as follows:

  For the Period Ending
September 30,
 
  2013  2012 

Annualized Volatility

  120.26%  118.64%
Risk Free  Interest Rate  0.66%  0.40%
Expected Life  3 years   3 years 
Dividend Rate  Nil   Nil 

The following share purchase warrant transactions have not been disclosed elsewhere.

On April 1, 2011, the former CFO was issued 100,000 share purchase warrants, which gave him the option of purchasing 100,000 shares of common stock for a period of 3 years at a price of $1.50 per common share. The value of this issuance,lease term using the Black Scholes pricing model was determined to $34,000 and this amount was recorded as a consulting expense.discount rate of 3.95%, which is the average commercial interest available at the time.

Notes to

The total rent expense for the Interim Financial Statements

three months ended September 30, 2013

GBS Enterprises Incorporated

Unaudited

In March 2012, the Company issued an aggregate of 2,020,000 warrants to five “accredited investors” pursuant to Section 4(a)(2) (formerly Section 4(2)) of the Securities Act. Each investor warrant is exercisable for the three-year period commencing from the date of issuance for $0.50 per share of Common Stock2021 and has the same terms as the Private Placement Warrants. As noted above investors immediately exercised warrants2020 was approximately $77,357 and purchased 900,000 shares of common stock for $450,000.On March 27, 2012, the Company issued an aggregate of 250,000 warrants to 3 outside consultants pursuant to Section 4(a)(2) (formerly Section 4(2)) of the Securities Act. Each warrant is exercisable for the three-year period commencing from the date of issuance for $1.10 per share of Common Stock and has the same terms as the Private Placement Warrants.$Nil, respectively. The value of this issuance, using the Black Scholes pricing model was determined to $270,208 and this amount was recorded as a professional expense.

In December 2012, The Company issued 16,875 warrants to an outside consultant pursuant to Section 4(a)(2) (formerly Section 4(2)) of the Securities Act. Each warrant is exercisable for the three-year period commencing from the date of issuance for $0.21 per share of Common Stock and has the same terms as the Private Placement Warrants. The value of this issuance, using the Black Scholes pricing model was determined to $2,624 and this amount was recorded as a consulting expense.

Notes to the Interim Financial Statements

September 30, 2013

GBS Enterprises Incorporated

Unaudited

  # of shares         Fair value        Balance 
  allowed to  Issue Expiry Strike  at        End of 
  purchase   Date  Date  Price  Issuance   Issued   Exercised  Period 
         $  $  #  #  # 
                       
                             
Opening - Jan 1, 2012  6,846,280                   5,000   6,841,280 
Amended  (2,000,000) 10/1/2010 6/1/2013  4.00   -   -   -   - 
Reissued  2,000,000  6/1/2012 6/1/2015  1.00   556,785   -   -   - 
Issued for legal services     3/31/2012 3/31/2012  1.10   270,208(2)  250,000   -   250,000 
Issued for nominal value     3/28/2012 3/28/2015  0.50   2,457,662   2,020,000   900,000   1,120,000 
Sold with share units     4/16/2012 4/16/2015  1.50   90,000   120,000   -   120,000 
Issued with debt conversion     4/28/2012 4/28/2015  1.75   -   550,000   -   550,000 
Issued with debt conversion     4/30/2012 4/30/2015  1.75   -   500,000   -   500,000 
Sold with share units     5/10/2012 5/10/2015  1.50   25,800   30,000   -   30,000 
Issued with debt     7/5/2012 7/5/2012  0.50   26,500   550,000   -   550,000 
Issued with debt     8/13/2012 8/13/2015  0.35   -   100,000   100,000   100,000 
Issued with debt     10/26/2012 10/29/2015  0.20   -   500,000   500,000   - 
Issued with debt     11/30/2012 11/30/2015  0.20   -   500,000   250,000   250,000 
Issued for consulting services     12/21/2012 12/21/2015  0.21   2,624(1)  16,875   -   16,875 
Closing - Dec 31, 2012                  5,136,875   1,755,000   10,328,155 
                             
Opening - Jan 1, 2013  10,328,155                       10,328,155 
Transfer (3/11/2011)  739,000  2/6/2013 3/11/2014  1.50   -   -   -   739,000 
Closing - Mar 31, 2013                  5,136,875   1,755,000   11,067,155 
                             
Issued with debt     4/26/2013 4/26/2016  0.25   -   400,000   -   400,000 
Closing - Jun 30, 2013                  5,536,875   1,755,000   11,467,155 
                             
Closing - September 30, 2013                  5,536,875   1,755,000   11,467,155 

(1) recorded as consultingtotal rent expense

(2) recorded as legal expense

Note 21        REVENUE ALLOCATION

Gross revenue may be broken down by the following products for the nine months ended September 30, 2013 are as follows:2021 and 2020 was approximately $168,769 and $Nil, respectively.

Sales Revenues9/30/2013
KUSD
Licenses2,605
Maintenance7,500
Service2,443
Third-Party Products1,736
LND Third-Party Products1,330
Others0
15,613

NotesThe following table summarizes supplemental balance sheet information related to the Interim Financial Statements

operating lease as of September 30, 20132021 and December 31, 2020.

GBS Enterprises IncorporatedSCHEDULE OF RIGHT-OF-USE ASSET AND RELATED LEASE LIABILITY

  September 30, 2021  December 31, 2020 
Right-of-use asset $1,163,159  $1,317,830 
         
Operating lease liabilities, current $260,106  $243,292 
Operating lease liabilities, non-current  941,732   1,074,538 
Total operating lease liabilities $1,201,838  $1,317,830 

UnauditedAs at September 30, 2021, the maturities of the lease liabilities for the periods ended December 31 were as follows:

SCHEDULE OF MATURITIES OF LEASE LIABILITIES

      
2021  $52,249 
2022   277,142 
2023   277,142 
2024   277,142 
2025   277,142 
Thereafter   130,950 
Total lease payments   1,291,767 
Total lease payments   1,291,767 
Less: present value discount   (89,929)
Total  $1,201,838 

RevenuesNOTE 6 – PROPERTY, PLANT AND EQUIPMENT, NET

Property, plant and equipment, summarized by geographical areamajor category, stated at cost, less accumulated depreciation at September 30, 2021 and December 31, 2020 consisted of the following:

SCHEDULE OF PROPERTY PLANT & EQUIPMENT

  September 30, 2021  December 31, 2020 
Furniture and equipment $701  $701 
Computer related  7,220   7,220 
Machinery and equipment  1,171   1,171 
Total $9,092  $9,092 
Less: accumulated amortization  (7,819)  (1,970)
Property, plant and equipment, net $1,273  $7,122 

Depreciation expense for the three months ended September 30, 2021 and 2020 was $1,425 and $1,313, respectively, and for the nine months ended September 30, 20132021 and 2020 was $5,849 and $1,313, respectively.

NOTE 7 – INTANGIBLE ASSETS

Krillase

As part of the asset acquisition of ACB Holding AB, Reg. No. 559119-5762, completed on September 12, 2018, Marizyme acquired all rights, titles, and interest in the Krillase technology, a group of intangible assets worth $28,600,000. Krillase is a naturally occurring enzyme that acts to break protein bonds and has applications in wound debridement, would healing, dental care and thrombosis. The useful lives of the intangible assets are based on the life of the patent and related technology. The patents and related technology for Krillase have not been amortized since the acquisition, as follows:they have not yet been put into operations.

Sales Revenues9/30/2013
by geographic areaKUSD
US2,550
Germany12,370
United Kingdom678
Others15
15,613

The Company anticipates Krillase being placed into service in 2023. The Company has evaluated this asset for impairment and has determined that due to COVID-19 delaying the next steps for roll out of this technology, along with the associated value of the research and development, the status of the clinical trials, and other pertinent proprietary technology, there is no impairment required.

Note 22          OTHER INCOME/EXPENSE

At the financial statement date, Other income was 20 KUSD (December 31, 2012 year end: Other Expense 33 KUSD).

4213
 

NotesDuraGraft

As part of Somah acquisition (Note 4), Marizyme purchased $18,170,000 of intangible assets related to the Interim Financial StatementsDuraGraft® technology.

September 30, 2013SUMMARY OF INTANGIBLE ASSETS AMORTIZATION EXPENSE

  September 30, 2021  December 31, 2020 
  Gross Carrying Amount  Accumulated Amortization  Net Carrying Amount  Gross Carrying Amount  Accumulated Amortization  Net Carrying Amount 
Krillase intangible assets $  28,600,000  $-  $  28,600,000  $  28,600,000  $-  $  28,600,000 
DuraGraft patent  5,256,000   (471,691)  4,784,309   14,147,729   (589,489)  13,558,240 
Distributor relationship  308,000   (35,933)  272,067   -   -   - 
IPR&D - Cyto Protectant Life Sciences  12,606,000   -   12,606,000   -   -   - 
Patents in process  122,745   -   122,745   119,971   -   119,971 
Total intangibles $46,892,745  $(507,624) $46,385,121  $42,867,700  $(589,489) $42,278,211 

GBS Enterprises Incorporated

UnauditedThe following changes to the Company’s intangible assets had taken place in the periods indicated:

 

Note 23          SUPPLEMENTAL CASH FLOW DISCLOSURESSCHEDULE OF INTANGIBLE ASSETS

Balance, December 31, 2019 $28,613,000 
Acquired in asset purchase agreement  14,147,729 
Additions  106,971 
Amortization expense  (589,489)
Balance, December 31, 2020  42,278,211 
Acquired in Somah Transaction1  4,022,271 
Additions  2,775 
Amortization expense1  81,864 
Balance, September 30, 2021 $46,385,121 

The significant non-cash transactions through September 30, 2013 were as follows:

1·On April 1, 2011,To account for Somah Transaction measurement period adjustments, the Company acquired Pavone AG,restated the Quarterly Report on Form 10-Q for 350 KUSD, assumption of $583,991 debtthe three and 1,000,000 shares of its common stock.
·Onsix month ended June 1, 2011, the Company acquired GroupWare, Inc., for 250 KUSD, assumption of $694,617 debt and 250,000 shares of its common stock.
·On July 25, 2011, the Company acquired IDC Global, Inc. for 750 KUSD, $ 883,005 assumption of debt, 25 (KUSD) reimbursement for accounting and legal fees, 35 KUSD signing bonuses and 880,000 shares of common stock.
·On September 27, 2011, the Company acquired SD Holdings Ltd for $525,529 and issued 612,874 shares of Common Stock.
·On February 27, 2012, an outstanding debt of GROUP was converted into an aggregate of 1,750,000 shares of GROUP common stock, increasing GROUP’s total outstanding common stock to 26,982,000 shares.30, 2021, originally filed on August 23, 2021. As a result of the foregoing increase inrestatement, the numbervalue of total outstanding shares of GROUP common stock,DuraGraft intangibles purchased with the CompanySomah Transaction increased its ownership of GROUP common stock to an aggregate of 13,525,000 shares, representing approximately 50.1%by $4,022,271 and related overestimated amortization of the outstanding common stock of GROUP,intangibles decreased by purchasing the 883,765 shares of GROUP common stock from GAVF LLC for an average purchase price of $0.70 per share.
·On March 31, 2012, warrants were issued in lieu of consulting services and the fair value, based on the Black Scholes pricing model, was determined to be $ 270,208 and recorded as Additional Paid-In Capital.
·On April 28, 2012, $ 632,500 in notes payable to RealRisk Ventures, LL were converted into 550,000 shares of common stock and into 550,000 warrants with each warrant allowing the holder to purchase one common share at $1.75 for a period of 3 years.
·On April 30, 2012, $ 460,000 in notes payable to Lotus Holdings Ltd. were converted into 400,000 shares of common stock and 400,000 warrants, with each warrant allowing the holder to purchase one common share at $1.75 for a period of 3 years.
·On April 30, 2012 $ 172,500 of accounts payable due to Vitamin B Venture, GmbH was converted into 150,000 shares of common stock in satisfaction of a converted note to Kjell Jahn.
·On July 5, 2012, promissory notes for $552,500 were issued at 8.5% and had a conversion feature. Similar notes without the conversion were issued at 20%898,026. Therefore, it was determined that the conversion feature had a value which was calculated by discounting the note as if the cost of capital was 20% and based on the due date set forth of 6 months. The calculated value was classified as discounted debt and amortized over the life of the promissory notes resulting in additional Interest expense and a credit to Additional Paid-In Capital for $26,700.

Notes to

The Company has recorded amortization expense of $108,777 and $326,331 for the Interim Financial Statements

three and nine months ended September 30, 20132021, respectively and $341,270 for the three and nine months ended September 30, 2020.

GBS Enterprises Incorporated

UnauditedFuture amortizations for DuraGraft related intangible assets for the next five years will be $435,108 for each year from 2021 through 2026 and $2,880,836 for 2027 and thereafter. Amortization related to in process research and development will be determined upon the Company achieving commercialization.

·On December 21, 2012, warrants were issued in lieu of consulting services and the fair value, based on the Black Scholes pricing model, was determined to be $ 2,624 and recorded as Additional Paid-In Capital.

·On March 1, 2013, $700,000 of Notes Payable and Accounts Payable due to Vitamin VbV GmbH was dissolved as payment against a Loan Payable from Group AG.

·On March 20, 2013, 450,960 shares were issued at a rate of .30/share on conversion of accrued interest due on a Note Payable to John Moore.

·On March 27, 2013, 200,000 shares were issued at a rate of .30/share on conversion of accrued interest due on a Note Payable to Stephen Baksa. Also on March 27, 2013, 200,000 shares were issued in lieu of services and the fair value based on the Black Scholes pricing model, was determined to be $ 70,000 and recorded as Additional Paid-In Capital.

·On August 6, 2013, 25,000 shares were issued at a rate of .16/share in lieu of consulting services and recorded as Additional Paid-In Capital.

Note 24        SUBSEQUENT EVENTSNOTE 8 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES

On July 10, 2013, the BoardAccounts payable and accrued expenses, summarized by major category, as of DirectorsSeptember 30, 2021 and December 31, 2020 consists of the Company reappointed Joerg Ott as the Chief Executive Officer (Principal Executive Officer) of the Company, effective immediately. Mr. Ott replaced Mr. Gary D. MacDonald who had been serving as the Company’s Interim Chief Executive Officer since July 11, 2012.following:

SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

  September 30, 2021  December 31, 2020 
Trade accounts payable $1,117,517  $325,830 
Accrued expenses  180,846   21,555 
Accrued compensation expenses  98,582   130,718 
Total accounts payable and accrued expenses $1,396,945  $478,103 

NOTE 9 - CONVERTIBLE PROMISSORY NOTES AND WARRANTS

On August 2, 2013, Gary D. MacDonald resigned as member of the Board of Directors of the Company and as, Managing Director of GBS-UK. From March 1, 2012 to the date of his resignation, Mr. MacDonald also served as member of the Board’ Audit Committee. Mr. MacDonald’s resignation was not due to any disagreement with the Company or the Board.

On August 13, 2012,May 27, 2021, the Company entered into a note purchase and security agreement (the “LoanUnit Purchase Agreement (“Unit Purchase Agreement”) with John A. Moore,to sell up to 4,000,000 units (the ‘Units’) at a memberprice per Unit of $2.50. Each Unit is comprised of (i) a convertible promissory note (the “Convertible Note”) convertible into common stock of the Board. PursuantCompany at a price per share of $2.50, (ii) a warrant to purchase one share of common stock of the Company (the ‘Class A Warrant’); and (iii) a second warrant to purchase common stock of the Company (the “Class B Warrant”).

In May 2021, the Company issued and sold 29,978 Units at a price of $2.50 per Unit for gross proceeds of $74,945, consisting of Convertible Notes of $74,945, Class A Warrants for the purchase of 29,978 shares of common stock and Class B Warrants for the purchase of 29,978 shares of common stock. The Company incurred related issuance costs of $6,745.

In July 2021, the Company issued and sold 440,000 Units under the Unit Purchase Program for gross proceeds of $1,100,000. The Units included the Convertible Notes for $1,100,000, Class A Warrants for 440,000 shares of common stock and Class B Warrants for 440,000 shares of common stock. The Company incurred related issuance costs of $99,000.

14

On September 29, 2021, the Company, with the consent of all Unit holders, amended the May 2021 Unit Agreements. By rescinding their investment, the Unit holders agreed to amend the Unit Purchase Agreement resulted in the following changes to the Loanoffering:

(i)Decreased the offering price under the Unit Purchase Agreement from $2.50 per Unit to $2.25 per Unit for all future sales under the Unit Purchase Agreement. No proceeds from the initial investment were returned,
(ii)Decreased the conversion price from $2.50 per share to $2.25 per share for all current Unit holders and all future investors, and
(iii)Cancelled all Class A Warrants and Class B Warrants and replaced them with Class C Warrants.

The Company determined that the modifications of Unit Purchase Agreement were not significant enough to be considered substantial, therefore the values of original instruments issued were not adjusted. As a result of this modification, the total of 469,978 Units previously issued were replaced with an aggregate of 522,198 pro-rata Units.

The Company determined that the optional and automatic conversion feature and the share redemption feature attached to the convertible notes meet the definition of derivative liabilities and that the detachable warrants issued do not meet the definition of a liability and therefore will be accounted for as an equity instrument.

The initial $571,807fair value of the warrants and $391,648fair value of derivative liabilities issued have been recorded as debt discount and are being amortized to interest and accretion expense using the effective interest method over the term of the Convertible Notes.

 SCHEDULE OF CONVERTIBLE NOTES

  September 30, 2021  December 31, 2020 
Convertible notes issued $1,174,945  $        - 
Issuance costs  

(105,745

)  - 
Debt discount  (964,153)  - 
Debt accretion  74,410   - 
Convertible notes, net of debt discount $179,457  $- 

During the three and nine months ended September 30, 2021, the Company recognized interest and accretion expense of $70,221 and $74,410, respectively (September 30, 2020 - $Nil and $Nil) in the condensed consolidated statements of operations.

Convertible Notes Terms

The Convertible Notes mature in 24 months from the initial closing date and accrue 10% of simple interest per annum on the outstanding principal amount.The Convertible Notes principal and accrued interest can be converted at any time at the option of the holder at a conversion price of $2.25 per share (before the modification - $2.50 per share). In the event the Company consummates, while the Convertible Note is outstanding, an equity financing with a gross aggregate amount of securities sold of not less than $10,000,000 (“Qualified Financing”), then all outstanding principal, together with all unpaid accrued interest under the Convertible Notes, shall automatically convert into shares of the equity financing at the lesser of (i) 75% of the cash price per share paid in the financing and the conversion price of $2.25 per unit. The Convertible Notes are secured by a first priority security interest in all assets of the Company.

Warrants Terms

Class A

Exercise price is the lower of (i) $3.13 per share, or (ii) the Automatic Conversion Price (the lesser of (i) 75% of the cash price per share paid by the other purchasers of next round securities in the Qualified Financing and (ii) the Conversion Price ($2.50, subject to Customary Antidilution Adjustments).
Exercisable for a period of 5 years from issuance.
Warrant Coverage: 100%.

Class B

Exercise price is $5.00 per share,
Exercisable for a period of 5 years from issuance.
Warrant Coverage: 100%.

Class C

Exercise price is the lower of (i) $2.25 per share, or (ii) the Automatic Conversion Price (the lesser of (i) 75% of the cash price per share paid by the other purchasers of next round securities in the Qualified Financing and (ii) the Conversion Price ($2.25, subject to Customary Antidilution Adjustments).
Exercisable for a period of 5 years from issuance.
Warrant Coverage: 200%.

NOTE 10 – STOCKHOLDERS’ EQUITY

a) Preferred stock

The Company is authorized to issue a total number of 25,000,000 shares of “blank check” preferred stock with a par value of $0.001. As of September 30, 2021, and December 31, 2020, there were 0 shares of preferred stock issued or outstanding.

15

b) Common stock

The Company is authorized to issue a total number of 75,000,000 shares of common stock with a par value of $0.001.

As of September 30, 2021 and December 31, 2020, there were 35,928,188 shares of common stock issued and outstanding. The company did not issue any common stock during the three and nine months ended September 30, 2021.

c) Options

On January 13, 2021, the Board of Directors approved the Marizyme’s 2021 Stock Incentive Plan (“SIP”). The SIP incorporates stock options issued prior to January 13, 2021. The SIP authorized 5,300,000 options for issuance. As of September 30, 2021, there remains 1,527,183 options available for issuance.

During the nine months ended September 30, 2021, the company granted 732,500 (December 31, 2020 – 1,340,000) share purchase options to directors, officers, employees, and consultants of the Company. The weighted-average assumptions used to estimate the fair value of stock options using the Black-Scholes option valuation model were as follows:

SCHEDULE OF SHARE BASED STOCK OPTION VALUATION ASSUMPTIONS

  2021  2020 
Risk-free interest rate  0.69%  0.93%
Volatility  232.69%  241.88%
Exercise price $1.25  $1.37 
Dividend yield  0%  0%
Forfeiture rate  0%  0%
Expected life (years)  3   10 

The Company recognizes forfeitures as they occur.

The summary of option activity for the nine months ended September 30, 2021 is as follows:

SCHEDULE OF STOCK OPTION ACTIVITY

  Number of
Options
  Weighted
Average
Exercise Price
  Weighted
Average
Contractual Life
  Total Intrinsic
Value
 
Outstanding at December 31, 2019  2,715,000  $1.50   9.48  $N/A1
Granted  1,340,000   1.25         
Exercised  (254,057)  1.02         
Outstanding at December 31, 2020  3,800,943  $1.36   8.82  $123,600 
Granted  732,500   1.25         
Forfeited  (760,626)  1.25         
Outstanding at September 30, 2021  3,772,817  $1.37   8.13  $97,850 
Exercisable at September 30, 2021  3,074,476  $1.39   3.77  $97,850 

1Total intrinsic value for stock options outstanding as at December 31, 2019 is not available as it was not disclosed in the previous years filings.

d) Warrants

The warrant activity for the periods presented is as follows:

Schedule of Options Outstanding and Issued

  Number  Weighted Average
Exercise Price
 
December 30, 2019  113,637  $3.00 
Issued on Somah acquisition (Note 4)  3,000,000   5.00 
Issued  280,014   1.38 
December 30, 2020  3,393,651  $2.13 
Issued  1,044,396   2.25 
September 30, 2021  4,438,047  $2.16 

During the three and nine months ended September 30, 2021, the Company issued the following:

On May 27, 2021, pursuant to the Unit Purchase Agreement (Note 9) the Company issued Class A Warrants for the purchase of 29,978 shares of common stock and Class B Warrants for the purchase of 29,978 shares of common stock. The Class A warrants had a strike price of $3.13 per share and a term of five years. The Class B warrants had a strike price of $5.00 per share and a term of five years.

In July 2021 pursuant to the May Unit Purchase Agreement the Company issued a secured promissory note, dated October 26, 2012 (the “Note”),Class A Warrants for 440,000 shares of common stock and Class B Warrants for 440,000 shares of common stock.

On September 29, 2021, pursuant to Mr. Moore for the principal amount of $1,000,000, bearing interest at a rate of 20% per year and maturing onmodification to the earlier of the first anniversary date of the date of issuance or such other timeUnit Purchase Agreement as described in more detailNote 9, all Class A and Class B warrants were replaced with an aggregate of 1,044,396 pro-rata Class C warrants. The warrants have a strike price of 2.25 per share and a term of five years. The detachable warrants issued were accounted for as an equity instrument and were ascribed the fair market value of $571,807 using the residual fair value allocation method.

16

During the year end December 31, 2020, the Company issued the following:

On July 31, 2020, the Company completed the Somah Acquisition (Note 4) whereas 10,000,000 shares of common stock and 3,000,000 warrants were issued. The warrants have a strike price of $5.00 per share and a term of five years. The valuation of the warrants granted was completed in the Note, without any penaltysix months ended June 30, 2021, and the fair market value was determined to be $0.40 per share or $1,200,000.

On September 25, 2020, the Company issued two warrants for prepayment. To secureservices. The warrants were to purchase for 168,008 and 112,006 shares with a strike price of $1.375 and a term of five years. The fair market value was determined to be $0.9062 per share or $152,249 and $101,500, respectively, or $253,749, collectively.

e) Stock-based compensation

During the obligationsthree and nine month ended September 30, 2021, the Company recorded $64,074 and $593,116, respectively, in non-cash share-based compensation (September 30, 2020 - $1,107,085 and $1,674,200 respectively). Additionally, the Company recognized $33,333of stock-based compensation on restricted common stock in the nine months ended September 30, 2021.

As of September 30, 2021, the Company had $652,932 of unrecognized stock-based compensation expense, which is expected to be recognized over a weighted-average period of 2.44 years.

NOTE 11 – RELATED PARTY TRANSACTIONS

As at September 30, 2021, the Company owed an aggregate of $638,530 (December 31, 2020 - $Nil) to related parties of the Company, undercomprised of the Note,following:

i.During the three months ended September 30, 2021, the Company entered into a promissory note agreement with a related party of the Company, for the total proceeds of $151,000. The note bears no interest, unsecured, and has no terms of repayment.
ii.During the nine months ended September 30, 2021, the Company entered into another promissory note agreement with a related party and shareholder of the Company, for the total proceeds of $215,000. The note bears no interest, unsecured, and has no terms of repayment.
iii.The Company received consulting services from a shareholder and consultant of the Company, and pursuant to the agreement incurred $30,000 and $270,000 in professional expenses in the three and nine months ended September 30, 2021, respectively (three and nine months ended September 30, 2020 - $90,000). The related party also incurred $2,530 in administrative and general expenses on behalf of the Company. As at September 30, 2021, the Company owes the related party a total of $272,530 for consulting services and expenses reimbursement (December 31, 2020 – $Nil).

Additionally, as part of the Somah transaction in 2020 (Note 4), the Company granted Mr. Moorerecorded a secured priority security interestprepaid royalty to the shareholders of Somahlution. The primary beneficial owner is Dr. Vithal Dhaduk, currently the Interim CEO, a director, and significant shareholder of the Company. As at September 30, 2021, the company had $340,969 in prepaid royalties (December 31, 2020 - $344,321) which had been classified as non-current in the Company’s Accounts Receivable and its subsidiaries locatedcondensed consolidation balance sheets.

NOTE 12 – COMMITMENTS AND CONTINGENCIES

Legal Matters

The Interim CEO of Marizyme, Dr. Vithal D. Dhaduk, also, a co-founder of Somahlution, LLC (“Dhaduk”), was the subject of a complaint filed in the United States District Court, Middle District of America,Pennsylvania, Civil Action No. 3:17 cv 02243 in December 2017 by Mukeshkkumar B. Patel (“Patel”), a former business partner of Dhaduk, which complaint made claims of breach of contract, promissory estoppel and unjust enrichment regarding a Memorandum of Understanding, dated July 16, 2015, between Patel and Dhaduk (“MOU”). The MOU provided that Dhaduk would pay Patel $9,450,000 as more fully describedconsideration for Patel’s agreement to, among other things, (i) exit certain legal entities that were purportedly jointly owned by certain affiliates of Dhaduk and Patel, including Somahlution LLC, and (ii) relinquish his ownership interests in such entities. On December 2, 2019, the court granted Patel’s motion for summary judgment on his breach of contract claim.

The complaint was settled between Dhaduk and Patel in the full text ofnine months ended September 30, 2021, with no financial impact to the document.Company.

Contingencies

a.·In connection with the execution of the Loan Agreement, on October 26, 2012,On July 13, 2019, the Company issuedsigned a consulting agreement, whereby the Lender a common stock purchase warrant (the “Warrant”), pursuant to which the Lender is entitledindividual will receive:

$30,000 per month through July 13, 2022,
Option to purchase 100,000250,000 shares of common stock at an exercisea strike price of $0.35 until$1.50, which vest monthly through July 13, 2021. The vesting of these options was accelerated by the third anniversary dateBoard of Directors on September 2, 2020.
Royalties based on sales of Krillase assets, equal to 10% of net sales of the dateproduct. During the nine months ended September 30, 2021, no revenues were derived from sales of issuance. The Warrant was issued in a private transaction betweenKrillase product.

17

b.As part of the DuraGraft Acquisition, completed on July 31, 2020 (Note 4), the Company andentered into the Lender and was exempt from registration underAgreement with Somah stockholders, whereby Marizyme is legally obligated to pay royalties on all net sales for Somahlution, Inc. The royalties associated with the Securities and Exchange Act of 1933,Agreement are calculated as amended, pursuant to Section 4(2) thereof. On October 16, 2013, Mr. Moore exercised the right to purchase 100,000 shares of common stock at the price of $0.35.follows:

Royalties on U.S. sales equal to:

5% on the first $50,000,000 of net sales,
4% on net sales of $50,000,001 up to $200,000,000, and
2% on net sales over $200,000,000.

Royalties on sales outside of the U.S.:

6% on the first $50,000,000 of net sales,
4% on net sales of $50,000,001 up to $200,000,000, and
2% on net sales over $200,000,000.

The royalties are in perpetuity. As at September 30, 2021, the Company had not earned any revenues from Krillase and did not have any sales of the DuraGraft products in U.S., therefore no royalties have been accrued or paid in the period.
c.The Company has entered into arrangements for office and laboratories spaces. As at September 30, 2021, minimum lease payments in relation to lease commitments are payable as described in Note 5.

NOTE 13 - SUBSEQUENT EVENT

On October 23, 2013,November 1, 2021, Marizyme entered into a definitive arrangement agreement with Health Logic Interactive Inc. (“HLII”) pursuant to which the Company filedwill acquire My Health Logic Inc., a lawsuit (GBS Enterprises,wholly-owned subsidiary of HLII (the “Transaction”).

The Transaction will be effected by way of a plan of arrangement under the Business Corporations Act (British Columbia). In connection with the plan of arrangement, Marizyme will issue an aggregate of 4,600,000 shares of its common stock to HLII, which will be subject to certain terms and restrictions. Upon closing, My Health Logic Inc. v. Reliance Globalcom, Inc.) inwill be a wholly-owned subsidiary of Marizyme.

The acquisition is subject to, among other things, the Superiorapproval of the Supreme Court of British Columbia, the State of California, County of San Francisco, seeking a declaratory judgment that the Company has no obligation to Reliance Globalcom Inc. (“Reliance”) for any claims or liabilities in connection with a Master Services Agreement (“MSA”) executed by Reliance and IDC Global Inc. (“IDC”) a then wholly owned subsidiaryapproval of the Company in March 2010. On February 1, 2013, GBS sold IDC to Global Telecom & Technology Inc. (“GTT”). Pursuant to the governing Stock Purchase Agreement (SPA), GTT gained all right, title and interest in 100% of all of IDC’s stock, all of which had been owned by GBS. Pursuant to the Stock Purchase Agreement, GTT withheld $528,777.93NEX board of the purchase price from payment to GBS to cover potential exposure due toTSX Venture Exchange, and requires the Identified Dispute described herein between IDC and Reliance. The Stock Purchase Agreement requires that, within three daysapproval of notice to GTT that the Identified Dispute described herein has been resolved, GTT will release the $528,777.93 to GBS. The Company is seeking declaratory relief from the Court stating the Company is not liable to Reliance and that GTT may release the $528,777.93 in funds owed to the Company. There were no material developments in this case since the filingat least two-thirds of the lawsuit.votes cast by HLII shareholders at the upcoming annual and special meeting of HLII shareholders. The Transaction is expected to close in December 2021.

The Company intends to vigorously defend its interests in this matter.

18

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Item 2.

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with the unaudited interim financial statements and notes thereto included in this Quarterly Report on Form 10-Q and with our audited financial statements and notes thereto for the year ended December 31, 2020 and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Note Regarding Forward-Looking Statements

The following discussion and analysis should be readOperations, both of which are contained in conjunction with our financial statements and the notes to those financial statements that are included elsewhere in the Quarterly Report. Our discussion includes forward-looking statements based upon current expectations that involve risks and uncertainties, such as our plans, objectives, expectations and intentions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of a number of factors, including those set forth under the “Risk Factors,” “Cautionary Notice Regarding Forward-Looking Statements” and “Description of Business” sections in the Company’s latest Annual Report on Form 10-K for the year ended December 31, 2020 (“2020 Form 10-K”).

FORWARD-LOOKING STATEMENTS

This quarterly report on Form 10-Q contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 under Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and subsequent filings. WeSection 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements other than statements of historical facts contained in this quarterly report, including statements regarding our future results of operations and financial position, business strategy, research and development plans and costs, the impact of COVID-19, the timing and likelihood of regulatory filings and approvals, commercialization plans, pricing and reimbursement, the potential to develop future product candidates, the timing and likelihood of success of the plans and objectives of management for future operations, and future results of anticipated product development efforts, are forward-looking statements. These statements are often identified by the use of words such as “anticipate,“may,“estimate,” “plan,” “project,” “continuing,” “ongoing,“will,” “expect,” “believe,” “anticipate,” “intend,” “may,” “will,“could,” “should,” “could,“estimate,“predict,or “continue,” and similar expressions to identifyor variations. The forward-looking statements. Although we believe the expectations expressedstatements in this quarterly report are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, operating results, business strategy, short-term and long-term business operations and objectives. These forward-looking statements speak only as of the date of this quarterly report and are based on reasonablesubject to a number of risks, uncertainties and assumptions, withinincluding those described in the bounds ofPart II, Item 1A under the heading “Risk Factors.” The events and circumstances reflected in our knowledge of our business, ourforward-looking statements may not be achieved or occur and actual results could differ materially from those discussed in these statements. We undertake no obligation to update publicly any forward-looking statements for any reason even if new information becomes available or other events occurprojected in the future.forward-looking statements. Except as required by applicable law, including the securities laws of the United States, we do not intendplan to publicly update or revise any of the forward-looking statements to conform these statements to actual results. Readers are urged to carefully review and consider the various disclosures made throughout the entirety of this quarterly report, which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operations, and prospects.

OVERVIEW

GBS Enterprises Incorporated, a Nevada corporation (the “Company,” “GBS,” “GBSX,” “we,” “us,” “our” or similar expressions), conducts its primary business through its 50.1% owned subsidiary, GROUP Business Software AG (“GROUP”), a German-based public-company whose stock trades on the Frankfurt Exchange under the stock symbol INW. GROUP’s software and consulting business is focused on serving IBM’s Lotus Notes and Domino market. GROUP caters primarily to mid-market and enterprise-size organizations with over 3,500 customers in thirty-eight countries spanning four continents, representing more than 5,000,000 active users of its products. GROUP’s customers include Abbot, Ernst & Young, Deutsche Bank, Bayer, HBSC, Merck and Toyota. GROUP provides IBM Lotus Notes/Domino Application and Transformation technology. Headquartered in Eisenach, Germany, GROUP has offices throughout Europe and North America. The Company maintains a website at www.gbsx.us. GROUP maintains a website at www.gbs.com. The information contained in the Company’s and GROUP’s websites is not incorporated by reference herein.

Products and Services

GBS has consolidated the fragmented Lotus Software market through the acquisition of companies with complementary product, technology or services offerings. GBS has continuously developed its software and service business to service and support GBS’s IBM Lotus customer base.

Historically, GROUP had achieved growth by acquiring companies with complimentary operations and leveraging GROUP’s expertise to turnaround and integrate these companies. Key success factors for this strategy are: enhanced portfolio, positioning GROUPherein, whether as the ‘one-stop-shop’ for Lotus applications and services, expanded customer support, fast code migration, and cloud enablement/XPages conversion of acquired applications.

In 2012, in order to reduce overhead and administrative costs, we decided to restructure the Company’s multilevel subsidiary-structure. As of the fiscal quarter ended September 30, 2013, we restructured or sold the following subsidiaries:

nSD Holdings, Ltd./GBS India Private Limited
nPavone AG
nGroupWare AG
nPavone, Ltd.
nebVokus, GmbH
nB.E.R.S. AD (Investment)
nIDC Global, Inc.
nGroup Live, NV.

45

SD Holdings, Ltd./GBS India Private Limited. On April 1, 2012, we sold SYN and its wholly-owned subsidiaries, Synaptris and Synaptris India, to Lotus for $1,877,232. On July 1, 2012, the Company entered into a purchase agreement with SYN for $1,877,232, which transferred all SYN’s assets, including intellectual property rights, and liabilities of the IntelliPRINT and FewClix product lines, customer contracts and certain employees for operations in a new subsidiary, GBS India Private Limited, an Indian company (“GBS India”). A royalty fee in the amount of approximately $350,000 has been agreed upon for the benefit the Company. Additionally a profit based fee of up to $700,000 may be earned based on license and revenue recognized from the sold IntelliVIEW and IntelliVIEW NXT products. On August 1, 2012, the Company acquired 100% of the outstanding capital stock of GBS India. We anticipate GBS India’s presence in India to accelerate our plan to expand our product development team particularly for our strategic offerings in India.

Pavone AG/Groupware AG. On July 6, 2012 and August 9, 2012, wholly-owned subsidiaries Pavone AG and Groupware AG, respectively, were merged and consolidated into one wholly-owned subsidiary, Pavone GmbH. The mergers were consummated solely for administrative purposes.

Pavone, Ltd. On July 8, 2012, Pavone, Ltd., a subsidiary of Pavone AG and a shell company, was dissolved. The Company serves the United Kingdom market through GROUP’s subsidiary GBS, Ltd.

EbVokus, GmbH. On October 1, 2012, GROUP sold all of the software and operational assets (constituting substantially all of the assets) of its wholly-owned subsidiary, ebVokus GmbH, along with the associated maintenance and project agreements to a non-affiliated third party for a purchase price of approximately $459,000, approximately $258,000 (200,000 Euros: 1 EUR = $1.29 USD on October 1, 2012) was paid at closing and the remaining $201,000 was paid on February 15, 2013 (150,000 Euro: 1EUR = $1.35 USD on February 15, 2013).

B.E.R.S. AD. On November 23, 2012, GBS AG sold its entire participation (50%) in B.E.R.S AD for a total of 25,000 BGN.

IDC Global, Inc. On February 1, 2013, GBS entered into a Stock Purchase Agreement, dated February 1, 2013 (the “Agreement”), with IDC Global, Inc., a Delaware corporation and a wholly-owned subsidiary of GBS (“IDC”), and Global Telecom & Technology Americas, Inc., a Virginia corporation (“GTT). Pursuant to the Agreement, we sold 100% of the issued and outstanding capital stock of IDC to GTT for a purchase price of $4,600,000 (the “Purchase Price”), subject to certain holdback provisions, including a holdback of approximately $217,000 for accounts receivable and which is to be paid by GTT to GBS within one business day of IDC receiving such payment, $334,000 for GroupLive liabilities and liens on IDC which is to be paid by GTT to GBS within three business days that GTT is reasonably satisfied that such liabilities and liens have been removed, less any amounts up to $12,500 which GTT or IDC is required to pay to either satisfy the obligations or purchase replacement equipment; and approximately $528,000 for an outstanding dispute which is to be paid by GTT to GBS within three days that GTT is reasonably satisfied has been resolved, subject however to a term of 18 months from the closing date or, if after 18 months, the holdback will be used to offset any indemnifications by GBS under the Agreement. The Purchase Price was also subject to adjustment on a dollar-for-dollar basis for adjustments to the Net Working Capital (defined as Current Assets minus Current Liabilities) of IDC by GTT.

Group Live N.V. operating under the laws of the Netherlands and a 100% subsidiary of GROUP declared its end of business May 31, 2012, registered in the commercial register June 22, 2012. Following the local procedures the Company has been dissolved from the register as per April 5, 2013, registered April 16, 2013.

The Board of Directors of the Company has approved each of the transactions discussed above.

Messaging and Business Applications Software & Solutions

GBS Messaging and Business Application Software & Solutions product lines include software and advisory services for email and Instant Messaging (IM) Management, Security, Compliance, Archiving and Productivity, CRM Applications, Governance, Risk & Compliance (GRC) Management software, Workflow and Business Process Management software, ePDF Archiving & Document Management.

GBS develops, sells and installs well-known business process and management software suites based on Lotus Notes / Domino and IBM Portal technology, mainly for major international companies and medium-sized customers.

Through GBS’s comprehensive messaging software product lines and associated services, Lotus Notes, Microsoft Exchange or SMTP-based-email customers, as well as Lotus Sametime, customers are able to provide their users with a secure, efficient and centrally administered use of e-mail and IM while maintaining control over their compliance with current legal requirements and corporate guidelines.

Consulting Services

GBS develops, sells and orchestrates customer-specific Lotus Domino strategy and consulting services, such as CIO and IT department leader Strategic Advisory Services, Managed Services, Outsourcing, Administration, Assessments and Implementations, Performance Improvements, Custom Application Development, Governance and Security, Technical Support, and Training, as well as Email Migration Services.

Based on GBS’s unique concentration of industry talent and expertise, mainly in the areas inside and around IBM Lotus Notes/Domino, inside and around corporate messaging (IBM, Microsoft, SMTP) and inside and around IT environmental and application assessment, analysis and reporting, commercial and governmental customers, as well as Software Integrators (SI) and channel partners, are able to rely on the company’s strategic and tactical advisory services for evaluating, planning, staffing and execution of related customer projects. GBS Consulting Services’ global teams of consultants use modern project management techniques, proprietary methodologies and GBS accelerator technologies to complete client projects on time and with reduced risk.

We believe that our focus on recruiting and retaining top Lotus expertise positions our team to offer leading-edge Lotus Notes / Domino subject matter knowledge to our customers.

As a Premier IBM Business Partner, GBS is one of the few partners that can sell and support licenses for all five IBM software brands: Lotus, WebSphere, Rational, Tivoli, and DB2.

Market Trends

As IT departments face continuous budget reductions and constant pressure for higher performance and efficiency, CIOs are focusing on modern technologies to support their need for increased scalability, flexibility and lower costs. GBS has identified this demand as a strategic growth opportunity for the company and has placed a significant focus on expanding its Modernizing/Migrating technology, which will assist client companies as they move to scale and adapt while remaining cost conscious.

GBS Lotus Application Modernization and Migration

GBS Lotus Application Modernization and Migration activities are focused on the IBM Lotus / Domino applications market and the offering spans from expert services and accelerator technologies to modernized, web enabled (also named “cloud” or “cloud computing”) and migrated Lotus applications; and thus ultimately to take the Lotus applications from legacy to the future. The foundation of the Modernizing/Migrating Suite Software offering is GBS’s significant R&D investment in a set of methodologies and key technology accelerators to automate the conversion of traditional Notes based client-server applications, into the IBM XPages framework which enables Domino applications to be run and accessed via the Lotus client, a web browser or on a mobile device. The patent-pended software that underpins Modernizing/Migrating was developed by GBS with assistance and guidance from IBM’s Software Group to ensure alignment with future releases of the IBM Lotus / Domino and XPages technology.

Revenue Model

GBS generates its revenue from the sale of internally created software, third-party developed software and the delivery of related services, including IT systems planning, administration, support, hosting, implementation and integration.

Strategy and Focus Areas

Based on current market demands for modern, Cloud-based and mobile-device capable business applications, we have acquired and developed a set of unique technologies that help organizations reduce the time, cost, resources and risks associated with modernizing or migrating their existing applications.

We generate revenue from subscription and usage fees and related services, including support and strategic consulting services. The subscription period is typically based on a yearly or multi-year contract with our customers. Another sector of our strategic portfolio is a suite of tools and methodologies we have developed to rapidly convert Lotus Notes applications into web and modern mobile applications. This portfolio includes a set of powerful analysis tools known as Insights that identify all of the Lotus Notes applications within an organization and provide metrics about the uses and users of those applications. Because of the nature of Lotus Notes and Domino, the applications within a customer environment tend to be highly distributed and number in the thousands. For many organizations, this fact alone makes it extremely difficult to plan for projects that involve modernizing these applications for use in a browser and on mobile devices or migrating them to another platform. Our technologies help them to dramatically reduce the cost, risk, time and resources associated with these highly complex projects.

We generate revenue with our analysis tools by charging a fee for the use of our technology and for the associated cost of the services to produce a report and set of recommendations for the customer. Additional revenues come from consulting services that result from helping our customers implement those recommendations. For use of our conversion tools, referred to as Modernizing/Migrating, we charge a flat fee for the conversion and additional hourly rates to perform additional supporting development or testing as needed. We also believe there is a significant revenue opportunity in licensing these tools to a network of global partners who also have existing presence and expertise in the Lotus Notes and Domino market. We have established partner agreements for the use of the analysis and conversion tools with partners in several countries and directly with IBM.

General Corporate History

The Company was originally incorporated in the state of Nevada on March 20, 2007 as SWAV Enterprises Ltd. (“SWAV”). SWAV was in a different industry and had a different management team and Board of Directors.

On April 26, 2010, SWAV purchased certain technology assets of Lotus Holdings Ltd. (“Lotus”) in consideration for 2,265,240 shares of SWAV common stock. Also on April 26, 2010, Lotus (on behalf of the SPPEF Members as discussed below) purchased an aggregate of 11,984,770 of the outstanding shares of SWAV common stock from certain selling shareholders of SWAV for an aggregate purchase price of $370,000. As a result of these two setsany new information, future events, changed circumstances or otherwise.

OVERVIEW

Marizyme is a multi-technology platform life science company with clinically tested and patented product platforms for myocardial and vein graft preservation, protein enzyme therapeutics for wound healing, thrombosis and pet health. Marizyme is dedicated to the acquisition, development and commercialization of transactions, Lotus acquired an aggregate of 14,250,010 shares of SWAV common stock which constituted approximately 95.0% of the 15,000,000 outstanding shares of SWAV common stock on April 26, 2010.

Upon the consummation of the April 26, 2010 acquisition, the then executive officerstherapies, devices and directors of SWAV resignedrelated products that maintain cellular viability and Mr. Joerg Ott, the Chief Executive Officer of GROUPsupport metabolism, thereby promoting cellular health and a GROUP Major Shareholder, was appointed the Chief Executive Officer of SWAV and sole member of SWAV’s Board of Directors. Mr. Ott currently serves as the Chairman of the Board of Directors of GBSX and the Chief Executive Officer of GROUP.

On September 6, 2010, SWAV’s name was changed to GBS Enterprises Incorporated. On October 14, 2010, the Company’s trading symbol on the OTC Bulletin Board was changed from SWAV to GBSX. The Company’sproper function. Our common stock is currently quoted on the OTC Market OTCQBMarkets’ QB tier under the ticker symbol GBSX.“MRZM.” The Company is actively working toward listing its common stock on the NASDAQ Stock Market within the next twelve months from the date of this report. We may also examine our options with respect to listing of our common stock on the New York Stock Exchange (“NYSE”).

Our Products

Krillase - through our acquisition of the Krillase technology from ACB Holding AB in 2018, we purchased a European Union researched and evaluated protease therapeutic platform that has the potential for use in the treatment of chronic wounds and burns, and other clinical applications. Krillase is a drug which has been classified as a Class III medical device in Europe for treating chronic wounds. Krillase, derived from Antarctic krill, shrimp-like crustaceans, is a combination of endo and exopeptidases that safely and efficiently breaks down organic material. The mix of proteinases and peptidases in Krillase helps the Antarctic krill digest and break down its food in the extremely cold Antarctic environment. As a result, this specialized collection of enzymes provides a unique biochemical “cutting” capability. As a “biochemical knife”, Krillase can potentially break down organic matter, such as necrotic tissue, thrombogenic material, and biofilms produced by microorganisms. As such, it may be useful in the mitigation or treatment of multiple disease states in humans. For example, Krillase may dissolve arterial thrombogenic plaque safely and efficiently, promote faster healing and support the grafting of skin for the treatment of chronic wounds and burns, and reduce bacterial biofilms associated with poor oral health in humans and animals.

We have acquired a Krillase-based product pipeline that is focused on developing products that treat several conditions across the critical care market. Itemized below is a breakdown of our projected Krillase development pipeline:

MB101 – Therapy for complex wounds and burns,
MB102 – Therapy for acute ischemic stroke,
MB104 – Therapy for deep vein thrombosis, and
MB105 – Therapy for dissolving plaque and biofilms on teeth.

 

About Lotus Holdings, Ltd.Krillase received medical device status in the European Union for debridement of deep partial and full-thickness wounds in hospitalized patients, on July 19, 2005.

LotusAs of the date of this filing, the Company continues to evaluate commercial, clinical, research, and regulatory considerations involved in marketing our Krillase-based product line. Our commercial strategy in developing this product line is a holding company which was formed under the laws of Gibraltartwo-fold:

First, leverage and maximize near-term revenue generating opportunities with products for commercial or clinical applications that have low regulatory risk, and
Second, develop products for applications of the Krillase platform that address unmet medical needs or address medical market needs better than existing products in the marketplace, in clinical applications that have higher regulatory risk, but significant commercial potential.

We anticipate finalizing our development, operation, and commercial strategy for the purposeKrillase platform by 2022 and expect the first stream of financing mergerrevenue from sale of the product to be generated in 2023.

19

DuraGraft – through our acquisition of Somah in July 2020, we acquired its key intellectual products, based on its cytoprotective platform technology, to prevent ischemic injury to organs and acquisition projects, specificallytissues in grafting and transplantation surgeries. Its products and product candidates, which are referred to as the Somah Products, include DuraGraft, a one-time intraoperative vascular graft treatment for use in vascular and bypass surgeries that maintains endothelial function and structure, thereby reducing the incidence and complications of graft failure and improving clinical outcomes post bypass surgery.

DuraGraft is an “endothelial damage inhibitor” indicated for cardiac bypass, peripheral bypass, and other vascular surgeries. It is CE marked and is approved for marketing in 33 countries worldwide on 4 continents including, but not limited to the European Union, Turkey, Singapore, Hong Kong, India, the Philippines, and Malaysia. Somahlution has also been focused on developing products to mitigate the effects of ischemia reperfusion injury in other grafting and transplantation surgeries and other indications in which ischemic injury can cause disease. Multiple products derived from the cytoprotective platform technology for several indications are under various stages of development.

According to market analysis reports, the size value of the coronary artery bypass graft market globally was approximately $16 billion. This market is forecasted to increase at a CAGR of 5.8% from 2017 to 2025 (Grand View Research, March 2017). Globally, it is estimated that approximately 800,000 CABG procedures are performed each year (Grand View Research, March 2017), with procedures performed in the niche marketU.S. being a substantial percentage of small or microcap companies listed on the Frankfurt Stock Exchange with complex shareholder structurestotal global procedures performed. In the U.S., it is estimated that approximately 340,000 CABG surgeries are performed each year. The number of CABG procedures performed is predicted to decline at a rate of approximately 0.8% per year to less than 330,000 annually by 2026, primarily due to medical and whose stock is trading below one Euro (€1.00) per share.

SPPEFs

Lotus typically finances its merger and acquisition projects throughtechnological advances in the use of Special Purpose Private Equity Funds (“SPPEFs”)percutaneous coronary intervention, also known as “angioplasty” (idata Research, September 2018). Typically, SPPEFs are funded

In 2017, the number of peripheral vascular surgeries, which include angioplasty and bypass of peripheral arteries, vein removal, thrombectomy, and endarterectomy operations, were approximately 3.7 million worldwide. The number of peripheral vascular procedures is forecasted to increase at a CAGR of 3.9% in years 2017 to 2022 and is expected to exceed 4.5 million procedures by 2022 (Research and Markets, October 2018).

The Company is currently working with local distributors of cardiovascular disease-related products, in accordance with local regulatory requirements, to sell and increase the market share of DuraGraft in Europe, South America, Australia, Africa, the Middle East, and the Far East. As of the date of this filing, the Company anticipates that the submission of a company’s major shareholders (the “Major Shareholders”) seekingde novo 510k application to the U.S will occur in the second quarter of 2022 and is optimistic that the approval will be granted by the end of 2022.

In anticipation of the filing of the de novo 510k application for DuraGraft, the company plans to submit a pre-submission document to the FDA that describes the strategy for demonstrating the clinical safety and efficacy of the product. FDA application for the use of DuraGraft in CABG procedures is expected to take place in 2022.

DuraGraft commercialization plan with CE Mark and existing distribution partners in select European and Asia countries will begin in Q2 2022, with a targeted approach based on market access, existing KOL’s, clinical data and revenue penetration. The company will also begin the process of developing the US CABG market for DuraGraft with the development of KOL’s, existing publications, select clinical studies, digital marketing, and multiple sales channels.

Key Elements of our Strategy

Continue to grow the core of our business through the current market channels for DuraGraft and expand the sale of DuraGraft into additional markets globally as well as explore further use of the cytoprotective platform for new research and clinical applications,
Continue the integration of the Somah assets and begin the marketing and distribution of the Somah products in Europe and other global markets, which will allow the Company to continue its growth and international product rollout,
Focus our efforts and resources on continuous development, seek regulatory approval and commercialization of DuraGraft and related Somah Products in the United States,
Begin to commercialize our Krillase platform through the development of manufacturing and distribution in Europe and South America of a Krillase wound healing product, and
Expand our product portfolio through the identification and acquisition of additional life science assets in areas of innovative medicine.

We have incurred losses for each period from our inception. For the nine months ended September 30, 2021 and 2020, our net loss was approximately $5.5 million and $3.0 million, respectively. We expect to incur expenses and operating losses over the next several years. Accordingly, we will need additional financing to support our continuing operations. We will seek to fund our operations through public or private equity offerings, debt financings, government or other third-party funding, collaborations and licensing arrangements. Adequate additional financing may not be available to us on acceptable terms, or at all. Our failure to raise capital for projectsas and who fund at least 50%when needed would impact our going concern and would have a negative impact on our financial condition and our ability to pursue our business strategy and continue as a going concern. We will need to generate significant revenues to achieve profitability, and we may never do so.

20

KEY 2021 HIGHLIGHTS

Acquisition of My Health Logic

On November 1, 2021, Marizyme entered into a definitive arrangement agreement with Health Logic Interactive Inc. (“HLII”) pursuant to which the SPPEF,Company will acquire My Health Logic Inc. (“MHL”), a wholly owned subsidiary of HLII (the “Transaction”).

The Transaction will be effected by way of a plan of arrangement under the Business Corporations Act (British Columbia). In connection with the remaining portion being provided through the investment community and networkplan of investors in Lotus. Each SPPEF is co-managed by a representative of the Major Shareholders (the “Representative Secretary”) and an attorney appointed by Lotus (the “Lotus Representative”).

On February 25, 2010, a group of shareholders (the “GROUP Major Shareholders”) of GROUP Software AG, a German public company trading on the Frankfurt Stock Exchange under the symbol “INW” (“GROUP”), engaged Lotus to provide financial consulting and advisory services, on a non-exclusive basis, for the primary task of establishing a SPPEF. On March 12, 2010, the GROUP Major Shareholders and Lotus established and funded a SPPEF with $1,400,000, consisting of $1,000,000 from the GROUP Major Shareholders and $400,000 from a Lotus investor (collectively, the “SPPEF Members”).

In early April 2010, the SPPEF Members decided to acquire SWAV. As disclosed above, on April 26, 2010, Lotus, on behalf of the SPPEF Members, acquiredarrangement, Marizyme will issue an aggregate of 11,984,7704,600,000 shares of SWAVits common stock to HLII, which will be subject to certain terms and restrictions. Upon closing, My Health Logic Inc. will be a wholly owned subsidiary of Marizyme. The transaction is expected to close on or before December 31, 2021.

The acquisition will provide Marizyme with access to consumer-focused handheld point-of-care diagnostic devices that connect to patients’ smartphones and digital continued care platforms, developed by MHL. My Health Logic Inc. plans to use its patent pending lab-on-chip technology to provide rapid results and facilitate the transfer of that data from the selling shareholders of SWAVdiagnostic device to the patient’s smartphone. MHL expects this data collection will allow it to better assess patient risk profiles and provide better patient outcomes. My Health Logic Inc.’s mission is to empower people with the ability to get early detection anytime, anywhere with actionable digital management for an aggregate purchase price of $370,000. The 11,984,770 shares of SWAV common stock shares represented approximately 79.9%chronic kidney disease.

With the completion of the 15,000,000 outstanding shares of SWAV common stock on April 26, 2010.

Transactions following the April 26, 2010 Transaction

On November 1, 2010,transaction, the Company repurchasedwill acquire MHL’s digital diagnostic device MATLOC1. MATLOC 1 is the proprietary diagnostic platform technology in development for the testing of different biomarkers, with a current focus on the urine-based biomarkers albumin and creatinine for chronic kidney disease screening and eventual diagnosis. The Company anticipates MATLOC 1 device will be submitted for FDA approval in late 2022 and the management is optimistic that the approval will be received by mid-2023.

Financing

In May 2021, the Company began its offering in a private placement under Rule 506 of Regulation D under the Securities Act up to 4,000,000 units (the “Offering”), comprised of a convertible notes and warrants, with the intent to raise up to $10,000,000 on a rolling basis. The certain terms and conditions of the Offering were amended in September 2021. For the nine-month period ended September 30, 2021, the Company sold and issued an aggregate of 3,043,985522,198 Units for the total proceeds of $1,060,949. The proceeds from the offering will be used to sustain the Company’s growth and meet its capital obligations.

Operational

During the nine months ended September 30, 2021, Marizyme has been undergoing a corporate restructuring, whereby the key officers, directors, and management team has changed in order to accelerate Company’s progress toward meeting its key objectives and deliver on its strategy. After the closure and completion of MHL transaction, the Company anticipates more changes to its key management team to further streamline and improve the overall performance of the 11,984,770 sharesCompany.

FINANCIAL OPERATIONS REVIEW

Component of Results of Operations

Revenue

Revenue represents gross product sales less service fees and product returns. For our Distribution Partner channel, we recognize revenue for product sales at the time of delivery of the Company’s commonproduct to our Distribution Partner. As our products have an expiration date, if a product expires, we will replace the product at no charge. Currently, all of our revenue is generated from the sale of DuraGraft in European and Asian markets where the product met the required regulatory approvals.

Direct Costs of Revenue

Direct costs of revenue include primarily product costs, which include all costs directly related to the purchase of raw materials, charges from our contract manufacturing organizations, and manufacturing overhead costs, as well as shipping and distribution charges. Direct costs of revenue also include losses from excess, slow-moving or obsolete inventory and inventory purchase commitments, if any.


Professional Fees

Professional fees include legal fees relating to intellectual property development and corporate matters, and consulting fees for accounting, finance, and valuation services. We anticipate increased expenses related to audit, legal, regulatory, and tax-related services associated with maintaining compliance with exchange listing and Securities and Exchange Commission requirements.

Salaries and Stock-Based Compensation

Salaries consists of compensation and related personnel costs. Stock-based compensation represents the fair value of equity-settled share awards on stock originally purchasedoptions granted by Lotus on April 26, 2010. In consideration for these 3,043,985 shares, the Company to its employees, officers, directors, and consultants. The fair value of awards is calculated using the Black-Scholes option pricing model, which considers the following factors: exercise price, current market price of the underlying shares, expected life, risk-free interest rate, expected volatility, dividend yield, and forfeiture rate.

Other General and Administrative Expenses

Other general and administrative expenses consist principally of marketing and selling expenses, facility costs, administrative and office expenses, director and officer insurance premiums, and investor relations costs associated with operating a public company.

21

Other Income and Expenses

Other income and expenses consists of mark to market adjustments on contingent liabilities assumed on the acquisition of Somah and interest and accretion expenses related to our convertible notes issued pursuant to Lotus a Secured Demand Note, dated November 1, 2010 (the “First Demand Note”),the Unit Purchase Agreement.

RESULTS OF OPERATIONS

Comparison of the Nine Months Ended September 30, 2021 and 2020

The following table summarizes our results of operations for the principal amountnine months ended September 30, 2021 and 2020:

  Nine Months Ended
September 30,
    
  2021  2020  Change 
          
Revenue $271,952  $124,985  $146,967 
             
Operating expenses:            
Direct costs of revenue  168,419   25,714   142,705 
Professional fees  1,808,093   494,295   1,313,798 
Salary expenses  2,478,357   433,318   2,045,039 
Stock-based compensation  626,449   1,674,200   (1,047,751)
Other general and administrative expenses  1,071,017   468,782   602,235 
Total operating expenses  6,152,335   3,096,309   3,056,026 
Total operating loss $(5,880,383) $(2,971,324) $(2,909,059)
Other income (expenses):            
Interest and accretion expenses  (74,410)  -   (74,410)
Change in fair value of contingent liabilities  472,000   -   472,000 
Net loss $(5,482,793) $(2,971,324) $(2,511,469)

Revenue

We recognized revenue of $300,000, bearing interest at the rate of 5% per annum. The First Demand Note was repaid in September 2011.

Effective December 30, 2010, pursuant to securities purchase agreements between the Company and six GROUP Major Shareholders, the Company purchased an aggregate of 7,115,500 shares of GROUP common stock from the six GROUP Major Shareholders in consideration$0.27 million for the 3,043,985 sharesnine months ended September 30, 2021 compared to $0.12 million for the nine months ended September 30, 2020. The increase in revenue over the comparative period can be primarily attributed to the growing sales of GBS common stock (the “December 2010 Transaction”). AsDuraGraft, which was acquired as part of the Somah Transaction.

Direct Costs of Revenue

During the nine months ended September 30, 2021, we incurred $0.17 million in direct costs of revenue, representing increase of $0.15 million if compared to $0.03 million of the direct cost of revenue incurred during the nine months ended September 30, 2020. Cost of sales grew at a higher rate if compared to the revenue growth, predominantly due to shortage of the raw materials as a result of COVID-19 pandemic which directly impacted the costs of finding, securing, and acquiring alternative high-quality materials.

Professional Fees

Professional fees increased by $1.3 million or 266% to $1.81 million for the period ended September 30, 2021, compared to $0.49 million for the period ended September 30, 2020. The Company owned approximately 28.2%has undergone a number of corporate transactions, including acquisition of the outstanding common stock of GROUP.

Reverse Merger

After the December 2010 TransactionSomah entities and a corporate restructuring, which resulted in legal fees increasing significantly period over period. The increase in professional fees was completed, the additional GROUP Major Shareholders decided to accept the share swap offer from the Company and to effectuate a reverse merger of GROUP and the Company. To effectuate the reverse merger, on January 5, 2011, the Company repurchased from Lotus an aggregate of 2,361,426 of the 11,984,770 shares of the Company’s common stock originally purchased by Lotus on April 26, 2010. In consideration for these 2,361,426 shares, the Company issued to Lotus a Secured Demand Note, dated January 5, 2011 (the “Second Demand Note”), for the principal amount of $200,000, bearing interest at the rate of 5% per annum. The Second Demand Note was repaid in November 2011.

Effective January 6, 2011, pursuant to securities purchase agreements between the Company and the remaining GROUP Major Shareholders, the Company purchased an aggregate of 5,525,735 shares of GROUP common stock from the remaining GROUP Major Shareholders in consideration for the 2,361,426 shares of GBS common stock (the “January 2011 Transaction”). These 5,525,735 GROUP shares represented approximately 21.9% of the outstanding shares of common stock of GROUP. Asalso a result of the December 2010 TransactionCompany’s preparations for the FDA approval and January 2011 Transaction, the Company had acquired an aggregateother advancement and development of 12,641,235 sharesintellectual property. Additionally, Marizyme relied on number of GROUP common stock from the GROUP Major Shareholders in consideration for an aggregate of 5,405,411 shares of GBS common stock, resulting in GBS owning approximately 50.1%external consulting firms to oversee multiple facets of the outstanding GROUP common stockbusiness, including finance and effectuating a reverse mergeraccounting functions of the Company and GROUP whereby GROUP becameCompany. In the accounting acquirer.

Additional GROUP Acquisition

On February 27, 2012, we acquired an additional 883,765 shares of GROUP common stock for $619,000 in ordernine months ended September 30, 2021, Marizyme has also initiated the public offering transaction, which further contributed to maintain our 50.1% majority ownership of GROUP due to anthe professional fees increase in the outstanding common stock of GROUP.period.

Executive OfficesSalary Expenses

 

Our principal executive office is located at 585 Molly Lane, Woodstock, Georgia 30189 and our telephone number is (404) 891-1711. GROUP’s executive offices are located at Hospitalstrasse 6, 99817 Eisenach, Germany. We maintainSalary expenses for the period ended September 30, 2021, were $2.48 million, a website at www.gbsx.us. GROUP maintains a website at www.gbs.com.$2.05 million or 472% increase from the comparative period. The information containedincrease in the Company’ssalary cost is attributable to the restructuring and GROUP’s websites is not incorporated by reference herein.growth of the organization as the Company continues to expand into the new markets and working towards commercialization of the DuraGraft in the United States.

ChangesOther General and Administrative Expenses

Other general and administrative expenses increased $0.6 million or 128% to $1.07 million in Financial Condition

Assets:

Total Assets decreased from $56,802,492 at December 31, 2012 to $47,279,675 atthe nine months ended September 30, 2013.  Total Assets consists2021. The increase was due to the Company’s restructuring, growth, and increased marketing and public relations expenses associated with product branding and costs attributed to running a public company. Due to the planned continued buildout of Total Current Assetsadministrative and Total Non-Current Assets.commercial functions we expect general and administrative expenses to increase in future periods.

22

Total Current AssetsOther Income and Expenses

AtDuring the nine months ended September 30, 2013, Total Current Assets were $4,294,2242021, the Company conducted the Offering, which included multiple closings in tranches on a rolling basis. The interest and accretion costs associated with convertible notes issued at discount as comparedpart of the Offering agreements.

Additionally, the company recognized $0.47 million of fair value gain from mark to $6,444,192 at December 31, 2012. Total Current Assets consist of: Cash and Cash Equivalents, Accounts Receivable, Inventory, Prepaid Expenses, and Other Receivables-current.market adjustments on the contingent liabilities assumed on the acquisition of Somah.

nCash and Cash Equivalents decreased from $1,154,602 at December 31, 2012 to $259,614 at September 30, 2013 as a result of our investments in strategic technology areas such as application migration and modernization and the associated costs necessary to build and implement the go- to- market strategy and losses in operations.

nAccounts Receivable decreased from $4,143,448 at December 31, 2012 to $3,528,260 at September 30, 2013 due to increased collections during the reporting period and less revenue.

nInventory increased from $nil at December 31, 2012 to $21,684 at September 30, 2013.

nPrepaid Expenses increased from $84,304 at December 31, 2012 to $207,811 at September 30, 2013 from prepaid rent, insurance and advances on technological events.

nOther Receivables-current decreased from $676,976 at December 31, 2012 to $276,856 at September 30, 2013.

Total Non-Current Assets

At September 30, 2013, Total Non-Current Assets were $42,985,450 as compared to $50,358,300 at December 31, 2012.  Total Non-Current Assets consist of: Property Plant and Equipment, Other Receivables non-current, Deferred Tax Assets non-current, Goodwill, Software, and Other Assets.

nNet Property (plant and equipment) decreased from $332,839 at December 31, 2012 to $282,601 at September 30, 2013.

nOther Receivables non-current decreased from $428,422 at December 31, 2012 to $1,217 at September 30, 2013 and consisted of cooperative shares.

nDeferred Tax Assets non-current decreased from $1,132,103 at December 31, 2012 to $1,076,010 at September 30, 2013 and consisted of Deferred Tax Assets derived from financial assets and losses carried forward.

nGoodwill decreased from $34,254,881 at December 31, 2012 to $31,260,500 at September 30, 2013. The decrease in goodwill of $2,994,381 resulted from the sale of the subsidiary IDC Global, Inc. on February 1, 2013.

nSoftware decreased from $12,207,031 at December 31, 2012 to $10,232,633 at September 30, 2013, as a result of the quarterly re-calculation of capitalized development costs, product rights and license for our expert business software, legacy business software and strategic business software all in the developmental or improvement stage. The decrease is also related to an overall cost reduction program, resulting in less contribution of capitalized software development.

nOther Assets decreased from $156,379 at December 31, 2012 to $132,489 at September 30, 2013. This category includes rent and other security deposits.

Liabilities

Total Liabilities decreased from $22,269,060 at December 31, 2012 to $16,870,431 at September 30, 2013.  Total Liabilities consistsComparison of Total Current Liabilities and Total Non-Current Liabilities.

Total Current Liabilities

At September 30, 2013, Total Current Liabilities were $16,698,017, compared to $18,227,184 at December 31, 2012.  Total Current Liabilities consist of Notes Payable, Liabilities to Banks, Accounts Payable and Accrued Liabilities, Deferred Income, and Other Liabilities.

nNotes Payable decreased from $2,313,572 at December 31, 2012 to $1,775,010 at September 30, 2013 based on repayments of short terms loans during the quarter.

nLiabilities to Banks increased from $6,774 at December 31, 2012 to $3,887,764 at September 30, 2013 and included a line of credit and cash in transit. The increase was mainly as a result from reclassification from non-current liabilities to current liabilities.
nAccounts Payable and Accrued Liabilitiesdecreased from $6,241,733 at December 31, 2012 to $3,946,070 at September 30, 2013. The decrease was due to the reduction of trade payables by approximately $1,034,000 and a decrease in accrued liabilities of approximately $1,262,000 by repayment and as a result of the sale of subsidiary IDC Global. The remaining amounts were reclassified into other short term notes and due to related parties.

nDeferred Income increased from $6,099,570 at December 31, 2012 to $6,846,920 at September 30, 2013, and consists mainly of maintenance income collected in advance of the contractual maintenance period.
nOther Liabilities of $860,032 at December 31, 2012 decreased to $242,352 at September 30, 2013 and includes miscellaneous short term obligations including current amounts due on business assets.

Total Non-Current Liabilities

At September 30, 2013, our Total Non-Current Liabilities were $172,414 compared to $4,041,876 at December 31, 2012.  Total Non-Current Liabilities consist of Liabilities to Banks, Retirement Benefit Obligation, Liabilities Held for Sale, and Deferred Tax Liabilities non-current.

nLiabilities to Banks decreased from $3,716,102 at December 31, 2012 to $Nil at September 30, 2013 as a result from reclassification from non-current liabilities to current liabilities.

nRetirement Benefit Obligation increased from $165,876 at December 31, 2012 to $172,414 at September 30, 2013.
nLiabilities Held for Sale decreased from $159,898 at December 31, 2012 to $Nil at September 30, 2013 as a result of the sale of IDC Global, Inc. on February 1, 2013.

Results of Operations

Three Months Ended September 30, 2013 Compared to the Three Months Ended September 30, 20122021 and 2020

Revenues

For the three months ended September 30, 2013,The following table summarizes our total revenue decreased to $5,065,656 from $ 5,709,778results of operations for the three months ended September 30, 2012, a decline2021 and 2020:

  Three Months Ended
September 30,
    
  2021  2020  Change 
          
Revenue $37,215  $124,985  $(87,770)
             
Operating expenses:            
Direct costs of revenue  18,356   25,714   (7,358)
Professional fees  556,254   170,753   385,501 
Salary expenses  617,826   433,318   184,508 
Stock-based compensation  64,074   1,107,085   (1,043,011)
Other general and administrative expenses  536,483   453,158   83,325 
Total operating expenses  1,792,993   2,190,028   (397,035)
Total operating loss $(1,755,778) $(2,065,043) $309,265 
Other income (expenses):            
Interest and accretion expenses  (70,221)  -   (70,221)
Change in fair value of contingent liabilities  194,000   -   - 
Net loss $(1,631,999) $(2,065,043) $239,044 

Revenue and Direct Cost of $644,122 or 11%. The Company generatesRevenue

We recognized revenue from two divisions. The Product division of Revenues includes revenue generated from the sale of Licenses, Maintenance, Third-Party Products, and Other revenues. The Service division includes revenue generated from services rendered.

The Product division decreased to $4,133,565$0.04 million for the three months ended September 30, 2013 from $4,719,4462021 compared to $0.12 million for the three months ended September 30, 2012,2020, which represents a 70% decrease period over period. During the three months ended September 30, 2021, we incurred $0.02 million in direct costs of revenue, representing a decrease of $585,881 or 12%. The primary contributing29% if compared to $0.03 million in the direct cost of revenue incurred during the three months ended September 30, 2020.

COVID-19 pandemic resulted in shortage of the raw materials and interruptions in global supply chains. Additionally, during 2021, Marizyme’s business partners were focused on addressing specific manufacturing needs of the U.S. government in battling COVID-19 pandemic. Moreover, during 2021, demand for elective surgeries have decreased due to overloaded medical systems and potential risks related to patients’ recovery during the pandemic. All of these factors were decreases in License revenueshave negatively impacted the Company’s revenue and direct costs of approximately $655,000, Third Party Product revenues of $350,000, increases in Maintenance revenues of approximately $490,000 and decreases in Other revenues of approximately $65,000sales for the three months ended September 30, 2013 compared2021.

Professional Fees

Professional fees increased by $0.39 million to the three months ended September 30, 2012. This is mainly as a result of economic conditions causing an increase in the sales cycles, whereby strategic customers are giving greater consideration towards the modernization/migration of their current application platform.

The Service division of revenue decreased $56,634 or 6% from $990,333$0.56 million for the three months ended September 30, 20122021 compared to $932,091$0.17 million for the three months ended September 30, 2013, primarily as a result2020. The increase in professional fees period over period relates to due diligence process associated with My Health Logic Inc.’s acquisition and finalizing of the salevaluation process of subsidiary companies that were contributors toassets acquired and liabilities assumed on completion of the Service division of revenue.Somah Transaction.

Cost of Goods SoldSalary Expenses

For the three months ended September 30, 2013, total Cost of Goods Sold decreased to $2,273,055 from $3,212,767Salary expenses for the three months ended September 30, 2012,2021, were $0.62 million, a $0.18 million or 43% increase from the comparative period. The increase in the salary cost reduction of $_939,712 or 29%.

The Company’s Cost of Goods Sold is segmented into two divisions. The first are costs relatedattributable to the Product divisiongrowth of revenue which includes the total cost of materials. The second are the costs related to the Service division of revenue which includes; other operating expenses, depreciation & amortization expense, and personnel expenses.

Within the Costs of Goods Sold related to the Product division,organization as the Company saw a $358,890continues to expand into the new markets and works towards commercialization of the DuraGraft in the United States.

Other General and Administrative Expenses

Other general and administrative expenses increased $0.08 million or 39% decrease from $ 922,839 for18% to $0.5 million in the three months ended September 30, 20122021. The increase was predominantly due to $_563,950 forthe legal, regulatory, and due diligence efforts related to the acquisition of My Health Logic Inc.

Other Income and Expenses

During the three months ended September 30, 2013. The primary factors contributing to the Company’s lower Costs of Goods Sold related to the Product division of revenues was a reduction of $282,639 in product material costs and of $76,250 in third party product material costs for the three months ended September 30, 2013 compared to the three months ended September 30, 2012.

Within the Costs of Goods Sold related to the Service division,2021, the Company had a reductioncompleted its second and the biggest tranche of $580,822 or 25%, in the total costsOffering and issued the highest amount of services from $ 2,289,927 for the three months ended September 30, 2012convertible notes to $ 1,709,105 for the three months ended September 30, 2013.date. The primary factor contributing to the Company’s reduction in the costs of services was a decrease in the volume of services renderedinterest and a reduction in personnel costs, depreciation and amortizationaccretion costs associated with convertible notes issued at discount as part of the sale of subsidiary companies. Additional personnel costs relating to Services are included in Selling Expenses and these were also reduced from the quarter ending September 30, 2012 as indicated below.Offering agreements.

 

Operating Expenses

The Company’s total operating expense consists of three segments; selling, administrative and general expenses. For the three months ended September 30, 2013, total operating expenses decreased $878,493 or 21% to $3,294,910 from $4,173,403 for the three months ended September 30, 2012. 

For the three months ended September 30, 2013, Selling Expenses decreased $592,531 or 23% to $ 2,033,242 from $2,625,773 for the three months ended September 30, 2012.  This was primarily due to decreases in cost of materials of $13,269, personnel expense of $532,914 and in other selling expense of $81,705, coupled with a reduction in other operating income of $9,522 and a slight increase in depreciation expense of $480.

For the three months ended September 30, 2013, Administrative Expense decreased by $83,977 or 7% to $1,145,304 from $1,229,281 for the three months ended September 30, 2012. This was primarily due to a reduction in personnel costs of $55,535 coupled with an increase in other operating income of $1,116 and decreases in other administrative expense of $ 142,207 and depreciation expense of $3,812.

5123
 

ForDuring the three months ended September 30, 2013, General Expense decreased $197,9862021, the company recognized $0.19 million of fair value gain from mark to $120,364market adjustments on the contingent liabilities assumed on the acquisition of Somah

LIQUIDUTY AND CAPITAL RESOURCES

We have incurred net losses and negative cash flows from $318,350operations since our inception and anticipate we will continue to incur net losses for the three months endedforeseeable future. As of September 30, 2012. This was primarily due decreases2021, we had cash and cash equivalents of $50,011 in other operating income and in personnel expense of $16,282, and other operating expense of $231,541. Depreciation of approximately $22,000 was at the same level as for the three months ended September 2012.$16,673.

Other Income (Expense)The Offering

 

ForIn May of 2021, Marizyme’s Board of Directors, authorized the three months ended September 30, 2013, net Other ExpensesCompany to initiate the Offering and sell up to 4,000,000 units (the “Units”) at a price per Unit of $95,487 increased from net Other Income$2.50. Each Unit was comprised of $759,169for(i) a convertible promissory note convertible into common stock of the three months ended September 30, 2012. This change is primarily dueCompany at an initial price per share of $2.50, (ii) a warrant to purchase one share of common stock of the Company (the ‘Class A Warrant’); and (iii) a decrease in Other Incomesecond warrant to purchase a share of $847,976 and an increase in net Interest Expensecommon stock of $6,472 for the three months ended September 30, 2013 compared to the three months ended September 30, 2012.Company (the “Class B Warrant”).

Nine Months Ended September 30, 2013 Compared to the Nine Months Ended September 30, 2012

Revenues

ForIn the nine months ended September 2021, the Company issued an aggregate of 469,978 Units in connection with the Offering, for the total proceeds of $1,060,949.

On September 29, 2021, the Company, with the consent of all Unit holders, amended the May 2021 Unit Agreements. By rescinding their investment, the Unit holders agreed to amend the Unit Purchase Agreement resulted in the following changes to the offering:

(iv)Decreased the offering price under the Unit Purchase Agreement from $2.50 per Unit to $2.25 per Unit for all future sales under the Unit Purchase Agreement. No proceeds from the initial investment were returned,
(v)Decreased the conversion price from $2.50 per share to $2.25 per share for all current Unit holders and all future investors, and
(vi)Cancelled all Class A Warrants and Class B Warrants and replaced them with Class C Warrants.

The Company determined that the modifications of the Unit Purchase Agreement were not significant enough to be considered substantial, therefore the values of original instruments issued were not adjusted. As a result of this modification, the total of 469,978 Units previously issued were replaced with an aggregate of 522,198 pro-rata Units.

The Company intends to raise up to $10,000,000 on a rolling basis. The proceeds from the offering will be used to sustain the Company’s growth and meet its capital obligations.

Funding Requirements and Other Liquidity Matters

Marizyme expects to continue to incur expenses and operating losses for the foreseeable future. We anticipate that our expenses will increase as a result of the following operational and business development efforts:

Increase our expertise and knowledge through hiring and retaining qualified operational, financial and management personnel, who will build efficient infrastructure to support development and commercialization of therapies and devices,
Expand our product portfolio through the identification and acquisition of additional life science assets, and
Seek to increase awareness about our products to boost sales and distributions internationally.

Until such time, if ever, as we can generate substantial product revenues to support our cost structure, the Company will continue to have to raise funds beyond its current working capital balance in order to finance future development of products, potential acquisitions, and meet its debt obligations until such time as future profitable revenues are achieved.

We expect to finance our cash needs through a combination of private and public equity offerings, debt financings, government or other third-party funding, and collaborations arrangements or acquisitions. To the extent that we raise additional capital through the sale of common stock, convertible securities or other equity securities, the ownership interest of our stockholders may be materially diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights of our common stockholders. Debt financing and preferred equity financing, if available, would result in increased fixed payment obligations and may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, that could adversely impact our ability to conduct our business. Securing additional financing could require a substantial amount of time and attention from our management and may divert a disproportionate amount of their attention away from day-to-day activities, which may adversely affect our management’s ability to oversee the development or acquisition of product.

If we raise additional funds through collaborations, strategic alliances or marketing, distribution, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.

24

Impact of the Coronavirus

On January 30, 2013,2020, the World Health Organization (“WHO”), announced a global health emergency because of a new strain of coronavirus, COVID-19 and the risks to the international community as the virus spreads globally beyond its point of origin. On March 11, 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally. The COVID-19 pandemic has affected the United States and global economies and may affect our total revenue decreased $3,151,581prospective current and future revenues, and our operations and those of third parties with whom we might interact, including by causing disruptions in the development of our product candidates, product marketing efforts and the conduct of current and expected future clinical trials.

In addition, the COVID-19 pandemic may affect the operations of the FDA and other health authorities, including such authorities in Europe, which could result in delays of reviews and approvals, including with respect to our product candidates and our plans to submit a Q-sub clinical proposal to the FDA for supporting an additional clinical study if required for the DuraGraft product. While there have been no specific notices of delay from federal or 16.8%foreign government authorities, potential interruptions, delays or changes to $15,613,048 from $ 18,764,628the operations of the FDA, or of any foreign authority with which we might interact, might impact the approval of any applications we plan and will need to file in the future.

Cash Flows

The following table sets forth a summary of the net cash flow activity for each of the periods indicated:

  Nine Months Ended
September 30,
    
  2021  2020  Change 
Net cash provided by/(used in):            
Operating activities $(4,313,038) $(948,305) $(3,364,733)
Investing activities  -   (130,333)  130,333 
Financing activities  1,426,949   6,275,064   (4,848,115)
Net increase/(decrease) in cash $(2,886,089) $5,196,426  $(8,082,515)

Operating Activities

Net cash used in operating activities was approximately $4.3 million and $1.0 million for the nine months ended September 30, 2012.2021 and 2020, respectively. The Company generates revenue from two divisions. The Product division of Revenues includes revenue generated from the sale of Licenses, Maintenance, Third-Party Products, and Other revenues. The Service division includes revenue generated from services rendered.

The Product division decreased $2,077,770 or 14% to $13,170,113 from $15,247,833net cash used in operating activities for the nine months ended September 30, 20122021 was due to approximately $1.8 million spent on professional fees and $2.5 million spent on salaries and related compensation expenses. The primary factors contributingnet change in operating assets and liabilities primarily related to the decline were decreases in License revenues of $954,414, Maintenance revenues of $116,808, Third Party Product revenues of $897,551 and Other revenues of $ 108,998 compared to the nine months ended September 30, 2012. This is mainly as a result of economic conditions causing an$1.0 million increase in accounts payable, accrued expenses, and amounts due to related parties in support of the sales cycles, whereby strategic customers are giving greater consideration towards the modernization/migrationgrowth of their current application platform.our operating activities.

The Service division of revenue decreased $1,073,810 or 31%, from $3,516,745Financing Activities

Net cash provided by financing activities for the nine months ended September 30, 20122021 was due to $ 2,442,935 for$0.4 million of money obtained from the issuance of promissory notes to related parties of the Company and $1.1 million of proceeds received from the Unit issuances pursuant to the Unit Purchase Agreement.

Contractual Obligations and Commitments

Other than disclosed below, there were no material changes outside the ordinary course of our business during the nine months ended September 30, 2013, primarily as a result2021 to the information regarding our contractual obligations that was disclosed in Management’s Discussion and Analysis of a reductionFinancial Condition and Results of Operations contained in service staff.our 2020 Form 10-K.

Cost of Goods SoldRoyalties and Other Commitments

ForUpon receiving the nine months ended September 30, 2013, total Cost of Goods Sold decreased $ 2,760,159 or 26% to $ 7,690,366 from $ 10,450,525FDA approval for the nine months ended September 30, 2012.DuraGraft and other key intellectual products, the Company:

Will pay royalties on net sales of all products obtained through acquisition of Somah’s assets,
Issue performance warrants with a strike price determined based on the average of the closing prices of the common shares for the 30 calendar days following the date of the public announcement of FDA approval, and
Upon liquidation of all or substantially all of the assets relating to the Somah products, we will pay 15% of the net sale proceeds up to a maximum of $20 million.

The Company’s CostCritical Accounting Policies and Significant Judgments and Estimates

Our management’s discussion and analysis of Goods Sold is segmented into two divisions. The first are costs related to the Product divisionour financial condition and results of revenue which includes the total cost of materials. The second are the costs related to the Service division of revenue which includes; other operating expenses, depreciation & amortization expense, and personnel expenses.

Within the Costs of Goods Sold related to the Product division the Company shows a $1,095,001 or 29% reduction from $3,833,550 for the nine months ended September 30, 2012 to $2,738,549 for the nine months ended September 30, 2013. The primary factors contributing to the Company’s lower Costs of Goods Sold related to the Product division of revenues was a reduction of $863,080 in product material costs and a reduction of $231,921 in third party product material costs, for the nine months ended September 30, 2013 compared to the nine months ended September 30, 2012.

Within the Costs of Goods Sold related to the Service division, the Company had a reduction of $_1,665,158 or 25% in the total costs of services from $6,616,975 for the nine months ended September 30, 2012 to $4,951,817 for the nine months ended September 30, 2013. The primary factor contributing to the Company’s reduction in the costs of services was a decrease in the volume of services rendered and a reduction in personnel costs, depreciation and amortization costs associated with the cost reduction program.

Operating Expenses

The Company’s total operating expense consist of three segments; selling, administrative and general expenses. For the nine months ended September 30, 2013, total operating expenses decreased $ 3,703,409 or 25 % to $ 10,938,080 from $14,641,489 for the nine months ended September 30, 2012. 

For the nine months ended September 30, 2013, Selling Expenses decreased $3,362,859 or 34 % to $ 6,627,311 from $ 9,990,170 for the nine months ended September 30, 2012.  This was primarily due to decreases in cost of materials of $ 234,736, personnel expense of $ 2,510,500 and in other selling expense of $ 663,892, coupled with a reduction in other operating income of $ 41,904 and a slight increase in depreciation expense of $ 4,365.

For the nine months ended September 30, 2013, Administrative Expense decreased by $ 17,652 or .45% to $3,922,440 from $3,940,092 for the nine months ended September 30, 2012. This was primarily due to an increase in other operating income of $ 76,593, an increase in personnel expenses of $ 211,539, increase in depreciation expense of $ 16,270 offset by a decrease in other operating expenses of $ 168,868

For the nine months ended September 30, 2013, General Expense decreased by $318,898 or 45 % to $392,329 from $711,227 for the nine months ended September 30, 2012. This was primarily due to a decrease in other operating costs of $ 211,603 and a decrease in personnel expenses of $ 67,508, an increase in other operating income of $ 159,480 with an increase in depreciation expense of $ 119,649

Other Income (Expense)

For the nine months ended September 30, 2013, net Other Income of $20,517 increased from net Other Expense of $185,996 for the nine months ended September 30, 2012. This change is primarily due to an increase in Other Income of $513,887 and a net increase in Interest Expense of $307,374 for the nine months ended September 30, 2013 compared to the nine months ended September 30, 2012.

Liquidity & Capital Resources

As September 30, 2013, the Company had $ 259,614 in cash and cash equivalents, compared to $1,154,602 at December 31, 2012.

The Company's cash flow depends on the timely and successful market entry of its strategic offerings. The dependency accounts for revenue generated from direct customers engagements, as well as for revenue generated through the partner channel network.

Especially for strategic offerings for paradigm shifting technologies, management's budget planoperations is based on a series of assumptions regarding market acceptance, readiness and pricing. While management's assumptions are based on market research and customer surveys, assumptions bear the risk of being incorrect and may result in a delay in customer projects and consequently a delay or a reduction in related invoicing. In case these delaysour financial statements, which have an impact on the Company's liquidity and therefore its ability to support its operations with the necessary cash flow, the Company depends on its ability to generate cash flow from other resources, such as debt financing from related or independent resources or as equity financing from existing shareholders or through the stock market.

Since 2012, the Company has been exploring internal and external sources for financing. To date, these sources have provided necessary funds to support the working capital needs of the Company; mainly to finance the Company’s strategic offerings.  There can be no assurances, however, that the Company will be able to obtain additional funds from these or any other sources or that such funds will be sufficient to permit the Company to implement its intended business strategy. In the event the Company is not able to secure additional funds, management will postpone any strategic investment until the financing will be sufficient. However, management believes as a result of the assets purchased and sold to date,prepared in accordance with the above-mentioned statement, the Company will be able to provide sufficient cash flow to support its standard operations for the next 9 months.

From time to time, the Company has issued promissory notes to fund its operations. As of September 30, 2013, the Company had an aggregate of $nil.

During the nine-month period ended September 30, 2013, we raised capital by consummating the following transactions:

nOn February 1, 2013, we sold 100% of our ownership in IDC Global, Inc. for net proceeds of $3,577,195.

nOn February 12, 2013, we issued an aggregate of 500,000 restricted shares of Common Stock to Board Member Stephen Baksa, pursuant to exercise of a common stock purchase warrant issued on October 26, 2012 and exercisable for $0.20 per share, for total proceeds of $100,000.

nOn February 12, 2013, the Company issued an aggregate of 250,000 restricted shares of Common Stock to an Accredited Investor (as that term is defined the Securities Act) pursuant to exercise of a common stock purchase warrant issued on November 30, 2012 and exercisable for $0.20 per share, for total proceeds of $50,000.

nOn April 26, 2013, the Company entered into a note purchase and security agreement (the “Loan Agreement”) with Stephen D. Baksa (the “Lender’), a member of the Board. Pursuant to the Loan Agreement, the Company issued a secured promissory note, dated April 26, 2013 (the “Note”), to Mr. Baksa for the principal amount of $200,000, bearing interest at a rate of 2% per month and maturing on June 30, 2013 or such other time as described in more detail in the Note, without any penalty for prepayment. This Note is secured by fifty percent (50%) of certain financial holdbacks to the Company pursuant to the Stock Purchase Agreement, dated February 1, 2013, by and among the Company, IDC Global, Inc. and Global Telecom & Technology Americas, Inc.
§In connection with the execution of the Loan Agreement, on April 29, 2013, the Company issued the Lender a common stock purchase warrant (the “Warrant”), pursuant to which the Lender is entitled to purchase 100,000 shares of common stock at an exercise price of $0.25 from May 1, 2013 until April 30, 2016. The Warrant was issued in a private transaction between the Company and the Lender and was exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to Section 4(a)(2) (formerly Section 4(2)) thereof.

§In connection with the execution of the Loan Agreement, on April 29, 2013, the Company issued the Lender a conditional common stock purchase warrant (the “Conditional Warrant”) which is exercisable in the event that Note is not paid in full by June 30, 2013, pursuant to which the Lender is entitled to purchase 100,000 shares of common stock at an exercise price of $0.25 from July 1, 2013 until June 30, 2016 as described more fully in the Note. The Conditional Warrant was issued in a private transaction between the Company and the Lender and was exempt from registration under the Securities Act, pursuant to Section 4(a)(2) (formerly Section 4(2)) thereof.

§The Company aggressively re-negotiated the terms of the Loan Agreement with the Lender and has swapped the outstanding loan against receivables.

nOn April 26, 2013, the Company entered into a note purchase and security agreement (the “Loan Agreement”) with Vitamin B Venture GmbH (the “Lender”), an entity of which Joerg Ott, the Company’s Chairman and Chief Executive Officer, has voting and dispositive control. Pursuant to the Loan Agreement, the Company issued to the Lender a secured promissory note, dated October 26, 2012 (the “Note”), for the principal amount of $200,000, bearing interest at a rate of 2% per month and maturing on June 30, 2013 or such other time as described in more detail in the Note, without any penalty for prepayment. This Note is secured by fifty percent (50%) of certain financial holdbacks to be paid to the Company pursuant to the Stock Purchase Agreement, dated February 1, 2013, by and among the Company, IDC Global, Inc. and Global Telecom & Technology Americas, Inc.

§In connection with the execution of the Loan Agreement, on April 29, 2013, the Company issued the Lender a common stock purchase warrant (the “Warrant”), pursuant to which the Lender is entitled to purchase 100,000 shares of common stock at an exercise price of $0.25 from May 1, 2013 until April 30, 2016. The Warrant was issued in a private transaction between the Company and the Lender and was exempt from registration under the Securities Act pursuant to Section 4(a)(2) (formerly Section 4(2)) thereof.

§In connection with the execution of the Loan Agreement, on April 29, 2013, the Company issued the Lender a conditional common stock purchase warrant (the “Conditional Warrant”) which is exercisable in the event that Note is not paid in full by June 30, 2013, pursuant to which the Lender is entitled to purchase 100,000 shares of common stock at an exercise price of $0.25 from July 1, 2013 until June 30, 2016 as described more fully in the Note. The Conditional Warrant was issued in a private transaction between the Company and the Lender and was exempt from registration under the Securities Act, pursuant to Section 4(a)(2) (formerly Section 4(2)) thereof.

§The Company aggressively re-negotiated the terms of the Loan Agreement with the Lender and has swapped the outstanding loan against receivables.

nOn August  6, 2013the Company issued 25,000 restricted shares of Common Stock to a third party non-affiliated consultant in consideration for consulting services rendered by the consultant to the Company. The Company issued the securities in reliance on Section 4(a)(2) (formerly Section 4(2)) of the Securities Act due to the fact that the issuance was isolated and did not involve a public offering of securities.

Subsequent Events:

On August 13, 2012, the Company entered into a note purchase and security agreement (the “Loan Agreement”) with John A. Moore, a member of the Board. Pursuant to the Loan Agreement, the Company issued a secured promissory note, dated October 26, 2012 (the “Note”), to Mr. Moore for the principal amount of $1,000,000, bearing interest at a rate of 20% per year and maturing on the earlier of the first anniversary date of the date of issuance or such other time as described in more detail in the Note, without any penalty for prepayment. To secure the obligations of the Company under the Note, the Company granted Mr. Moore a secured priority security interest in the Company’s Accounts Receivable and its subsidiaries locatedgenerally accepted accounting principles in the United States, of America, as more fully described in the full text of the document.

·In connection with the execution of the Loan Agreement, on October 26, 2012, the Company issued the Lender a common stock purchase warrant (the “Warrant”), pursuant to which the Lender is entitled to purchase 100,000 shares of common stock at an exercise price of $0.35 until the third anniversary date of the date of issuance. The Warrant was issued in a private transaction between the Company and the Lender and was exempt from registration under the Securities and Exchange Act of 1933, as amended, pursuant to Section 4(2) thereof. On October 16, 2013, Mr. Moore exercised the right to purchase 100,000 shares of common stock at the price of $0.35.

In the future, the Company may supplement its liquidity to fund its operations or implement its business strategy through the sale of equity or debt securities or through short or long term loans. However, there can be no assurances that the Company will be successful in consummating any such financings on favorable terms, if at all.

Cash Flows

  For the Nine Months Ended
September 30,
 
  2013  2012 
       
Net cash provided (used in) Operating Activities $1,355,523  $(2,634,297)
Net cash provided (used) by Discontinued $  $63,246 
Net cash provided (used in) Investing Activities $487,309  $(2,491,803)
Net cash provided (used in) Financing Activities $(2,389,541) $2,548,096 
Effect of exchange rate changes on cash $(348,280) $6,991 
Net increase (decrease) in cash and cash equivalents during the period $(894,988) $(2,507,867)
Cash and cash equivalents, beginning of period $1,154,602  $3,250,821 
Cash and cash equivalents, end of period $259,614  $742,954 

Net cash provided by operating activities for the nine month period ended September 30, 2013 was $ 1,355,523 compared to net cash used in operating activities of $2,634,397 and net cash provided by discontinued operation of $63,246 for the nine month period ended September 30, 2012, an increase of approximately $3,989,920. This change is due to the effects of a group wide cost reduction program and due to a reduction in operating Net Loss of approximately $ 2,090,934, decrease in Accounts Receivable, Prepaid Assets and other Non Current Assets of approximately $ 2,140,311, Gains on Sale of Assets of approximately $ 1,566,119, Deferred Income Taxes of approximately $ 1,477,813, shares issued in lieu of Interest and Consulting expense of approximately $ 269,288, Depreciation and Amortization of approximately $109,817, Gains from Equity Investment of approximately $ 26,751 and increase in Retirement Benefit Obligation of $ 6,538. This is offset with a write off of Goodwill of approximately $ (3,079,168). change in Inventory of approximately $ (140,929) and increase in the payment of Accounts Payable and other liabilities of approximately $ (477,522).

Net cash provided by investing activities during the nine month period ended September 30, 2013 was $ 487,309 compared to cash used by investing activities in the comparative period ended September 30, 2012 of $ 2,491,803, increasing by approximately $ 2,797,112. The increase was due to cash provided by the Sale of Intangible Assets of approximately $ 4,146,894,and cash provided by the Sale of property plant and equipment of $ 579,206 as offset by a change in Financial Assets of approximately $ (1,928,988). 

Net cash used in financing activities during the nine month period ended September 30, 2013 was $ 2,389,541 compared to net cash provided by financing activities in the comparative period ended September 30, 2012 of $ 2,548,096 decreasing by approximately $ 4,937,637 for the nine month period ended September 30, 2013. This change was due to a $ 3,483,175 reduction in capital paid-in, coupled with cash used by net borrowings from banks of $ 902,508 and payments towards related party loans of $ 2,087,437. Other borrowings provided approximately$ 1,535,482.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

Critical Accounting Policies and Estimates

GAAP. The preparation of our financial statements in conformity with accounting principles generally accepted in the United States of America requires managementus to make estimates and assumptions that affect the reported amounts of assets, and liabilities and disclosuresexpenses and the disclosure of contingent assets and liabilities at the date ofin our financial statements and the reported amounts of revenuesaccompanying notes. We evaluate these estimates and expenses during the reporting period. Actual results could differ from those estimates.   The areas where critical estimates were made that have significant importance to the financial statements are as follows:

i.      Allowance for doubtful accounts. The company provides for potential bad debtsjudgments on an account-by-accountongoing basis. Bad debts have not been significantWe base our estimates on historical experience and our allowance has been accurate. Non-trade receivableson various other factors that we believe are also scrutinized and allowedreasonable under the circumstances, the results of which form the basis for based on expected recovery.

ii.     Allocation ofmaking judgments about the price paid when acquiring subsidiaries.  When the Company acquires subsidiary companies an allocation of the purchase is required.  The allocation is based on management’s analysis of thecarrying value of the net assets and is based on estimated future cash flows that each component will produce.  Such components might include software, customer lists and other intangible assetsliabilities that are not readily determinable.  The allocation hasapparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

25

For a significant impact ondescription of our critical accounting policies, please see the future earningssection entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations - Critical Accounting Policies and Estimates” contained in our 2020 Form 10-K. There have not been any material changes to the critical accounting policies discussed therein during the nine months ended September 30, 2021.

Other Company as certain assets, customer lists for example, must be amortized and charged to operations over time, while other assets, notably goodwill, does not.Information

JOBS Act

 

iii.     Impairment testingAs an emerging growth company under the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, we can, and intend to, take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We also intend to rely on intangibles and goodwill.  As noted in more detail below, these areas involve numerous estimates as to expected cash flows, expected rates of return and other factors that are difficult to determine and are often out ofexemptions provided by the Company’s direct control. 

iv.     Valuation of deferred tax credits.  The Company provides an allowance for tax recoveries arising from the application of losses carried forward.  An allowance is provided where management has determined that it is less than likely that the loss will be applied and income taxes recovered.

Comprehensive Income (Loss)

The Company adopted FASB Codification topic (“ASC”) 220, Reporting Comprehensive Income, which establishes standards for the reporting and display of comprehensive income and its components in the financial statements. Comprehensive income consists of net income and other gains and losses affecting stockholder's equity that are excluded from net income, such as unrealized gains and losses on investments available for sale, foreign currency translation gains and losses and minimum pension liability. Since inception, the Company’s other comprehensive income represents foreign currency translation adjustments and small net actuarial losses on pension plans.

Net Income per Common Share

FASB Codification topic (“ASC”) 260, Earnings per share, requires dual presentation of basic and diluted earnings per share (EPS) with a reconciliation of the numerator and denominator of the EPS computations. Basic earnings per share amounts are based on the weighted average shares of common stock outstanding. If applicable, diluted earnings per share would assume the conversion, exercise or issuance of all potential common stock instruments such as options, warrants and convertible securities, unless the effect is to reduce a loss or increase earnings per share. Diluted net income (loss) per share on the potential exercise of the equity-based financial instruments isJOBS Act, including without limitation, not presented where anti-dilutive. Accordingly, although the diluted weighted average number of common stock outstanding is disclosed on the statements of operation, the calculated net loss per share is the same for bother basic and diluted as both are based on the basic weighted average of common stock outstanding. There were no adjustmentsbeing required to net income forcomply with the period presented in the computationauditor attestation requirements of diluted earnings per share.

Financial Instruments

Financial instruments consistSection 404(b) of cash and cash equivalents, accounts receivable, financial assets, notes payable, liabilities to banks, accounts payable and accrued liabilities and other liabilities.  As of the financial statement date, the Company does not hold any derivate financial instruments. Financial assets and liabilities are measured upon first recognition and reviewed at the financial statement date.  Changes in fair value are recognized through profit and loss.  Unless otherwise noted, it is management’s opinion that the Company is not exposed to significant interest or credit risks arising from these financial instruments.

Currency RiskSarbanes-Oxley.

 

We usewill remain an emerging growth company until the US dollar as our reporting currency.  The functional currenciesearliest of (i) the last day of the fiscal year following the fifth anniversary of the consummation of our significant foreign subsidiaries areIPO, (ii) the local currency, which includeslast day of the Euro, the British pound, and the Indian rupee.  Accordingly, some assets and liabilities are incurred in those currencies and we are subject to foreign currency risks.

Fair Value Measurements

The Company follows FASB Codification topic (ASC”) 820, Fair Value Measurements and Disclosures, for all financial instruments and non-financial instruments accounted for at fair value on a recurring basis. This new accounting standard establishes a single definition of fair value and a framework for measuring fair value, sets out a fair value hierarchy to be used to classify the source of information used in fair value measurement and expands disclosures about fair value measurements required under other accounting pronouncements. It does not change existing guidance as to whether or not an instrument is carried at fair value. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities, which are required to be recorded at fair value, the Company considers the principal or most advantageous market in which the Company would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as inherent risk, transfer restrictions and credit risk.

The Company has adopted (“ASC”) 825, Financial Instruments, which allows companies to choose to measure eligible financial instruments and certain other items at fair value that are not required to be measured at fair value. The Company has not elected the fair value option for any eligible financial instruments.

Cash and Cash Equivalents

The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents.

Inventories

Pursuant to ASC 330 (Inventories), inventories held for sale are recognized under inventories. Inventories were measured at the lower of cost or market. Cost is determined on a first-in-first out basis, without any overhead component.

Goodwill and other Intangible Assets

Intangible assets predominately include goodwill, acquired software and capitalized software development. Intangible assets acquired in exchange for payment are reflected at acquisition costs. If the development costs can be capitalized per ASC 985-20-25, these are reflected as ascribable personnel and overhead costs.

Company created software can be intended for sale to third parties or used by the Company itself. If the conditions for capitalization are not met, the expenses are recorded with their effect on profit in thefiscal year in which they were incurred.

The Company amortizes intangible assets with a limited useful life towe have total annual gross revenue of at least $1.07 billion, (iii) the estimated residual book value in accordance with ASC regulations. In addition, in special circumstances according to ASC 350-30, a recoverability test is performed and, if applicable, unscheduled amortization is considered.

The useful life of acquired software is between three and five years and three years for Company-designed software.

Intangible assets obtained as part of an acquisition which do not meet the criteria for a separate entry are identified as goodwill. Goodwill is reviewed once a year during an impairment test, whereby the appraised fair valuelast day of the invested capital of the reporting unit, is compared with the carrying (book) value of its invested capital amount (including goodwill.) Use value is generally appliedfiscal year in order to determine the recoverability of goodwill and intangible assets with an indefinite useful life. The projected financial plan prepared by the management serves as the basis for this determination of use value and the planning assumptions are each adjusted for the current state of knowledge. Reasonable assumptions regarding macroeconomic trends and historical developments are taken into account in making these adjustments. Future estimated cash flows are determined based on the expected growth rates of the markets in question.

If the carrying amount of the reporting unit exceeds the appraised fair value, the impairment based on use value measures the amount of loss, if any, and an unscheduled amortization expense is recorded. If the appraised value of the reporting unit exceeds its carrying amount, goodwill of the reporting unit is not considered to be impaired.

Property, Plant and Equipment

Property, plant and equipment are valued at acquisition or manufacturing costs, reduced by scheduled and, if necessary, unscheduled depreciation. Fixed assets are depreciated on a straight-line basis, prorated over their expected useful life. Scheduled depreciation is mainly based on useful lives of 3 to 10 years. Leasehold improvements are depreciated up to 40 years.

If fixed assets are sold, retired or scrapped, the profit or loss arising from the difference between the net sales proceeds and the residual book value are included under other operating earnings and expenses.

Impairment or Disposal of Long-Lived Assets

The Company evaluates the recoverability of its fixed assets and other assets in accordance with ASC topic, 360.10. This guidance requires recognition of impairment of long-lived assets in the event the net book value of such assets exceeds its’ expected cash flows or appraised value In this instance, the asset is considered to be impaired and is written down to fair value.

Revenue Recognition

License Revenues

Our license revenues consist of revenues earned from the licensing of our software products. These products are generally licensed on a perpetual basis. Pricing models have generally been based either upon the physical infrastructure, such as the number of physical desktop computers or servers, on which our software runs or on a per user basis. License revenues are recognized when the elements of revenue recognition for the licensed software are complete, generally upon electronic shipment of the software and the software key to provide full access to all functionalities for our customers. In general our invoices reflect license, service and maintenance components. In the case of multi element contracts, the revenues allocated to the software license in most cases represent the residual amount of the contract after the fair value of the other elements has been determined. Certain products of our software offering are licensed on a subscription basis.

Software Maintenance Revenues

Software maintenance revenues are recognized ratably on a pro-rata basis over the range of the contract period. Our contract periods typically range from one to five years. Vendor-specific objective evidence (“VSOE”) of fair value for software maintenance services is established by the rates charged in stand-alone sales of software maintenance contracts or the stated renewal rate for software maintenance. Customers who are party to software maintenance agreements with us are entitled to receive support, product updates and upgrades on a when-and-if-available basis.

Professional Services Revenues

Professional services include pre-project consulting, software design, customization, project management, implementation and training. Professional services are not considered essential to the functionality of our products, as these services do not alter the product capabilities and may be performed by our customers or by other vendors. Professional services engagements performed for a fixed fee, for which we are abledeemed to make reasonably dependable estimatesbe a “large accelerated filer” as defined in Rule 12b-2 under the Exchange Act, which would occur if the market value of progress toward completion, are recognized on a proportional performance basis based on hours incurred and estimated hours of completion. Professional services engagements that are on a time and materials basis are recognized based on hours incurred. Revenues on all other professional services engagements are recognized upon completion. Our professional services may be sold with software products or on a stand-alone basis. Vendor Specific Objective Evidence (VSOE) of fair value for professional services is based upon the standard rates we charge for such services when sold separately.

Foreign Currency Translation

The functional currencyour common stock held by non-affiliates exceeded $700.0 million as of the Company is US dollars. For financial reporting purposes, the financial statements of GROUP were translated into US dollars. Assets and liabilities were translated at the exchange rates at the balance sheet dates and revenue and expenses were translated at the average exchange rates and stockholders’ equity was translated at historical exchange rates. Any translation adjustments resulting are not included in determining net income but are included in foreign exchange adjustment to other comprehensive income, a component of stockholders’ equity.

Other Provisions

According to FASB ASC 450 Contingencies, provisions are made whenever there is a current obligation to third parties resulting from a past event which is likely in the future to lead to an outflow of resources and of which the amount can be reliably estimated. Provisions not already resulting in an outflow of resources in the following year are recognized at their discounted settlement amount on the financial statement date. The discount taken is based on market interest rates. The settlement amount also includes the expected cost increases. Provisions are not set off against contribution claims. If the amended estimate leads to a reductionlast business day of the obligatory amount, the provision is proportionally reversed and the earnings are recognized in other operating earnings.

Deferred Taxes

Income taxes are provided in accordance with FASB Codification topic 740, Accounting for Income Taxes. A deferred tax assetsecond fiscal quarter of such year, or liability is recorded for all temporary differences between financial and tax reporting and net operating loss-carry forwards.

Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that, some portion or all of the deferred tax asset will not be realized. Deferred tax assets and liabilities are adjusted for the effect of changes in tax laws and rates on(iv) the date of enactment.

Recent Accounting Pronouncements

In July 2012, the FASBon which we have issued ASU 2011-08, Intangibles - Goodwill and Other (Topic 350): Testing Goodwill for Impairment. With the objective of reducing the cost and complexity of performing an impairment test for indefinite-lived intangible assets by simplifying how an entity tests those assets for impairment and to improve consistency in impairment testing guidance among long-loved asset categories. The amendments permit an entity first to assess qualitative factors to determine whether it is more likely than not that an indefinite-lived intangible asset is impaired as a basis for determining whether it is necessary to perform the quantitative impairment test in accordance with Subtopic 350-30, Intangibles - Goodwill and Other - General Intangibles Other than Goodwill. The more-likely-than-not threshold is defined as having the likelihood of more than 50 percent. The amendments are effective for annual and interim impairment tests performed beginning April 1, 2013. Adoption of this new standard is not expected to have significant impact to$1.0 billion in non-convertible debt securities during the Company’s financial statement.prior three-year period.

Principles of Consolidation and Reverse Acquisition

OFF-BALANCE SHEET ARRANGEMENTS

As previously disclosed,

During the Company originally exchanged a total of 5,405,411 shares of common stock in exchange for 50.1% of the outstanding common shares of GROUP (and retained its 50.1% shareholding by acquiring an additional 883,765 shares of GROUP on February 27, 2012). Although the Company was the legal acquirer, the transaction was accounted for as a recapitalization of GROUP in the form of a reverse merger, whereby GROUP became the accounting acquirer and was deemed to have retroactively adopted the capital structure of the Corporation. Accordingly, the accompanying consolidated financial statements reflect the historical consolidated financial statements of GROUP for all periods presented and do not include the historical financial statements of the Company. All costs associated with the reverse merger transaction were expensed as incurred. Those expenses totaled approximately $300,000 and were included in professional fees in administrative expenses.

The Company has based its financial reporting for the consolidation with GROUP in accordance with FASB Accounting Standard Codification (ASC) 805-40 as it relates to reverse acquisitions. Goodwill has been measured as the excess of the fair value of the consideration effectively transferred by the Company, the acquiree, for financial reporting purposes, over the net amount of the Company’s recognized identifiable assets and liabilities.

We have recorded the acquired assets and liabilities of GBSX on the acquisition date of January 6, 2011, at their fair value and the operations of GBSX have been included in the consolidated financial statements since the acquisition date.

The assets and liabilities of GROUP, the acquirer for financial reporting purposes, are measured and recognized in the consolidated financial statements at their precombination carrying amounts in accordance with ASC 805-40-45-2(a). Therefore, in a reverse acquisition, the non-controlling interest reflects the non-controlling shareholders’ proportionate interest in the pre-combination carrying amounts of GROUP’s net assets even though the non-controlling interests in other acquisitions are measured at their fair values at the acquisition date.

 .

OFF-BALANCE SHEET ARRANGEMENTS

We have not entered into any other financial guarantees or other commitments to guarantee the payment obligations of any third parties. We have not entered into any derivative contracts that are indexed to our shares and classified as shareholder’s equity or that are not reflected in our consolidated financial statements. Furthermore, we dodid not have, any retained or contingent interest in assets transferred to an unconsolidated entity that serves as credit, liquidity or market risk support to such entity. Wenor do notwe currently have, any variable interest in any unconsolidated entity that provides financing, liquidity, market risk or credit support to us or engages in leasing, hedging or research and development services with us.off-balance sheet arrangements as defined under SEC rules.

ItemITEM 3. QuantitativeQUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Interest Rate Risk

Our cash and Qualitative Disclosures about Market Risk.cash equivalents consist of cash in readily available checking accounts and money market funds. Our long-term debt bears interest at a fixed rate. As a result, the fair value of our portfolio is relatively insensitive to interest rate changes and we do not consider the effects of interest rate movements to be a material risk to our financial condition.

N/AEffects of Inflation

Inflation generally affects us by increasing our cost of labor and research and development contract costs. We do not believe inflation has had a material effect on our results of operations during the periods presented

Item

ITEM 4. Controls and Procedures.CONTROLS AND PROCEDURES

EvaluationConclusion Regarding the Effectiveness of Disclosure Controls and Procedures

As of September 30, 2013, our management, with the participation of our Chief Executive Officer (principal executive officer) and our Chief Financial Officer (principal financial and accounting officer),We evaluated the effectiveness of our disclosureinternal controls over financial reporting as defined by Rules 13a-15(e) and procedures pursuant to Rule 13a-15(b) promulgated15d-15(e) under the Securities Exchange Act as of 1934, as amended (the “Exchange Act”). Based on that evaluation,the end of the period covered by this quarterly report, with the participation, and under the supervision, of our management, including our Interim Chief Executive Officer and Vice President of Finance. Based upon this evaluation, our Interim Chief FinancialExecutive Officer and VP Finance concluded that as of September 30, 2013,2021, our disclosureinternal controls and proceduresover financial reporting were ineffective due to the material weakness described below.

A material weakness is a deficiency, or a combination of deficiencies, in internal controls over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim consolidated financial statements may not effectivebe prevented or detected on a timely basis.

Specifically, during the period ended September 30, 2021:

Marizyme did not have appropriate number of independent directors on its Board of Directors,
Marizyme had a shortage of in-house personnel with appropriate level of technical knowledge required to identify and address certain complex or non-routine transactions and related reporting issues. Management has and will continue to seek guidance from third-party experts and/or consultants to gain a thorough understanding of material, complex and non-routine transactions,
The shortage of in-house finance personnel resulted in inappropriate segregation of duties, and
Insufficient documentation of written policies and procedures over internal controls over financial reporting, transaction processing, and period end closing procedures.

26

We are taking steps to remediate the material weakness identified by:

Attracting and retaining independent directors to add to the Board of Directors and establish an Audit Committee comprised of the independent directors.
Attracting, retaining, and enabling external or internal top talent in accounting and finance functions to properly segregate duties and to ensure timely and accurate preparation of the financial statements.
Developing, documenting, and maintaining adequate written accounting policies and procedures.

We believe these measures will remediate the material weakness in ensuring thatinternal control over financial reporting described above by the information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, including ensuring that such material information is accumulated and communicated to our management, including our Chief Executive Officer and our Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.second quarter of 2022.

Changes in Internal Control Over Financial Reporting

 

As previously reported bydiscussed above, the Companymanagement is working on a Form 8-K filed withremediation the Commission on July 10, 2013, on July 10, 2013, the Board of Directors of the Company reappointed Joerg Ott as the Chief Executive Officer (Principal Executive Officer) of the Company, effective immediately. Mr. Ott replaced Mr. Gary D. MacDonald who had been serving as the Company’s Interim Chief Executive Officer since July 11, 2012.

Also as previously reported by the Company on a Form 8-K filed with the Commission on August 2, 2013, on August 2, 2013, Gary D. MacDonald resigned as member of the Board of Directors of the Company and as, Managing Director of GBS-UK. From March 1, 2012material weakness but due to the date of his resignation, Mr. MacDonald also served as member ofcorporate restructuring and multiple changes to our officers and management team, no significant steps have been taken to remediate the Board’ Audit Committee. Mr. MacDonald’s resignation was not due to any disagreement with the Company or the Board.

Other than the foregoing,material deficiency in our internal controls over financial reporting during the quarternine months ended September 30, 2013, there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.2021.

27

PART II-OTHERII. OTHER INFORMATION

ItemITEM 1. Legal Proceedings.LEGAL PROCEEDINGS.

On October 23, 2013, the Company filed a lawsuit (GBS Enterprises, Inc. v. Reliance Globalcom, Inc.)From time to time, we may become involved in various lawsuits and legal proceedings, which arise, in the Superior Courtordinary course of the Statebusiness. However, litigation is subject to inherent uncertainties and an adverse result in these or other matters may arise from time to time that may harm our business. We are currently not aware of California, County of San Francisco, seekingany such legal proceedings or claims that we believe will have a declaratory judgment that the Company has no obligation to Reliance Globalcom Inc. (“Reliance”) for any claimsmaterial adverse effect on our business, financial condition or liabilities in connection with a Master Services Agreement (“MSA”) executed by Reliance and IDC Global Inc. (“IDC”) a then wholly owned subsidiary of the Company in March 2010. On February 1, 2013, GBS sold IDC to Global Telecom & Technology Inc. (“GTT”). Pursuant to the governing Stock Purchase Agreement (SPA), GTT gained all right, title and interest in 100% of all of IDC’s stock, all of which had been owned by GBS. Pursuant to the Stock Purchase Agreement, GTT withheld $528,777.93 of the purchase price from payment to GBS to cover potential exposure due to the Identified Dispute described herein between IDC and Reliance. The Stock Purchase Agreement requires that, within three days of notice to GTT that the Identified Dispute described herein has been resolved, GTT will release the $528,777.93 to GBS. The Company is seeking declaratory relief from the Court stating the Company is not liable to Reliance and that GTT may release the $528,777.93 in funds owed to the Company. There were no material developments in this case since the filing of the lawsuit.operating results.

The Company intends to vigorously defend its interests in this matter.

ITEM 1A. RISK FACTORS.

Item 1A. Risk Factors.

The disclosure required under this item is not requiredThere have been no material changes to the risk factors disclosed in our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC on April 15, 2021, which may be reported by small reporting companies; as such term is defined by Item 503(e) of Regulation S-K.accessed via EDGAR through the Internet at www.sec.gov.

Item

ITEM 2. Unregistered SalesUNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

During the nine-month period ended September 30, 2021, we did not conduct any unregistered sales of Equity Securitiesour equity securities that were not previously disclosed in a current report of Form 8-K and Usewe did not repurchase any of Proceedsour common stock.

None

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

None.

ITEM 4. MINE SAFETY DISCLOSURES.

Item 3. Defaults Upon Senior Securities.

Not applicable.

None

ItemITEM 5. Other Information.OTHER INFORMATION.

NoneOn July 6, 2021, the Company’s Board of Directors appointed Dr. Vithal Dhaduk as Interim Chief Executive Officer. He will retain his position as Chairman of the Board of Directors.

On July 12, 2021, in connection with the termination of his consulting agreement, Bruce Harmon resigned as the Chief Financial Officer of Marizyme.

On November 10, 2021, the Board of Directors appointed David Barthel as Chief Executive Officer of Marizyme. Dr. Vithalbhai Dhaduk, the former Interim Chief Executive Officer, resigned from this position on November 10, 2021 and remains Chairman of the Board.

6028
 

Item

ITEM 6. Exhibits.EXHIBITS

The following exhibits are filed as part of this report or incorporated by reference:

ExhibitNo.Description
2.1 
No.DescriptionSigning of Definitive Agreement with Health Logic (filed as an exhibit 2.1 to Form 8-K filed on November 05, 2021)
   
31.1(1)3.1.1Rule 13(a)-14(a)/15(d)-14(a) CertificationArticles of Principal Executive OfficerIncorporation (filed as an exhibit to Form SB-2 (File No: 333-146748) filed January 14, 2008)
3.1.2Certificate of Amendment to Articles of Incorporation, effective September 6, 2010 (filed as an exhibit to Form 10-K filed July 16, 2012)
3.1.3Certificate of Amendment to Articles of Incorporation, effective November 22, 2010 (filed as an exhibit to Form 10-K/A filed July 15, 2011)
3.1.4Certificate of Amendment to the Articles of Incorporation regarding 1-for-29 Reverse Stock Split filed March 20, 2018 (filed as an exhibit to Form 10 (File No. 000-53223) filed on September 12, 2018)
3.1.5Articles of Merger between Marizyme, Inc. and GBS Enterprises Incorporated filed May 19, 2018 (filed as an exhibit to Form 10 (File No. 000-53223) filed on September 12, 2018)
3.1.6Series A Non-Convertible Preferred Certificate of Designation filed May 11, 2018 (filed as an exhibit to Form 10 (File No. 000-53223) filed on September 12, 2018)
3.2Bylaws (Filed as an exhibit to Form SB-2 (File No: 333-146748) filed January 14, 2008)
4.1Form of Placement Agent Common Stock Purchase Warrant for 2020 Common Stock and Warrant Private Placement (filed as an exhibit to Form 10-Q filed on August 14, 2020)
4.2Form of Incentive Stock Option Agreement (filed as an exhibit to Form 10-Q filed on November 13, 2019)
10.1Form of Subscription Agreement for 2020 Common Stock Private Placement (filed as an exhibit to Form 10-Q filed on August 14, 2020)
   
31.2(1)10.1.1 Rule 13(a)-14(a)/15(d)-14(a) CertificationAppointment of Principal Financial and Accounting OfficerDavid Barthel as the new CEO (filed as an exhibit 10.1 to Form 8-K filed on November 16, 2021)

10.2Form of Registration Rights Agreement for 2020 Common Stock Private Placement (filed as an exhibit to Form 10-Q filed on August 14, 2020)
10.3Employment Agreement dated November 1, 2020 with Dr. Neil J. Campbell (filed as an exhibit to Form 8-K filed on November 6, 2020)
10.4Indemnification Agreement dated November 1, 2020 with James Sapirstein (filed as an exhibit to Form 10-K filed on April 15, 2021)
10.5Indemnification Agreement dated November 1, 2020 with Terry Brostowin (filed as an exhibit to Form 10-K filed on April 15, 2021)
10.6Indemnification Agreement dated November 1, 2020 with Bruce Harmon (filed as an exhibit to Form 10-K filed on April 15, 2021)
   
32.1(1)10.7 Section 1350 CertificationForm of Principal Executive OfficerUnit Purchase Agreement, dated May 2021 (filed as an exhibit to Form 10-Q filed on August 23, 2021)
   
32.2(1)10.71 Section 1350 CertificationForm of Principal Financial and Accounting Officer10% Secured Convertible Promissory Note Agreement (filed as an exhibit to Form 10-Q filed on August 23, 2021)
   
101.INS (2)10.72 XBRL Instance DocumentForm of Class A Common Stock Purchase Warrant (filed as an exhibit to Form 10-Q filed on August 23, 2021)
   
101.SCH (2)10.73 XBRL Taxonomy Extension Schema DocumentForm of Class B Common Stock Purchase Warrant (filed as an exhibit to Form 10-Q filed on August 23, 2021)
   
101.CAL (2)10.74 XBRL Taxonomy Extension Calculation Linkbase DocumentForm of Placement Agency Agreement (filed as an exhibit to Form 10-Q filed on August 23, 2021)
   
101.LAB (2)10.75 Form of Placement Agent Warrant Agreement (filed as an exhibit to Form 10-Q filed on August 23, 2021)
31.1 Certification of Principal Executive Officer of Marizyme, Inc. required by Rule 13a-14(1) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2Certification of Principal Accounting Officer of Marizyme, Inc. required by Rule 13a-14(1) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1Certification of Principal Executive Officer of Marizyme, Inc. pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and Section 1350 Of 18 U.S.C. 63
32.2Certification of Principal Accounting Officer of Marizyme, Inc. pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and Section 1350 Of 18 U.S.C. 63
101.INSInline XBRL Taxonomy Extension LabelsInstance Document
101.SCHInline XBRL Taxonomy Extension Schema Document
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF
101.DEF (2)Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LABInline XBRL Taxonomy Extension Label Linkbase Document
101.PRE (2)Inline XBRL Taxonomy Extension Presentation Linkbase Document
104Cover Page Interactive Data File (embedded within the Inline XBRL document)

(1)Filed herewith.30

(2)To be filed by amendment.

SIGNATURES

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrantRegistrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

GBS ENTERPRISES INCORPORATEDMARIZYME, INC.
(Registrant)
Date: November 14, 201322, 2021By: /s/ JOERG OTT
Joerg OttBy: /s/ David Barthel
David Barthel
Chief Executive Officer
(Principal Executive Officer)
Date: November 14, 2013By: /s/ MARKUS R. ERNST
Markus R. Ernst
Chief Financial Officer
(Principal Financial and Accounting and Financial Officer)

6231